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introduction 
Prostate cancer remains a significant health problem; one out of ten men is affected by prostate 
cancer during their life span. It is the second leading cause of cancer death in men in western 
countries (1). Most patients have no complaints and the diagnosis is made only because of 
the elevated level of prostate-specific antigen (PSA), being a specific tumor marker for prostate 
cancer. Symptomatic patients complain of urinary problems such as hesitancy, frequency dur-
ing the day and at night, dysuria, weak stream, and rarely haematuria and urinary retention. 
After a wide clinical examination, patients with elevated PSA will undergo a biopsy of the 
prostate to establish the diagnosis histologically and to assess the stage and aggressiveness of 
their disease. Prostate cancer, as other cancers, would be staged according to the American 
Joint Committee on Cancer guidelines (TNM stage: Tumor-Node-Metastases). Tumor stage (T 
stage) can be determined by digital and ultrasonic rectal examination with or without additional 
CT or MRI scan. In short: T1 tumor not palpable by rectal examination and not visible by any 
radiological technique, T2 tumor palpable or visible but still confined to the prostate gland, T3 
tumor extends beyond the prostatic capsule or invades the seminal vesicles, and T4 tumor 
invades the adjacent structures (rectum, bladder or pelvic wall) (2). Lymph node involvement (N 
stage) can be detected by CT or MRI scan; for patients with high risk of lymph nodal spread, 
currently laparoscopic lymph node sampling is frequently the preferred diagnostic approach. 
In the nearby future more accurate assessment of the lymph nodal status can be done using 
advanced generation of MRI scanning with ultra-small iron oxide particles in order to contrast 
the involved nodes only. Bone scans are the standard method to detect skeletal metastases in 
patients with high risk criteria’s.
risk stratification
Prostate cancer patients are stratified into different risk groups based on clinical tumor stage, 
PSA-level at the time of diagnosis and Gleason score (a histological grading system which 
reflect the aggressiveness of prostate cancer including risk of extracapsular spread, lymph 
node involvement and distant metastases). The Gleason score is determined from the diag-
nostic biopsy of the prostate and is graded between 2-10; the higher the score, the more 
aggressive is the cancer.
In the Dutch randomized dose escalation trial, patients were divided into three risk groups 
(low-, intermediate- and high-risk), based on the single-factor model of Chism (3). Patients with 
T1-2 and Gleason 2-6 and PSA ≤ 10 mg/L, were considered to be at low risk, whereas patients 
with T3-4 or Gleason 8-10 or PSA > 20 mg/L were at high risk. All the other patients were 
considered as intermediate risk.
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treatment modalities
At present, when diagnosed with localized prostate cancer, several therapeutic options are avail-
able. These include open or laparoscopic prostatectomy (PR) (surgical removal of the prostate), 
or external beam radiotherapy (EBRT) with or without brachytherapy (BT). In case of BT, currently 
radioactive seeds e.g. I-125 for low-dose rate BT or plastic after-loading catheters for high-dose 
rate Ir-192 sources are implanted into the prostate. Impotence and urinary incontinence are 
well-known long-term complications after radical PR (4). Some believe that the incidence of 
these complications can to be reduced with the currently used nerve-sparing laparoscopic 
surgical techniques (5). Erectile dysfunction after EBRT is less common than after RP. According 
to recent data reported in the literature, however, no definitive dose-effect relationship has been 
demonstrated for erectile dysfunction (6-8). Van der Wielen et al. (6) from our group found no 
correlation between the radiation dose to different anatomical structures (neurovascular bundle, 
corpora cavernosa, penile bulb) and sexual problems. Patients treated with EBRT have a higher 
risk of bowel complications (9), while patients treated with BT have more genitourinary problems 
(10). 
With regard to the different treatment options available, no consensus was found regard-
ing the optimal treatment strategies. Apart from these options, watchful waiting can also be 
adopted in patients with early-stage disease with slowly rising PSA level and limited tumor load, 
specifically in patients with short life expectancy (below 10 years) from the date of diagnosis 
(11). 
Generally speaking, low-risk patients have a high probability of having organ-confined dis-
ease and therefore a higher chance of cure. On the other hand, high-risk patients have a high 
probability of having non-organ-confined disease and are at high risk of lymph node spread and 
micrometastases. These tumors are usually treated with adjuvant long-term hormonal therapy 
(HT) and 3-dimentional conformal radiotherapy (3DCRT). HT for 2-3 years appeared to improve 
survival by 20-30% in high-risk patients, because of the synergistic role of RT and HT in destroy-
ing micrometastases (12-14). Intermediate-risk patients are suitable candidates for radical PR 
or 3DCRT (with or without HT) (15). Besides the abovementioned prognostic criteria, selection 
of the appropriate treatment for patients with localized prostate cancer is frequently based on 
others factors, for instance general condition of the patient, comorbidity, age, possibility of 
treatment complications, patients’ preference, the treating doctor, and the available facilities at 
that particular cancer center. 
radiotheraPy of Prostate cancer
After diagnosis and decision making as to what type of treatment modalities are to be used, 
in case of radiation therapy as the treatment modality of preference, simulation will be the 
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next step. This procedure consist of a number of steps including patient preparation, patient 
positioning, planning CT scanning, target definition, RT planning, dose prescription and plan 
verification. Before the start of each fraction the patient is instructed to drink sufficiently to finally 
achieve a full bladder to a comfortable level, in order to reduce the volume of small bowel 
irradiated; also mild laxative are prescribed in order to have an empty rectum and consequently 
limit the high dose area of the anorectal wall (16). To ensure reproducibility of setup of daily 
radiation treatment delivery, patients treated with 3DCRT for prostatic cancer should be fitted 
in an easily reproducible supine position, usually without immobilization device. To allow the 
radiation oncologist to draw the prostate gland on the CT simulation image and to verify the 
radiation fields during the treatment using portal imaging technology, a number of institutions 
place fiducials markers in the prostate. Because of the multifocal nature of prostate cancer, the 
entire prostate gland is delineated as clinical target volume (CTV). A margin is then added to 
the CTV (nowadays ranging from 5 to 10 mm) (17) to allow for prostate movement, delineation 
uncertainties and patient setup variability on the treatment machine. This way new target volume 
called planning target volume (PTV) is defined. The radiation oncologist may also decide to 
include the seminal vesicles and/or the pelvic lymph nodes in the PTV in patients at significant 
risk for spread to these tissues. Multiple RT-fields (typically 3-6) are used in order to minimize 
the volume of normal tissue receiving a high dose. A 3D dose calculation is performed; the 
radiation oncologist reviews the overall treatment plan including field arrangement, doses at the 
surrounding critical organs and subsequently prescribed the dose. In general, the PTV should 
receive full prescription dose ± 5% to ensure adequate homogeneity of the dose throughout 
the intended target volume (18). Typical doses per fraction for 3DCRT are 1.8-2.0 Gy/day. The 
treatment is delivered on a daily basis 5 days per week over 6-8 weeks, somewhat depending 
on the dose per fraction and total dose. During the treatment, portal images are used to verify 
accurate alignment of the fields. Adjustment can be made on a daily basis if the prostate is 
not being accurately targeted. By the mid-1990’s, further development of treatment planning 
software coupled with the integration of multi-leaf collimators (MLC), a type of mechanized 
radiation beam shaping device, allowed for the introduction of a more conformal treatment 
mode, that is intensity modulated radiation therapy (IMRT). With this technique, the radiation 
beam is divided into individual beamlets, so that differences in position of tumor vs. normal 
tissue can be exploited with varying the dose. Planning is facilitated by assigning maximal dose 
to the target and minimal dose to normal tissue volumes at risk. IMRT has permitted not only 
further prostate dose escalation beyond 81 Gy but also a better understanding of the relation-
ship between doses to specific volumes of organs at risk and morbidity (19-21).
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dose-resPonse relationshiP 
It is a well-known fact that there is a dose-response relationship for clinical control of localized 
prostate cancer. The need for increased dose of above conventional levels (66-70 Gy) was 
suggested by dose-response studies (22-25). However, increasing the dose of RT above those 
levels using conventional RT techniques was limited by the dose of the surrounding normal criti-
cal structures. After the introduction of 3DCRT and IMRT, several phase II trials have shown that, 
with 3DCRT, higher than conventional doses are feasible (26-29). This advanced technology 
allows for the initiation of different phase III dose escalation trials in North America, the UK, The 
Netherlands, and France (30-34). 
scoPe of the thesis
As already mentioned, EBRT is an important treatment modality for prostate cancer patients. 
Level I evidence is nowadays available from different randomized controlled clinical trials (30-33) 
supporting the benefit of high-dose RT in the management of most of these patients. Although 
the toxicity of irradiated patients remains considerable, little is known from these studies about 
the impact of such treatment on the quality of life (QoL). Further improvement in clinical outcome 
of prostate cancer patients while maintaining the toxicity at acceptable levels could be achieved 
by careful selection of the patients for dose escalation of RT and the use of high accuracy 
radiation techniques. These topics are thoroughly studied in the next chapters of this book. This 
thesis is covering some of the related questions in the following chapters:
Chapter 2
Question: Is dose escalation of radiotherapy in patients with localized prostate cancer really 
necessary?
Paper: Update of the Dutch multicenter dose escalation trial of radiotherapy for localized pros-
tate cancer. 
Source: International Journal Radiation Oncology Biology Physics 2008;72:980-988.
Chapter 3
Question: Does the use of intensity-modulated radiotherapy reduce the radiation-related toxicity 
in patients treated with high-dose radiotherapy? 
Paper: The role of intensity modulated radiation therapy in reducing toxicity in dose escalation 
for localized prostate cancer.
Source: International Journal Radiation Oncology Biology Physics 2009;73:685-691.
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Chapter 4
Question: What are the clinical and dosemetric predictors of late urinary obstruction after dose 
escalation of radiotherapy in prostate cancer?
Paper: Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): 
specific relationships between local dose, acute effects and baseline characteristics. 
Source: International Journal Radiation Oncology Biology Physics 2010 (Epub ahead of print).
Chapter 5
Question: What is the impact of dose escalation of RT dose on QoL?
Paper: Dose-escalation and quality-of-life in patients with localized prostate cancer treated with 
radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 
trial).
Source: International Journal Radiation Oncology Biology Physics 2010 (Epub ahead of print).
Chapter 6
Question: Which subgroup of patients benefits most from dose escalation?
Paper: Subgroup analysis of patients with localized prostate cancer treated within the Dutch 
randomized dose-escalation trial.
Source: Radiotherapy and Oncology 2010;96:13-18.
Chapter 7
Question: What is the optimal management of high-risk prostate cancer?
Paper: Controversies in the treatment of high-risk prostate cancer: what is the optimal combina-
tion of hormonal therapy and radiotherapy: a review of literature.
Source: The Prostate 2010,70:701-709.
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abstract
Purpose 
To update the analysis of the Dutch dose escalation trial of radiotherapy for prostate cancer.
Patients and Methods 
A total of 669 patients with localized prostate cancer were randomly assigned to receive 68 or 
78 Gy. Patients were stratified by age, institution, use of (neo)adjuvant hormonal therapy, and 
treatment groups. The primary end point was freedom from failure (FFF), which was defined 
as clinical or biochemical failure (BF). Two definitions of BF were used; the ASTRO-definition 
(3 consecutive rises of PSA level) and the Phoenix definition (the nadir plus 2). Secondary end 
points were freedom from clinical failure (FFCF), overall survival (OS), genitourinary (GU) and 
gastrointestinal (GI) toxicity.
Results
After a median follow-up of 70 months, FFF (ASTRO) was significantly better in the 78-Gy arm 
compared with the 68-Gy arm (7-year FFF rate is 54% vs 47%; p= 0.04). FFF (Phoenix) was 
also significantly better in the 78-Gy arm with 7-year FFF rate of 56% vs 45%, respectively (p 
= 0.03). However, no differences in FFCF and OS were observed. The incidence of late GU 
toxicity grade ≥ 2 was similar in both arms (40% vs 41% at 7 years; p= 0.6), while the cumulative 
incidence of late GI toxicity grade ≥ 2 was increased in the 78-Gy arm (35% vs 25% at 7 years; 
p= 0.04).
Conclusion
The results of our study have shown a statistically significant improvement in FFF in prostate 
cancer patients treated with 78 Gy but with a greater rate of late gastrointestinal toxicity.
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introduction
The incidence of prostate cancer is rapidly increasing in all industrialized countries. External 
beam radiotherapy is one of the options used to treat about 8,000 men diagnosed with prostate 
cancer annually in The Netherlands. The need for increased dose of radiotherapy (RT) above 
conventional levels was suggested by dose response observations by Perez et al. (1) and 
Hanks et al. (2). The past few decades witnessed the development of new radiation techniques 
such as 3-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiotherapy 
(IMRT). These advanced techniques will achieve improved conformality of high dose levels of 
RT to the target volume while sparing the normal tissues, reducing complications and may 
permit safe dose escalation and therefore improving local control. Studies of dose escalation 
with 3D-CRT have been initiated by investigators in North America, the UK, France and in The 
Netherlands (3-8). These studies consistently showed an improvement in freedom from failure 
(FFF), but without improvement in overall survival (OS), probably because of the competing risk 
of death from intercurrent illnesses, the short follow-up period or because of lack of statistical 
power in these studies.
Because of the increasing need for a good definition for biochemical failure (BF) and the 
recent publications that the Phoenix definition (PSA nadir plus 2 mg/L after RT) is a better 
approximation of eventual clinical failure (CF) (9, 10, 11, 12, 13) than the ASTRO definition, we 
will make a comparison between the rate and pattern of failures according to both definitions.
In our first reported outcome results, this trial has shown, after a median follow-up of 51 
months, that high dose of RT (78 Gy) is beneficial in terms of FFF, without significant differences 
in freedom from clinical failure (FFCF) and OS (4). In this report we present the results on out-
come and toxicity of this, meanwhile more mature, trial with a median follow-up of 70 months. 
Patients and methods 
Study design 
This phase III multicenter randomized trial was designed to compare two different radiation 
doses delivered by conformal techniques for patients with localized prostate cancer and was 
carried out in four Dutch institutions. 
Participants
Patients with histologically proven T1a-4 adenocarcinoma of the prostate with initial prostate-
specific antigen (iPSA) less than 60 mg/L were eligible, provided there were no distant metastases 
and no cytologically or histologically proven positive regional lymph nodes. However, patients with 
T1a and well-differentiated (or Gleason score < 5) T1b-c with iPSA ≤ 4 mg/L were not included. 
Patients using anticoagulants, with previous radical prostatectomy or pelvic irradiation, previous 
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malignant disease (other than basal cell carcinoma), and patients having Karnofsky performance 
scores of ≤ 70, were excluded. TNM classification was done according to the AJCC 1997 
guidelines. All participants provided written informed consent. This study entered 669 patients 
with between June 1997 and February 2003. Patients were randomly assigned to receive either 
68 or 78 Gy. Stratification was performed at randomization to ensure balanced groups. Patients 
were stratified by age (≤ 70 v > 70 years), institution (A, B, C, or D), use of (neo)adjuvant hormonal 
therapy (HT) (yes or no), and treatment groups (groups I, II, III or IV). Patients were stratified 
into 4 treatment groups, defined according to the estimated risk of the seminal vesicles (SV) 
involvement, according to Partin (14) (Table 1). Patients who belong to treatment group I have 
an estimated risk of SV involvement of < 10%, while patients in group II have an estimated risk of 
10-25%. Patients in group III and IV have an estimated risk of SV involvement of > 25%. 
Table 1. Treatment groups, according to the risk of involvement of SV, Partin et al, 2004
  T1b, T1c, T2a* T2b, T3a* T3b, T4*
Gleason score
Differentiation 
grade
PSA 0-4 PSA 4-10 PSA 10-20 PSA 20-60 PSA 0-60 PSA 0-60
2-4 Good I I I II III IV
5-7 Moderate I II II III III IV
8-10 Poor II III III III III IV
* According to the American Joint Committee on Cancer 1997 guidelines
Retrospectively, patients were also divided into three prognostic risk groups (low-, intermedi-
ate- and high-risk), according to the single factor model of Chism et al. (15). Patients with T1-2 
and Gleason 2-6 and PSA ≤ 10 mg/L, were at low risk, whereas patients with T3-4 or Gleason 
8-10 or PSA > 20 mg/L were at high risk. All the other patients were at intermediate risk. 
(Neo)adjuvant hormonal therapy (HT) was allowed and prescribed in two institutions (n= 
143), mostly to high-risk patients (n= 125) and rarely to intermediate- or low-risk patients (n= 
18). The use of HT was well balanced between both treatment arms (Table 2). Institution A gave 
long-term HT (3 years), while institution B used short-term HT (6 months). Androgen depriva-
tion was achieved using 3-monthly depot injection of a luteinising hormone-releasing hormone 
analogue preceded by a short course of cyproterone acetate to prevent testosterone flare.
Radiation treatment
Simulation and treatment were carried out in supine position with a comfortably full bladder and 
without specific immobilization. All patients underwent CT scanning of the pelvis in treatment 
position. For both arms, the fraction size was 2 Gy prescribed to the isocenter (the ICRU 
reference point). The mean dose to the planning target volume (PTV) was between –5% and 
+7% of the prescribed dose, and 99% of the PTV received ≥ 95% of the prescribed dose. 
The rectum was defined from the anal verge until inferior border of the sacro-iliacal joints or to 
the point where the rectum was no longer close to the sacrum. The percentage of the rectum 
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receiving ≥ 74 Gy was limited to 40%, while the small bowel dose should not be > 68 Gy. The 
PTV included the prostate with or without the SV as clinical target volume (CTV), with a margin of 
10 mm during the first 68 Gy and 5 mm (except towards the rectum 0 mm) for the last 10 Gy in 
the high-dose arm. CTV for treatment group I was defined as the prostate only, and for group IV, 
it was the prostate and the SV. For treatment group II and III the CTV also included the prostate 
and SV, but the SV was excluded from the CTV after 50 and 68 Gy, respectively. 
Table 2. Patients, tumor and treatment characteristics
Characteristics 68-Gy arm (N = 331) 78-Gy arm (N = 333)
Mean age (year) 68.6 68.8
Median follow-up (months) 70.3 71
Radiation dose (%)   
 68 Gy 100  
 68-76 Gy  11
 78 Gy  89
Hormonal therapy (total) (%) 22 21
 Short-term 11 9
 Long-term 11 12
Institution (%)   
 A 61 61
 B 26 26
 C 10 10
 D 3 3
Treatment groups (%)   
 I 17 16
 II 20 20
 III 46 49
 IV 17 15
Risk groups (%)   
 Low 17 19
 Intermediate 27 27
 High 56 54
Gleason score (%)*   
 Gleason 2-6 49 51
 Gleason 7 34 35
 Gleason 8-10 17 14
Tumor stage (%)   
 T1 18 21
 T2 45 41
 T3 35 37
 T4 2 1
PSA (%)   
 0-10 36 41
 10-20 38 38
 20-60 26 21
* For 46 patients the Gleason score was not available and a score was assigned based on differentiation grade
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Institutions A, B and D used a three-field technique (n= 594), and institution C a four-field 
technique (n =70). For 41 patients in the high-dose arm, an IMRT-technique was used for the 
simultaneous integrated boost in institution B. For these patients the boost was irradiated to 78 
Gy with a fraction size of 2 Gy. The PTV minus boost region was defined by the 5-10 mm shell 
formed by the PTV from which the boost region was subtracted. This shell was irradiated to at 
least 95% of 68 Gy (64.6 Gy) in 39 fractions, resulting in dose per fraction in this shell, varying 
between 1.9 Gy (95% of 2 Gy) and 1.66 Gy (16)
Follow-up
All patients were scheduled to be seen every 3 months for the first year, every 4 months for 
the second year, every 6 months for the next 3 years, and annually thereafter. Assessment of 
disease status was made using history, clinical examination and PSA measurement. 
Toxicity 
Late radiation side effects were assessed at each follow-up visit, using patient’s question-
naires and slightly modified Radiation Therapy Oncology Group and European Organisation for 
Research and Treatment of Cancer (RTOG/EORTC) scoring criteria (17). We scored also more 
detailed gastrointestinal (GI) and genitourinary (GU) symptoms (17), called indicators for RTOG/
EORTC grade ≥ 2 (Table 3).
Table 3. Cumulative incidence at 7 years (Kaplan-Meier estimates) for all late GI and GU endpoints, including grade ≥ 2 toxicity 
indicators. Statistically significant (Log rank test) differences (P < 0.05) are indicated in bold.
 Cumulative incidence at 7 years (%)
Endpoints 68 Gy 78 Gy p value
GI    
 RTOG/EORTC ≥ 2 25 35 0.04
 RTOG/EORTC ≥ 3 4 6 0.3
 Rectal bleeding (laser / transfusion) 3 8 0.01
 Fecal incontinence (pads > 2 days a week) 7 13 0.02
 High stool frequency ( ≥ 6 a day) 7 10 0.2
 Steroids for proctitis 5 6 0.5
 Pain/cramps/tenesmus requiring medication 9 13 0.3
GU    
 RTOG/EORTC ≥ 2 41 40 0.6
 RTOG/EORTC ≥ 3 12 13 0.6
 Haematuria (laser / transfusion) 0.7 0.4 0.5
 Urinary incontinence (pads > 2 days a week) 7 7 0.9
 High urinary frequency during the day ( ≥ 16) 6 5 0.9
 Nocturia ( ≥ 4) 26 30 0.2
 Dysuria requiring medication 12 16 0.3
 Urinary obstruction requiring treatment 8 11 0.2
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End points
The primary end point was FFF, which was defined as BF or CF, whichever was first. BF was 
defined according to the ASTRO-definition (three consecutive rises in PSA with backdating to 
midway between the nadir and the first rise) (18). Because of concerns that backdating may 
influence the timing and the degree of BF (19), a second analysis was performed without 
backdating. In addition to the ASTRO definition, we also applied the Phoenix definition (rise of 
≥ 2 mg/L greater than the PSA nadir after RT) (12). CF was defined as local relapse (palpable 
and/or biopsy-proven), regional relapse, distant metastases (DM), or initiation of salvage HT 
because of a rising PSA level. Other end points were OS, GI and GU toxicity. Cancer-related 
death was defined as death resulting from loco-regional failure or DM. All other causes of death 
were considered as disease unrelated. 
Statistical analysis
FFF, FCFF, and OS were calculated using the Kaplan-Meier method, and the differences were 
assessed with the log-rank test. To detect a clinically relevant difference of 10% in the primary 
end point (FFF), 600 patients were required with sufficiently long follow-up, based on a two-
sided test with a = 0.05 and power of 80%. Analysis was done according to the intention-to-
treat principle. Multivariate analysis of prognostic factors was performed, using Cox proportional 
hazards regression model, to analyze differences between both arms. All p-values are based 
on two-side tests, with p-value < 0.05 considered statistically significant. Retrospectively, we 
performed subgroup analyses according to the risk groups (15) and a test of interaction by risk 
groups using odds ratios.
results
Between June 1997 and February 2003, 669 patients were enrolled in the study. Five patients 
were excluded because they were ineligible. From the remaining 664 patients, 331 patients 
were randomly assigned to receive 68 Gy and 333 patients entered into the high-dose arm 
of 78 Gy. The median follow-up was 70 months (range 10-115 months). All the patients in 
the 68-Gy arm received the prescribed dose. In the high-dose arm, however, 11% received a 
dose lower than 78 Gy: 6% received 68 Gy because of the dose constraints for rectum and 
small bowel, 3% between 74 and 76 Gy and 1.8% between 70 and 72 Gy because of acute 
toxicity, technical problems or because of patient’s request. One patient (0.3%) died during the 
treatment from a disease-unrelated cause and had received only 16 Gy. HT was prescribed in 
143 patients; 73 in the low-dose arm and 70 in the high-dose arm. Patient, tumor and treatment 
characteristics are provided in Table 2. 
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Outcome
The FFF was significantly better in the 78-Gy arm compared with the 68-Gy arm according 
to the ASTRO definition and Phoenix definition (7-year FFF rate ASTRO-definition is 54% and 
47%, respectively, p = 0.04 and for Phoenix definition is 56% and 45%, respectively, p = 0.03). 
Because we know that ASTRO definition with backdating might influence the timing and the rate 
of BF, we repeated the analysis without backdating. The FFF remained significantly different, in 
favour of the high-dose arm (49% and 37%, p = 0.04) (Figures 1A-C). There was no difference 
between high-dose and low-dose arms in FFCF rates (70% vs 68% at 7 years; p = 0.68) and 
in OS rates (75% both arms at 7 years; p = 0.45).
Salvage HT was started in 22 patients because a CF has occurred or because of a rising 
PSA level but before the point of a formal BF (ASTRO): 12 patients in the low-dose arm and 
10 patients in the high-dose arm. Eighty-three patients have developed clinical progression, 40 
patients in the low-dose arm and 43 in the high-dose arm. In total there were 23 local failures, 
12 regional failures and 56 DM. No significant differences were seen between both arms 
regarding the type of CF. There were 68 deaths in the high-dose arm, with 45 of those deaths 
prostate cancer-related, while 42 of the 75 deaths in the low-dose arm were prostate cancer-
related. The remaining patients died because of intercurrent diseases (mostly cardiovascular 
or pulmonary disease) or other malignancies. The type and number of failures as well as the 
deaths by treatment arm are shown in Table 4.
CONV 68
EXP  78
Logrank P =.04
N
331
333
F
165
143
CONV 68
EXP  78
At risk:
331
333
228
249
153
196
88
111
38
45
CONV 68
EXP  78
0
25
50
75
100
Years0 7
C
u
m
ul
at
iv
e 
p
er
ce
nt
a
ge
FFF-ASTRO
Figure 1A chapter 2
Figure 1A Kaplan-Meier curve of 7-year rates of freedom from failure (FFF) by dose randomization (68 vs. 78 Gy), defined 
according to the ASTRO definition (3 consecutive rises of PSA level, backdated to midway between the nadir and first rise)
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Figure 1C Kaplan-Meier curve of 7-year rates of freedom from failure (FFF) by dose randomization defined according to the Phoenix 
definition (the nadir plus 2 mg/L after RT)
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Figure 1B Kaplan-Meier curve of 7-year rates of freedom from failure (FFF) by dose randomization (68 vs. 78 Gy), defined 
according to the ASTRO definition without backdating.
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Retrospectively, we did a subgroup analysis based on the three risk groups (15) and a test 
of interaction between these risk groups. The odds ratio of the total group was equal to 0.75 
(p = 0.04) in favor of the high-dose arm. The benefit of high dose RT was most apparent in the 
intermediate-risk group with an odds ratio of 0.6 (95% CI = 0.33-0.87; p = 0.01). There was a 
clear trend in the high-risk group, but not in the low-risk group. Furthermore, when this analysis 
was done with actually given dose instead of dose at randomization, the difference in FFF in the 
high-risk group was statistically significant (p = 0.03).
Toxicity
The cumulative incidence of late GU toxicity grade ≥ 2 was 40% in high-dose arm and 41% in 
low-dose arm at 7 years (p = 0.6), while the cumulative incidence of late GI toxicity grade ≥ 2 
was increased in the 78-Gy arm (35% and 25%, respectively at 7 years, p = 0.04) (Figures 2A 
and 2B, and Table 3). No differences were found between high- and low-dose arm regarding 
late GU toxicity grade ≥ 3 (13% and 12%, respectively, p = 0.6) and late GI toxicity grade ≥ 3 
(6% and 4%, respectively, p = 0.3). One percent (n = 3) in both treatment arms developed late 
GU toxicity grade 4. Late GI toxicity grade 4 has been observed in 3 patients of high-dose arm 
(1%) but not in the low-dose arm. All 5 GI indicators were higher for the high dose arm. Rectal 
bleeding requiring laser or transfusion was significantly increased in the high-dose arm (8% vs 
3 %, Table 3 and Figure 3A). The incidence of rectal bleeding stabilized after 5 years, since no 
new cases were observed after 5 year. For fecal incontinence, the incidence was higher by a 
factor of two in the high-dose arm (13% vs 7 %, Table 3 and Figure 3B), but this incidence did 
not stabilize. 
Table 4. BF, CF and death by treatment arm
 Total 68-Gy arm 78-Gy arm
Failure (n = 664) (n = 331) (n = 333)
BF (ASTRO) (1) 244 135 109
BF (Phoenix) (1) 238 131 107
CF (total) 83 40 43
 Local 21 15 6
 Regional 5 1 4
 Distant metastases (DM) 49 21 28
 Local and DM 1 0 1
 Local and regional 1 1 0
 Regional and DM 6 2 4
Salvage HT (2) 22 12 10
Death (total) 143 75 68
 Cancer-related 87 42 45
 Non-cancer related 56 33 23
Abbreviation: BF: biochemical failure; CF: clinical failure; DM: distant metastases; Salvage HT: salvage hormonal therapy; (1) as first 
failure before CF; (2) only salvage HT without previously a formal ASTRO BF or a CF on the basis of rising PSA are counted here
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Figure 2B Kaplan-Meier curve of 7-year cumulative incidence of late GU toxicity grade ≥ 2 by randomization arm
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Figure 2A Kaplan-Meier curve of 7-year cumulative incidence of late GI toxicity grade ≥ 2 by randomization arm
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Figure 3B Kaplan-Meier curve of 7-year cumulative incidence of fecal incontinence by treatment arm.
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Figure 3A Kaplan-Meier curve of 7-year cumulative incidence of rectal bleeding requiring laser or transfusion by treatment arm. 
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discussion
Outcome
The development of more accurate radiation techniques has considerably altered the practice 
of radiation oncology, allowing for a higher dose to the prostate while limiting the dose to the 
bladder and rectum. Pollack et al. (5) published the first randomized trial, carried out at the MD 
Anderson Cancer Center. Long-term results of this trial showed a significant improvement in 
FFF with high dose RT (8-year FFF rate is 59% for the 70-Gy arm and 78% for the 78-Gy arm, 
p = 0.004) (20) and also an improvement in FFCF. Dearnaley et al. (21) reported a significant 
improvement of biochemical progression-free survival (bPFS) in the escalated group (74 Gy) 
in comparison with the standard group (64 Gy). The 5-year bPFS rates in the escalated and 
standard groups were 71% vs 60%, respectively (p = 0.007). The HR for clinical PFS was 0.69 
(p = 0.064). To date, at least five randomized trials, investigated the effect of dose escalation 
(3, 4, 6, 7, 8). All these trials, with the exception of that of Shipley et al. (7), have decisively 
demonstrated improved biochemical control by increasing the dose to the primary tumor of the 
prostate. 
Biochemical failure
Our trial showed a statistically significant improvement in FFF in prostate cancer patients treated 
with 78 Gy in comparison with 68 Gy, using the ASTRO definition (with and without backdating) 
and the Phoenix definition. In our earlier analysis (median follow-up: 51 months), the 5-year 
FFF-rate (Phoenix) was better in the high- than in the low-dose arm (67% vs. 61%), but this 
difference was statistically not significant (p = 0.2) (4). At that time, we had already realized that 
there is a backdating censoring artifact by using the ASTRO definition. Repeating the analysis 
without backdating also yielded a significant difference (p=0.02) between the treatment arms 
(4). Therefore it might be possible that in a randomized trial, the ASTRO definition (with and 
without backdating) might demonstrate a significant difference between the randomization arms 
earlier in time compared to the Phoenix definition
Definitions for biochemical failure
Despite the known shortcomings of the ASTRO definition, it is still used widely as indication 
of BF. Because of the recent recommendations (9, 10, 11, 12, 13, 22), one should use the 
Phoenix definition beside the ASTRO definition after RT for prostate cancer. Lack of specificity 
of the ASTRO-definition is one of those weaknesses when HT is used. These patients may 
show a transient rise of PSA level when the HT stopped. There is a potential for false positives 
secondarily to such a benign PSA bounce, but these false positives would have been present 
in both treatment arms. The second problem of the ASTRO-definition is the backdating, which 
is reasonably solved by performing the analysis without backdating. Another reason for using 
both definitions (ASTRO with and without backdating and Phoenix) is the fact that the ASTRO 
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definition (with backdating) systematically underestimates late BF. While using the Phoenix defi-
nition and the ASTRO definition (without backdating) the occurrence of BFs spread more evenly 
among years 0-10 (12, 23). We also have observed the same pattern of failures according to 
these three definitions. Early control rates look better using Phoenix definition, while later results 
favour the ASTRO definition with backdating (Figures 1A-C). The definition of BF according 
to Phoenix, has been found to be strongly related to clinical failure than the ASTRO-definition 
and less frequently influenced by the use of HT or the length of follow-up. Vicini et al (10) have 
studied 19 different definitions for BF and their correlation with CF and cause specific survival 
and found that nadir plus 2 is highly specific and very accurate for identifying BF and also better 
correlate with CF than other definitions using a specific number of consecutive rises in PSA 
level, as the ASTRO definition. 
Clinical failures
Biochemical control has been shown to correlate not only with local failure but also with DM, 
cause-specific survival and disease-free survival (9, 10). Morgan et al. (23) have shown that the 
5-year actuarial DM rates decreased from 8% to 2% with increasing radiation dose (p = 0.01). 
However, our trial did not show a significant difference between both treatment arms in terms 
of FFCF (p = 0.68). In our opinion, this is because most of the patients with CF developed a 
rising PSA value long before their CF became clinically manifest and some of them (n = 22) 
were started with salvage HT before the point of their CF has occurring. The use of HT is a 
potential confounding factor in the analysis of the effect of high dose RT on the rate of DM and 
local failure since HT could destroy micro-metastases and subsequently postpone or even 
definitively eliminate the appearance of DM or local recurrence. Our study did not find a lower 
DM rate in patients treated with higher dose RT, the likely explanations are either our study was 
underpowered for this purpose and/or because of the used HT. Morgan et al. (23) reported a 
reduction in the rate of DM in two waves. In patients receiving a dose ≥ 74 Gy, especially the 
late wave of DM appeared to be reduced to a greater degree. The reduction of DM rate in the 
high dose arm of our trial might, therefore, become manifested much later than the BF. Another 
factor which makes the assessment of CF rate difficult is the fact that we did not systematically 
performed prostate re-biopsy for men with post-radiation increase in the level of PSA, because 
it was difficult to encourage elderly men to undergo re-biopsy as a surrogate end point for local 
control.
Overall survival
Another critical, but much more complicated issue is whether improved biochemical control 
will eventually lead to a significantly better overall survival. The impact of high-dose RT on OS 
has been reviewed. Mathematical studies by Kuban and Yorke (24, 25) predict an increase in 
survival of 16-30% if 100% local control could be reached. A retrospective analysis from the 
RTOG suggest an improved survival in patients who received high dose RT. In comparison with 
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patients who received < 66 Gy, high grade cancer patients who received radiation doses ≥ 66 
Gy had a 20% lower risk of death from prostate cancer and a 27% reduction in overall mortality 
(26). A clear OS benefit of dose escalation was also demonstrated in the systemic review of van 
Tol-Geerdink et al. (27). An estimated increase in 5 year survival ranging from 10 to 11% was 
reported when the equivalent dose was increased from 70 to 80 Gy. No single randomized trial, 
including our own, so far has demonstrated a significant survival benefit from dose escalation. In 
our trial the 7-year OS rates were 75% for both treatment arms (p = 0.45), probably because our 
trial was underpowered for this end point. Also no differences were observed in cause-specific 
mortality between both arms. However, using this metric might overestimate percentage of men 
who actually died of prostate cancer because competing mortality is substantial. This bias is 
more pronounced in older men, in patients with low-risk disease and increasing with each year 
of follow-up (28).
The already reported and the ongoing dose escalation trials are going to recruit, in total, over 
4500 patients. When the data of all these trials are completely available, a meta analysis of all 
these randomized trials should give the answer on this critical issue. The ongoing RTOG 0126 
trial, in which OS is the primary end point, will probably help us to further resolve this problem. 
In the subgroup analysis, the odds ratios in these subgroups were not significantly differ-
ent from the odds ratio of the total group, because of the overlapping confidence intervals. 
Therefore we cannot exclude the possibility that also low-risk patients, or perhaps a subgroup of 
them, might also benefit from dose escalation in terms of outcome. Our study was not designed 
to detect differences between treatment arms.
Toxicity
In this study, late morbidities following high dose RT for localized prostate cancer were in line 
with experiences from other dose escalation trials (3, 5, 7, 8). The cumulative incidence of late 
grade ≥ 2 GU toxicity was the same in both arms, while the cumulative incidence of late grade 
≥ 2 GI toxicity was increased in the high-dose arm. No differences were found in the rate of late 
GI and GU grade ≥ 3 toxicities between both arms. As already reported analysis on toxicity from 
our group, Peeters et al. (17) have shown an increased incidence of grade ≥ 2 late GI toxicity 
by high-dose arm, especially in patients with history of abdominal surgery and in patients with 
pre-treatment GI-symptoms. However, even excluding these patients from our analysis, we still 
found a significant increase in the grade ≥ 2 late GI toxicity in the high-dose arm (results not 
shown). 
Rectal bleeding and fecal incontinence occurred in the high-dose arm about twice as often 
compared to the low-dose arm. Fortunately, the incidence of rectal bleeding stabilized at 5 
year because there were no new patients diagnosed with bleeding. The incidence of fecal 
incontinence did not stabilize and therefore the overall GI toxicity did not stabilize. In the most 
available dose escalation studies, however late GI toxicity seems to stabilize after a follow-up 
of 5 years. A possible explanation for this difference is that in our study the scoring of fecal 
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incontinence was done by the patients themselves, using questionnaires. It is quite possible 
that in the other studies, this complication was underscored. As reported by other investigators, 
the incidence of late GI toxicity can be significantly lowered by using IMRT. In a study by Zelefsky 
et al. (29), the 3-year actuarial incidence of late GI grade ≥ 2 in patients managed by 81 Gy with 
IMRT was 2% compared with 14% in those treated with 3D-CRT by the same dose (p=0.005). 
Although the incidences of late GU toxicity are higher than those of late GI toxicity, no dose 
escalation trial has shown a significant differences in late GU toxicity with higher dose RT. 
However, it is well known that GU symptoms tend to accumulate and continue to emerge during 
the next 15 years after treatment. Gardner et al. (30) showed that short follow-up period might 
underestimate urinary problems. In their long-term analysis of toxicity of 77.4 Gy in patients with 
prostate cancer, they reported a 15-year incidence of grade ≥ 2 GU toxicity of 59%. Despite 
improved conformality of high dose levels of radiotherapy, all of the prostatic urethra receives a 
full dose. Therefore, we share the concerns of the investigators of the Massachusetts General 
Hospital about the possibility of increasing late GU toxicity with increasing follow-up period. 
We have, therefore, scheduled the next analysis after a median follow-up of about 12 years. 
However, we also recognize the possible shortcomings of a longer follow-up time, such as the 
high death rate of this already old population of patients from other cancers and intercurrent 
diseases and the usual increase in urinary symptoms with advancing age. These factors make 
it impossible to distinguish between GU symptoms due to aging process and those due to late 
radiation effects. 
Future research
Even with the substantial gains realized in the external beam radiotherapy for prostate cancer 
there is still room for further improvement. Beside dose escalations, another approach that has 
received attention is the hypofractionated technique (31). The disparity between a/b of about 
3-4 Gy for late complications and a/b ≤ 2 for prostate tumors raises the prospect that one 
might improve outcomes after conformal RT for prostate cancer with hypofractionation. These 
schedules might lead to improvement of the therapeutic ratio and could achieve economic and 
logistic advantages. Therefore, a randomized multicenter phase III study has been started in 
The Netherlands to compare the relapse-free survival and toxicity of 78 Gy in daily fractions of 
2 Gy with a hypofractionated schedule of 19 fractions of 3.4 Gy, 3 times/week, to a total dose 
of 64.6 Gy.
conclusions
The data presented here confirmed our earlier findings that dose escalation of RT in patients with 
localized prostate cancer is feasible and associated with a statistically significant improvement 
of FFF but without differences in FFCF and OS. These findings further substantiate conclusions 
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of other investigators that dose escalation is strongly recommended in the treatment of patients 
with prostate cancer, especially for intermediate- and high-risk groups, but we cannot exclude 
that patients with low-risk, or at least a subgroup of those patients, might also benefit from 
high-dose RT. Dose escalation is also associated with a statistically significant increase in late 
GI toxicity without increase in late GU toxicity. In our opinion, the higher rate of late GI toxicity can 
dramatically be lowered with the use of innovative radiotherapy techniques as IMRT and IGRT 
(image-guided radiotherapy). 
C
ha
pt
er
 2
36
references 
 1.  Perez CA, Hanks GE, Leibel SA, et al. Localized carcinoma of the prostate (Stages T1B, T1C, T2, and 
T3). Int J Radiat Oncol Biol Phys 1993;72:3156-3173.
 2.  Hanks GE. Optimizing the radiation treatment and outcome of prostate cancer. Int J Radiat Oncol Biol 
Phys 1985;11:1235-1245.
 3.  Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal 
radiotherapy in prostate cancer: PSA control and side effects. B J Cancer 2005;92:488-498.
 4.  Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized 
prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of 
radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-1996.
 5.  Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the 
M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-1105.
 6.  Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external beam 
radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer 
of the prostate. J Clin Oncol 2005;23:1192-1199.
 7.  Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized 
comparative trial of high dose irradiation boosting with conformal protons compared with conventional 
dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995;32:3-12.
 8.  Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal 
radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. 
JAMA 2005;294:1233-1239.
 9.  Horwitz EM, Thames HD, Kuban DA, et al. Definition of biochemical failure that best predict clinical 
failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional 
pooled analysis. J Urol 2005;173:797-802.
 10.  Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements 
with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 
2000;88:2305-2318
 11.  Kestin LL, Vicini FA, Martinez AA, et al. Practical application of biochemical failure definitions: what to 
do and when to do it. Int J Radiat Oncol Biol Phys 2002;53:304-315.
 12.  Roach M III, Hanks G, Thames H Jr., et al. Defining biochemical failure following radiotherapy with or 
without hormonal therapy in men with clinically localized prostate cancer. Recommendations of the 
RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
 13.  Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based 
on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 
1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:929-943.
 14.  Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason 
score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
 15.  Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk 
models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat 
Oncol Biol Phys 2004;59:380-385.
 16.  Bos LJ, Damen EMF, de Boer RW, et al. Reduction of rectal dose by integration of the boost in the 
large-field treatment plan for prostate irradiation. Int J Radiat Oncol Biol Phys 2002;52: 254-265.
 17.  Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy 
for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat 
Oncol Biol Phys 2005;61:1019-1034.
 18.  Cox J, Grignon D, Kaplan R et al. Consensus statement: Guidelines for PSA following radiation 
therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
Chapter 2 37
 19.  Gretzer MB, Trock BJ, Han M, et al. A critical analysis of the interpretation of biochemical failure 
in surgically treated patients using the American Society for Therapeutic Radiology and Oncology 
criteria. J Urol 2002;168:1419-1422.
 20.  Kuban DA, Tucker SC, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-
escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys Article in press.
 21.  Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radio-
therapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 
2007;6:459-460.
 22.  Buyyounouski MK, Hanlon AL, Pollack A, et al. Defining biochemical failure after radiotherapy with and 
without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 2005;63:1455-1462.
 23.  Morgan PB, Hanlon AL, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J 
Radiat Oncol Biol Phys 2007;67:1074-1081.
 24.  Kuban DA, El Mahdi AM, Schellhammer PF. Potential benefit of improved local tumor control in 
patients with prostate carcinoma. Cancer 1995;75:2373-2382.
 25.  Yorke ED, Fuks Z, Norton L, et al. Modeling the development of metastases from primary and locally 
recurrent tumors: comparison with clinical data base for prostate cancer. Cancer Res 1993;53:2987-
2993.
 26.  Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clini-
cally localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 
2000;18:2740-2746.
 27.  Van Tol-Geerdink JJ, Stalmeier PF, Pasker-de Jong PC, et al. Systematic review of the effect of 
radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J 
Radiat Oncol Biol Phys 2006;64:5343-5345.
 28.  Albersten PC, Hanley JA, and Murphy-Setzko M. Statistical considerations when assessing outcomes 
following treatment for prostate cancer. J Urol 1999;162:439-444.
 29.  Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal 
radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-881.
 30.  Gardner BG, Zietman AL, Shipley WU, et al. Late normal tissue sequelae in the second decade 
after high dose radiation therapy with combined photons and conformal protons for locally advanced 
prostate cancer. J Urol 2002;167:123-126.
 31.  Lukka H, Hayter C, Julian JA er al. Randomized trial comparing two fractionation schedules for 
patients with localized prostate cancer. J Clin Oncol 2005;23:6132-6138.

Chapter 3
The role of intensity modulated radiation 
therapy in reducing toxicity in dose 
escalation for localized prostate cancer
Abrahim Al-Mamgani 
Wilma D Heemsbergen 
Stephanie TH Peeters 
Joos V. Lebesque 
 Int J Radiat Oncol Biol Phys 2009;73:685-691 
C
ha
pt
er
 3
40
abstract
Purpose
To compare acute and late gastrointestinal (GI) and genitourinary (GU) toxicities in prostate can-
cer patients treated to a total dose of 78 Gy with either a 3D-conformal radiotherapy technique 
with a sequential boost (SEQ) or a simultaneous integrated boost using IMRT (SIB-IMRT).
Patients and methods
A total of 78 prostate cancer patients participating in the randomized Dutch trial comparing 68 
Gy to 78 Gy are the subject of this analysis. They were all treated in the same institution to a total 
dose of 78 Gy. The median follow-up was 76 months and 56 months for SEQ and SIB-IMRT 
respectively. The primary end points were acute and late GI and GU toxicity. 
Results
A significantly lower incidence of acute grade ≥ 2 GI toxicity occurred in patients treated with 
SIB-IMRT compared to SEQ (20% vs 61%, p = 0.001). For acute GU toxicity and late GI and 
GU toxicity, the incidences were lower with SIB-IMRT, but these differences were not statistically 
significant. There was no statistically significant difference in 5-year freedom from biochemical 
failure (Phoenix) between the two groups (70% for the SIB-IMRT vs 61% for the SEQ, p = 0.3). 
The same was true for the 5-year freedom from clinical failure (90% vs 72%, p = 0.07). 
Conclusion 
The results of our study have shown that SIB-IMRT reduced the toxicity without compromising 
the outcome in patients with localized prostate cancer treated to 78 Gy radiation. 
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introduction
Confirmation that high dose radiotherapy (RT) improves biochemical no evidence of disease 
(bNED) comes from different randomized dose escalation trials (1-4). Our Dutch phase III trial, 
comparing 68 Gy to 78 Gy, has shown 11% improvement of 7-year FFF (Phoenix) from 45% in 
the low-dose arm to 56% in the high-dose arm (p = 0.03) (4). However, the improved biochemi-
cal control in these dose escalation studies was also associated with an increased rate of late 
complications, mainly late GI toxicity. In our Dutch phase III trial the 7-year rate of late grade ≥ 
2 GI toxicity was 35% in high-dose arm vs 25% in the low-dose arm (p = 0.04) (4). As already 
known, GI complications were already reduced using 3D conformal RT (3D-CRT) rather than 
conventional RT techniques (5). Despite these tremendous gains, the radiation oncology com-
munity continues to struggle with the question how to further reduce the late complications of 
RT, because decreasing these complications has an important impact on the quality of life of 
prostate cancer patients treated with high dose RT. IMRT is a new conformal RT technique that 
produces highly conformal dose distributions, facilitating selective dose escalation to the target 
volume with acceptable normal tissue dose, therefore producing better local tumor control 
without a concomitant increase in normal tissue toxicity. In a prostate cancer study by Zelefsky 
et al. (6), the 3-year actuarial incidence of late grade ≥ 2 GI toxicity in patients managed by 81 
Gy with IMRT was 2% compared with 14% in those treated with 3D-CRT by the same dose 
(p=0.005). These data serve as proof-of-principle that IMRT can effectively reduce the volume 
of normal tissue irradiated to higher doses. 
To further validate this approach, an unplanned subset analysis was performed to compare 
the toxicity of 41 prostate cancer patients treated with IMRT to 78 Gy with that of 37 patients 
treated with the 3D-CRT approach at the same dose level within the Dutch dose escalation trial.
Patients and methods
Participants 
Seventy-eight prostate cancer patients participating in a Dutch randomized trial comparing 68 
Gy to 78 Gy (4, 5) are the subject of this analysis. They were all treated in the same institution 
to a total dose of 78 Gy. Details on pre-treatment imaging, planning, patient preparation and 
delivery of treatment to patients participated in that trial are described thoroughly elsewhere 
(4, 5). In brief, four dose-volume groups were defined according to the risk of involvement of 
the seminal vesicles (SV), as described by Partin et al. (7). Patients with a T1b, T1c and T2a 
prostate cancer with a risk of involvement of < 10%, 10-25% and > 25% were included in dose-
volume groups I, II and III respectively. All patients with a T2b and T3a were treated in group 
III. Group IV comprised all patients with a T3b or T4. For each dose-volume group, specific 
planning target volumes (PTV) were defined. The clinical target volume (CTV) for treatment group 
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I was defined as the prostate only, and for group IV, it was the prostate and the SV. For treatment 
group II and III the CTV also included the prostate and SV, but the SV was excluded from the 
CTV after 50 and 68 Gy, respectively. The mean dose to the PTV was between –5% and +7% 
of the prescribed dose, and 99% of the PTV received ≥ 95% of the prescribed dose. The PTV 
included the prostate with or without the SV as CTV, with a margin of 10 mm during the first 68 
Gy and 5 mm (except towards the rectum 0 mm) for the last 10 Gy in both groups. 
Radiation treatment
Two different techniques were used; a 3D-conformal technique using a sequential boost (SEQ) 
and an IMRT technique using a simultaneous integrated boost (SIB-IMRT). The SEQ was used 
at the beginning of the trial, while the SIB-IMRT was introduced later. The first thirty-seven 
patients were treated with a SEQ technique using one anterior and 2 lateral wedged fields. 
The following 41 patients were treated with a SIB-IMRT technique as described by Bos et al. 
(8). For these patients the boost region was irradiated to 78 Gy with a fraction size of 2 Gy. 
The PTV minus the boost region was defined by the 5-10 mm shell formed by the PTV from 
which the boost region was subtracted. For the large-field and boost irradiation, we employed 
five fields consisting of intensity-modulated beams, applied in a “step-and-shoot” mode, using 
several segments per beam orientation. The SIB-IMRT technique combines the large-field and 
the boost irradiation plan. Hence, the SIB-IMRT consists of five beam orientations consisting 
of 11 segments that were defined for the PTV and 11 segments defined for the boost region. 
Beam-weight optimization of the plans was performed using an optimization module of the 
treatment planning system (8). A verification procedure, using orthogonal portal imaging, with 
decision rules for setup corrections was specified according to the guidelines published by a 
collaborative study in The Netherlands. Using this protocol, systemic errors should not exceed 
5 mm (9).
Toxicity
Patients completed a self-assessment questionnaire at the start of therapy, during therapy and 
at each follow-up visit. Side effects occurring within 120 days from start of RT were considered 
to be acute toxicity. Late toxicity was scored from 120 days after start of the treatment. For 
acute morbidity we used a slightly modified RTOG scoring system. For late toxicity the patient’s 
questionnaire, together with the physicians notes, were used to classify late GI and GU symp-
toms according to the GI and GU RTOG/EORTC scoring systems (10). Because we know that 
a general toxicity scale such as the RTOG/EORTC should not be used alone to investigate 
dose-volume effects because of the possible loss of information (11), we used for the evalua-
tion of late toxicity more detailed GI and GU symptoms, called ‘indicators’, in order to be able to 
analyze the origin of high scores and differences between the various scoring systems. Scoring 
for an indicator results in a grade ≥ 2 in one or both scoring systems. Six indicators were defined 
for the GU symptoms and 5 for GI symptoms.
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As shown in Table 1, we have generated different dose-volume histogram (DVH) parameters 
which were strongly correlated with acute and late GI and GU toxicities in different studies (2, 
11, 12, 13). The rectal parameters derived were maximal dose, mean dose, and the relative 
rectal wall volumes receiving 35, 60, 65 and 70 Gy (rV35, rV60, rV65 and rV70). For the 
bladder, the absolute dose-surface histograms (DSHs) of the bladder surface were generated 
for each patient. Hoogeman et al. (14) from our group, found that the absolute histograms were 
more invariant under changes in the bladder filling during treatment than the relative histograms. 
The bladder parameters derived were maximal dose, mean dose, and the absolute bladder 
surface receiving 30, 45, 65 and 80 Gy (aS30, aS45, aS65, and aS80). 
Many authors reported on the predictive value of acute proctitis for the development of late 
grade ≥ 2 GI toxicity (15-17). We looked, therefore, specifically to the incidence of that endpoint 
in our patients.
Outcome
FFF was defined as biochemical (BF) or clinical failure (CF), whichever was first. BF was defined 
according to the Phoenix definition (rise of ≥ 2 mg/L greater than the PSA nadir after RT) because 
in the recent publications this definition seems to be a better approximation of eventual CF than 
the ASTRO-definition (18). CF included local relapse, regional relapse, distant metastases or 
initiation of salvage HT.
Table 1. Dosimetric parameters for rectum and bladder
 SEQ SIB-IMRT p-value
Rectum
Dmean (Gy) 47.6 46.3 0.3
Dmax (Gy) 78.8 76.8 < 0.001
rV35 (%) 68 72 0.08
rV60 (%) 39 30 < 0.001
rV65 (%) 33 22 < 0.001
rV70 (%) 26 15 < 0.001
Bladder
Dmean (Gy) 44.5 45.5 0.6
Dmax (Gy) 79.7 79.8 0.6
aS30 (cm2) 143 126 0.08
aS45 (cm2) 122 90 < 0.001
aS65 (cm2) 68 51 < 0.001
aS80 (cm2) 2.1 1.3 0.3
Abbreviations: SEQ: sequential boost 3D-CRT; SIB-IMRT: simultaneous integrated boost with IMRT; rV35: relative volume of rectum 
received 35 Gy; aS30: absolute bladder surface received 30 Gy. Statistically significant (Log rank test) differences (p < 0.05) are 
indicated in bold.
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Follow-up
Follow-up visits were scheduled once every three months in the first year, every four months 
in the second year, biannually in the following three years and yearly thereafter. When patients 
were diagnosed with a loco-regional recurrence or distant metastasis, further assessment 
of complications was omitted from that moment on, as distinction between treatment- or 
recurrence-related symptoms can be difficult.
Statistical analysis 
The occurrence of acute and late GI and GU toxicities was the primary end point in our analy-
sis. Cumulative incidences of toxicity at 5 years were calculated using Life Table estimates. 
For comparing the toxicities between the two techniques, the total curves were evaluated by 
calculating Log Rank statistics. 
 Table 2. Distribution of patients by pretreatment characteristics and treatment technique
SEQ SIB-IMRT
n=37 n=41
Mean age (years) (SD)  69.1 (6.3)  68.3 (6.1)
Median follow-up (months) 76 56
Dose-volume groups
 Group I  2 (6%)  3 (7%)
 Group II  7 (19%)  11 (27%)
 Group III  19 (51%)  22 (54%)
 Group IV  9 (24%)  5 (12%)
T-stage
 T1  3 (8%)  13 (32%)
 T2  17 (46%)  15 (38%)
 T3  17 (46%)  13 (32%)
Gleason score
 2-4  3 (8%)  4 (10%)
 5-7  28 (76%)  29 (70%)
 8-10  6 (16%)  8 (20%)
Abdominal surgery  12 (32%)  6 (15%)
Mean initial PSA (µg/L) (SD)  17.3 (10.1)  15.5 (12.3)
Hormonal therapy  10 (27%)  17 (41%)
TURP  3 (8%)  3 (7%)
Diabetes mellitus  3 (8%)  4 (10%)
Cardiovascular history  14 (38%)  18 (44%)
Smoking  9 (24%)  13 (32%)
Use of acetyl salicylic acid  7 (19%)  6 (15%)
Abbreviations: SEQ: sequential boost 3D-CRT; SIB-IMRT: simultaneous integrated boost with IMRT; SD: standard deviation; TURP: 
transurethral resection of the prostate
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results
Pre-treatment characteristics for both treatment techniques are shown in Table 2. More patients 
with a past history of abdominal surgery were treated with SEQ than with SIB-IMRT (12 vs 6, 
p = 0.06). The lower abdominal surgery which is expected to cause higher complication rate 
was equally distributed between both groups (5 vs 4). More patients treated with SEQ had 
upper abdominal or laparoscopic surgery (7 vs 2). More patients with dose-volume group IV 
were treated with SEQ than with SIB-IMRT (24% vs 12%), but this difference was statistically 
not significant (p = 0.3). The median age of both groups of patients was 69 year. The median 
follow-up was 76 months (range 12-110) and 56 months (range 30-77) for the SEQ and SIB-
IMRT, respectively. The SEQ was used at the beginning of the trial, while the SIB-IMRT was 
introduced later. This is the main reason why the follow-up of patients treated with SEQ is longer 
than those treated with SIB-IMRT. 
Toxicity
As shown in Figure 1, there was a significantly higher incidence of acute grade ≥ 2 GI toxicity 
in patients treated with SEQ compared to SIB-IMRT (61% vs 20%, p = 0.001). No patient 
treated with SIB-IMRT developed acute grade ≥ 3 GI toxicity, while 5 patients (13%) in the 
SEQ-group developed acute grade ≥ 3 GI toxicity (p = 0.001). The incidence of acute proctitis 
was significantly reduced by using SIB-IMRT compared to the SEQ (15% vs 38%, p = 0.03). 
The incidence of acute grade ≥ 2 GU toxicity was higher with the SEQ, but this difference was 
statistically not significant (69% vs 53%, p = 0.3). Regarding the incidences of acute grade ≥ 3 
GU toxicity, no differences were found between both groups.
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Figure 1. Incidences of acute GI and GU toxicity for SEQ (conformal) and SIB-IMRT.
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As shown in Tables 3, Figure 2A and 2B, both incidences of late GI and GU toxicities were 
lower in patients treated with SIB-IMRT than with SEQ, but the differences were statistically 
not significant. The cumulative incidence of late grade ≥ 2 GI toxicity at 5 year was 21% for 
SIB-IMRT group and 37% for SEQ group and (p = 0.16), while the incidence of late grade ≥ 3 GI 
toxicity at 5 year was 0% and 7%, respectively (p = 0.1). The cumulative incidence of late grade 
≥ 2 GU toxicity at 5 year was 43% for SIB-IMRT group and 45% for SEQ group (p = 1.0), while 
the cumulative incidence of late grade ≥ 3 GU toxicity at 5 year was 15% and 22%, respectively 
(p = 0.5). Also for all other endpoints (indicators), except for ‘pain/cramps/tenesmus requiring 
medication’, dysuria, and ‘frequency during day’ the cumulative incidences of toxicity were 
lower using SIB-IMRT, but these differences were statistically not significant.
Figure 3A and Table 1 show that from all the analyzed relative rectal DVH parameters, V60, 
V65 and V70 were significantly reduced by using SIB-IMRT compared to SEQ (p = < 0.001). 
Regarding absolute DSH parameters of the bladder, aS45 and aS65 were significantly reduced 
by using SIB-IMRT compared to SEQ (p = < 0.001). Both aS30 and aS80 were also lowered, 
although statistically not significant (p = 0.08 and p = 0.3, respectively) (Figure 3B and Table 1). 
Table 3. Cumulative incidence at 5 years (Life Table estimates) for all late GI and GU endpoints, including grade ≥ 2 toxicity 
indicators comparing SEQ and SIB-IMRT.
Cumulative incidence at 5 years (%)
Endpoints SEQ SIB-IMRT p-value
GI
 RTOG/EORTC ≥ 2 37 21 0.16
 RTOG/EORTC ≥ 3 7 0 0.1
 Rectal bleeding (laser / transfusion) 10 3 0.2
 Fecal incontinence (pads > 2 days a week) 9 8 0.7
 High stool frequency ( ≥ 6 a day) 21 5 0.06
 Steroids for proctitis 7 0 0.1
 Pain/cramps/tenesmus requiring medication 11 13 0.5
GU
 RTOG/EORTC ≥ 2 45 43 1
 RTOG/EORTC ≥ 3 22 15 0.5
 Haematuria (laser / transfusion) 4 0 0.3
 Urinary incontinence (pads > 2 days a week) 20 6 0.1
 High urinary frequency during the day ( ≥ 16) 0 7 0.09
 Nocturia ( ≥ 4) 33 30 0.9
 Dysuria requiring medication 18 20 0.5
 Urinary obstruction requiring treatment 18 10 0.4
Abbreviations: GI: gastrointestinal; GU: genitourinary; SEQ: sequential boost 3D-CRT; SIB-IMRT: simultaneous integrated boost. 
p-value: Log rank test.
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Figure 2A. Kaplan-Meier curve of the cumulative incidences of late GI RTOG/EORTC grade ≥ 2 toxicity for both treatment 
techniques.
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Outcome
There was no statistically significant differences in 5-year FFF rate (Phoenix) and 5-year freedom 
from clinical failure (FFCF) between both groups (FFF 70% for the SIB-IMRT vs 61% for the SEQ 
; p = 0.3, FFCF 90% vs 72%, p = 0.07). However, these results should be interpreted with 
caution because of the non-randomized nature of the cohorts.
discussion
The significant improvement in bNED in different randomized dose escalation trials (1-4) for 
prostate cancer patients was associated with increased side effects. Late grade ≥ 2 rectal 
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Figure 3A. Cumulative dose-volume histogram of anorectal wall (relative) for SEQ and SIB-IMRT shows that the rectal wall volume 
irradiated to any dose is lowered by using IMRT, except for the intermediate-dose region (35-45 Gy). Error bars indicate 1 standard 
deviation.
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Figure 3B. Cumulative dose-surface histogram of bladder wall (absolute) for SEQ and SIB-IMRT shows that the bladder surface 
irradiated to any dose is lowered by using IMRT. Error bars indicate 1 standard deviation.
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toxicity was increased from 25% to 35% at 7-years (0.04) in our Dutch trial (4), from 12% to 26% 
at 6-years (p = 0.001) in the trial of the M.D. Anderson Cancer Center (2) and from 9% to 18% 
at 5-years (p = 0.005) in the MGH/Loma Linda University Medical Center trial (1). In an attempt 
to reduce these toxicities without compromising the outcome, we have used the advantage of 
IMRT in enhancing conformality and allowing greater sparing of the surrounding normal tissues. 
In this study we found a significant decrease in acute GI toxicity by using IMRT. The late GI, 
early and late GU toxicities were also decreased, albeit statistically not significant. Regarding 
outcome, patients treated with IMRT technique had comparable FFF and FFCF. 
Different studies have also shown that despite the enhanced conformality achieved with 
implementing an IMRT-technique, the bNED is apparently not compromised. In a study by 
Zelefsky et al. (6), the 3-year actuarial incidence of late grade ≥ 2 GI toxicity in patients managed 
by 81 Gy with IMRT was 2% compared with 14% in those treated with 3D-CRT by the same 
dose (p=0.005), while the 3-year bNED was similar in patients treated with both techniques 
and varied from 92% for favorable and 81% for unfavorable risk groups. The therapeutic gain 
achieved in our study and in that of others is likely owing to the dosimetric advantages of 
IMRT. In most reports, no correlation between rectal DVHs and acute rectal toxicity could be 
found (2, 19), whereas this correlation was clearly demonstrated in the study of Peeters et al. 
(12) from our group. They showed that rectal wall volumes treated to intermediate (V35) and 
high doses (V65) were significant variables in predicting acute GI toxicity in the multivariate 
analysis. Even with a low V65 (10%), the probability of acute GI toxicity was still around 40% 
(12). The significant decrease in acute grade ≥ 2 GI toxicity observed in our patients treated with 
SIB-IMRT compared to those treated with SEQ (p = 0.001) may be explained by the significant 
reduction of V65 (p = < 0.001) by using IMRT. 
Several authors have pointed out the importance of different DVH parameters for the devel-
opment of late GI toxicity. V60, V65, and V70 were the most significant parameters associated 
with late grade ≥ 2 GI toxicity (2, 11, 12). In many ways, it should not be surprising that we 
have also shown a decrease in late GI toxicity by using IMRT in comparison with 3D-CRT, 
albeit statistically not significant. Pollack et al (2) concluded in the M.D. Anderson study that 
dose escalation techniques limiting the V70 to < 25% will dramatically reduce late GI toxicity. 
According to that study, when the V70 was limited to ≤ 25%, the overall late grade ≥ 2 GI toxicity 
at 6 year was 16%, compared with 46% by a V70 > 25% (p = 0.001). In our patients, we found 
a V70 of 14% and 26% for SIB-IMRT and SEQ, respectively (p < 0.001), with a corresponding 
decrease in late grade ≥ 2 GI toxicity. V65 is the most significant parameter associated with 
rectal bleeding according to Peeters and colleagues (12). The incidence of this complication 
at 4 years was only 1% when V65 was below 23%, whereas it was about 10% when V65 was 
≥ 28%. In this analysis, we found a V65 of 22% in patients treated with SIB-IMRT vs 33% in 
patients treated with SEQ (p < 0.001), with the corresponding incidences of rectal bleeding at 
5 years of 3% vs 10%, respectively (p = 0.2). 
C
ha
pt
er
 3
50
The significant reduction of acute GI toxicity achieved with IMRT might also be partially 
responsible for the subsequent reduction of the late GI toxicity. A number of investigators have 
shown a strong correlation between the incidence and severity of acute and chronic GI toxicity 
in prostate cancers treated with RT (15). Heemsbergen et al. (15) concluded that acute GI 
toxicity and more specifically acute proctitis were both significant predictors of late GI toxicity, 
suggesting a significant consequential component in the development of late grade ≥ 2 GI tox-
icity. Patients with acute proctitis had a higher risk for developing late grade ≥ 2 GI toxicity with 
40% cumulative incidence at 5-year vs 16% in patients without acute proctitis. The significant 
decrease in the incidence of acute proctitis achieved with use of IMRT in our patients (from 
38% to 15%, p = 0.03) might lead to further decrease in late grade ≥ 2 GI toxicity with longer 
follow-up. Acute proctitis as a predictor of late GI toxicity was also reported by Denham et al. 
(16) and Zelefsky et al. (17).
Regarding GU toxicity, Peeters et al. (12) found a significant correlation between acute GU 
toxicity and aS45 and aS65 at the multivariate regression analysis. In our analysis, both aS45 
and aS65 were significantly decreased by using IMRT technique (p < 0.001). In order to reduce 
late grade ≥ 3 GU toxicity and grade ≥ 2 urinary retention, Harsolia et al. (13) recommended to 
limit the V30 to < 30 cm3 and the V82 to < 7 cm3, when possible. In our group, both parameters 
were reduced by using IMRT. Cheung et al. (20) found a significant higher rate of late GU toxicity 
when the dose to 2.9% of the bladder was ≥ 78 Gy. Once again, this parameter was also 
reduced in our patients treated with SIB-IMRT and was < 2.9 % (results not shown). However 
bladder doses were lowered with IMRT in our patients (Table 1 and Figure 3B), but this still did 
not translate to reduction of acute and late GU toxicity. The lack of differences in observed rate 
of late GU toxicity between both techniques may related to similarities in urethral dose, which 
was not specifically constrained, because we know that all of the prostatic urethra receives a 
full dose as well by using 3D-CRT as by IMRT technique. Whether IMRT can restrict the dose to 
the urethra without creating unacceptable cold spots in the PTV is unknown. 
Peeters et al. (10) from our group performed a Cox proportional hazard analysis testing all 
potential prognostic clinical factors for the end points late grade ≥ 2 GI and GU toxicity and 
found that a history of abdominal surgery and pre-treatment GI symptoms were associated with 
a higher incidence of late grade ≥ 2 GI toxicity, whereas hormonal therapy, pre-treatment GU 
symptoms, and prior transurethral resection of the prostate were all highly significant (p ≤ 0.006) 
prognostic factors for late grade ≥ 2 GU toxicity. These prognostic clinical factors were equally 
distributed among both groups and have, therefore, not influenced the incidence of late toxicity 
in our analysis. However, more patients in the SIB-IMRT had upper abdominal or laparoscopic 
surgery than in the SEQ group, the incidence of GI toxicity is unlikely to be influenced by this 
type of surgery.
Our analysis contains a number of limitations. First, the follow-up is relatively short, espe-
cially for late GU toxicity, and the number of patients treated is limited. Although the SEQ and 
SIB-IMRT groups were well-balanced in terms of patient’s characteristics, the major difference 
Chapter 3 51
between both groups was the significantly longer follow-up in the SEQ patients. This was due 
to the relatively recent implementation of IMRT in our patients at that time. The difference in 
number of patients of group IV (24% vs 12%, p = 0.3) could possibly have biased the results of 
the reduced GI toxicity for the SIB-IMRT group. In order to study the impact of this difference, 
we did an additional analysis of GI toxicity after stratifying patients in 4 dose-volume groups. 
The acute and late GI toxicity was still better in patients treated with SIB-IMRT (p= 0.001 and 
p = 0.1, respectively). Moreover, the rectum dose in group II-IV was similar, but higher than in 
group I. The distribution of our patients among group I and group II-IV was identical. Therefore 
the distribution of patients among the dose-volume groups might not have biased our results 
regarding GI toxicity. The difference between both groups regarding FFF might have been 
influenced by the slightly more patients in group IV treated with SEQ than with SIB-IMRT.
Our results raise also the question whether the improvement seen here is also clinically 
significant. Although low grade symptoms were common, these are not trivial and may results in 
considerable distress with subsequent decrease in the quality of life of these patients. Denham 
et al. reported that fecal urgency and bleeding have the highest impact on quality of life (16), 
while the analysis of Koper et al. revealed that mucus discharge, soiling and fecal loss were the 
most bothering complaints (21). It is our belief that the favorable impact of IMRT on chronic GI 
sequelae is clinically significant and justifies the increased cost and time of IMRT planning and 
treatment in these patients.
Another potential concern that has been raised with the use of IMRT-treatment delivery tech-
nique is the greater chance of geometrical uncertainties. As a result of enhanced conformality, 
one might be afraid of increasing treatment uncertainties and target motion with IMRT. Bos et 
al. (22) have applied different IMRT-techniques for 5 patients in order to determine the effect of 
geometrical uncertainties on IMRT dose distributions for the prostate. They found that the IMRT-
technique used in our patients to be insensitive to geometrical uncertainties (organ motion and 
patient set-up) and guarantees adequate coverage of the CTV. Therefore, we can reasonably 
conclude that concerns about geographic miss of the target are unfounded, also because our 
results showed comparable biochemical and clinical control rates for patients treated with IMRT 
compared to those treated with 3D-CRT.
Finally, we believe that the recent implementation of image-guided RT will further enhance 
the safety and accuracy of IMRT by better correction of both inter-fraction positional variation 
and intra-fraction prostate motion and achieve, therefore, further decrease in the late toxicity. 
conclusion
Our results provide the first assessment of toxicity in prostate cancer patients treated with IMRT 
within the Dutch dose escalation trial. The acute toxicity is significantly lowered by using IMRT. 
Overall, the risk and severity of chronic GI toxicity in these patients were low and compared 
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favorably to that seen in patients treated with SEQ. Moreover, the improved toxicity profile 
achieved with IMRT was not achieved at the cost of tumor control. However, these results 
should be interpreted with caution, given the relatively short follow-up and limited number 
of patients. Nonetheless, our results are promising and suggest that the dosimetric benefits 
achieved with IMRT planning in prostate cancer patients may translate into long-term benefits in 
patients’ outcome and toxicity. 
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abstract 
Purpose
To investigate the relationship between late urinary obstruction and details of the dose distribu-
tion of irradiated prostate cancer patients, taking into account baseline symptoms and acute 
complaints.
Methods
We selected patients of the Dutch multicenter trial randomizing between 68 Gy and 78 Gy, for 
whom toxicity data and dose data were available (n = 557). Absolute dose surface parameters 
of the delineated bladder were calculated. Next we constructed 3D dose maps of the area 
around the prostate, providing an approximate identification of corresponding anatomical loca-
tions. Dose difference maps were constructed by subtracting the mean dose maps of patients 
with and without late urinary obstruction. Selected local dose points were analyzed in a Cox 
regression analysis.
Results
For 40 patients late urinary obstruction was scored: 19/296 patients receiving 68-72 Gy, 
21/261 76-78 Gy. There were 19 events within 2 years after irradiation and 21 later on. The 
bladder surface receiving ≥ 80 Gy predicted (p< 0.01) for obstruction within 2 years. The 
dose difference map indicated highly significant differences in the bladder neck situated in 
the trigonal region (p< 0.001), which where especially predictive for obstructions after 2 years 
and for diagnosed bladder neck obstruction. Baseline complaints as well as TURP and acute 
complaints were mainly predictive for obstruction within 2 years.
Conclusions
Relatively early events of urinary obstruction are associated with urinary problems existing 
before RT, acute toxicity, previous TURP and hotspots in the bladder. Events after a lag period 
of 2 years were associated with the local dose in the trigonal area.
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introduction 
External radiotherapy for prostate cancer is the main treatment option when there is considerable 
risk for tumor invasion of the prostatic capsule and/or seminal vesicles. Nowadays conformal 
radiotherapy with dose levels of 74-80 Gy has become clinical practice since several studies 
reported improved freedom from failure compared to levels of 64-70 Gy. (1) Side-effects of 
radiotherapy mainly concern the rectum and bladder. A severe complication can be urinary 
retention. This symptom is in most cases the result of a severe outflow obstruction (stricture) in 
the bladder neck or urethra, which can be divided in the proximal part close to the bladder neck, 
the prostatic urethra, and the distal urethra near the external sphincter. Possible other causes of 
obstruction are ureter obstruction, and an enlarged prostate.
In a recent study (2) of prostate cancer patients (n = 6597), the estimated cumulative 
incidence of treated urethral strictures at 4 years was 5 % for external radiotherapy, 11 % for 
brachytherapy and 11 % for radical prostatectomy. In their study they noticed that prostatec-
tomy and brachytherapy leads to relatively early obstructions (within 24 months) whereas onset 
of obstruction was delayed after radiotherapy. Harsolia et al. (3) studied a trial population of 332 
patients with a median follow up of 1.6 years who received high doses (median 79 Gy). The 
cumulative incidence of treated urinary retention at 3 years was 5 % in their population. In our 
Dutch trial, the cumulative incidence at 3 years was similar: 6 % in the 78 Gy arm and 4 % in the 
68 Gy arm. (4) At 7 years this incidence was increased to 11 % and 8 %. (1) 
Data on hypothesized radiation dose-effect relationships concerning urinary toxicity are not 
conclusive. The elderly patient population is also subject to development of complaints due to 
aging, which obscures toxicity scoring. Another aspect is that a number of these patients were 
visiting an urologist because of pre-existing urinary problems, when their prostate cancer was 
diagnosed. Apart from determining the most relevant toxicity, also the measurement of relevant 
dose parameters is not trivial. Studied dose parameters are usually derived from the total 
delineated bladder without evaluating local structures (like the bladder neck) separately. Due 
to variable filling and stretching of the bladder during treatment, the position of the bladder on 
the planning CT scan is probably of limited value which can obscure dose-effect relationships. 
A number of reported baseline parameters associated with GU toxicity are: prostate volume, 
hormonal therapy, diabetes and TURP (3-5). A consequential relationship between acute and 
late GU toxicity has also been reported (3, 6, 7). 
In the present study, we investigated the relationship between dose parameters and late 
urinary obstruction, taking into account baseline problems and specific acute complaints. We 
analyzed absolute dose surface data as well as dose maps representing the dose in the total 
“bladder region” around the prostate. We hypothesized that such dose maps could be useful 
to identify more local dose-effect relationships for late GU toxicity. 
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Patients and methods
Patient group
In the Dutch trial, 664 patients were randomized to 68 Gy or 78 Gy. Its patient population and 
treatment has been described extensively elsewhere (1, 4). We selected patients for whom 
acute and late toxicity was scored using checklists, which was the case for most of the patients 
treated at two hospitals (n=566). For five patients, no late toxicity data were available due to 
limited follow-up and for four patients, not all dose data were available, leaving 557 patients for 
our current analysis. 
Treatment
Treatment plans were constructed using CT scan data. The Clinical Target Volume (CTV) was 
defined as the prostate or prostate plus seminal vesicles (SV), depending on the estimated risk 
of SV invasion. Delineations were done in the transversal CT slides and at that time the software 
did not allow to check delineations in sagittal view, which caused typical deformations like the 
CTV shape in Fig. 1. There was no MRI available to establish the border between prostate 
and bladder neck; therefore part of the bladder neck was included in the CTV for a number of 
patients. A 1 cm margin was applied to the CTV for construction of the Planning Target Volume 
(PTV) for the first 68 Gy (2 Gy per fraction). A margin of 5 mm (0 mm towards the rectum) was 
applied for the 10 Gy boost. Bladder and rectum were delineated. For the bladder there were 
no dose constraints in the trial protocol. 
Toxicity scoring
Acute (28-120 days after start of RT) and late toxicity (> 120 days) was scored by the trial 
data managers, using the RTOG/EORTC and LENT/SOMA toxicity scales. (4) Patients reported 
complaints on a checklist, before during and after radiotherapy. This checklist included: (high) 
frequency during day and/or night, pain/cramps when passing urine, urinary incontinence 
(leakage) and a weak urinary stream. We labeled patients as having urinary obstruction when 
they were treated for symptoms of (complete) urinary retention: scoring on Grade ≥2 items of 
catheterization, TUR and / or dilatation. We also analyzed the events by defining relatively early 
events and events after a lag period. As a cutoff we took 2 years of follow-up. Because of the 
delay in reporting events (follow up was scheduled every 3-6 months) we included events 
reported up to 26 months after start of radiotherapy as events < 2 years. 
Dose Surface Histogram parameters 
We used a volumetric database that had direct access to the CT images, dose distributions and 
delineations. For each patient the outer bladder wall was delineated on the planning CT scan 
and the 2D contours were triangulated to a 3D surface. We calculated the absolute surface 
receiving ≥ 5 Gy – ≥ 80 Gy, with dose steps of 5 Gy. As described by Hoogeman et al. (8), 
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absolute dose-surface data are the best choice because they are less variant under bladder 
filling changes than relative data or dose-volume data.
Construction of dose maps 
Dose maps offer a method to compare or combine the treatment planning dose distributions of 
different patients in 3D. We visualized the dose in the bladder region using dose maps, without 
considering the delineated bladder contours. Within 6 cm outside the prostate surface of each 
patient, the dose was calculated for the same set of dose points, defined by their radius from 
the surface and their direction relative to the center of mass (given by two angles). We started 
with the coordinates of dose grid voxels of a first patient (the template patient). For all other 
patients, dose values for the same sets of radius - angle values were calculated, by trilinear 
interpolation of the nearest dose points of the individual dose grid. In this way, the obtained dose 
maps of all patients were comparable and could be averaged by averaging the dose in the dose 
points with identical radius and angle. Mean dose maps of patients without and with obstruction 
were created and subtracted to form a dose difference map. This map visualizes the local areas 
where patients with obstruction received more dose than patients without obstruction. For each 
point in the dose difference maps, we also calculated the p value for the local dose differ-
ence (based on t-distributions) in order to determine roughly the regions of interest. Mapped 
dose distributions were visualized using the anatomy of the template patient. This patient had 
a prostate volume of 52 cm3, a rectal volume of 41 cm3, and a bladder volume of 389 cm3. 
Selection of dose points
From our dose difference maps, we selected 2 dose points for further evaluation. First, we 
selected a dose point (referred to as trigone point) in the trigonal area of our template patient. 
The trigonal area is defined as the triangle-shaped area where the bladder neck is situated, the 
urethra starts, and where the ureters end in the bladder. For this purpose, we looked up the 
coronal CT slice where the prostatic urethra was visible (Fig. 1A) and we followed visually the 
urethra to the prostate edge where the urethra starts. Then we marked a point in the trigone 
area 2 cm above the starting point of the prostatic urethra. It is not expected to find dose-effect 
relationships for dose points closer to the prostate contour and bladder neck because this part 
will be mainly situated in the PTV, receiving about the same dose as the targeted prostate. We 
also picked a second dose point in the dose difference map where the dose differences were 
most significant (referred to as max point). 
Validation of dose maps
We picked the trigone point in our template patient, assuming that this point was situated in 
the trigone area for all other patients as well. In order to validate this assumption, we manually 
checked this for 69 patients. For this purpose, we determined individually the correspond-
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ing point in the same way as we did for the template patient (as described in the previous 
paragraph). 
The local dose and the anatomical position (dose map coordinates) of this manual trigone 
point were then compared with those of the trigone point from the mapping procedure. For this 
procedure we selected 23 patients with a determined bladder neck obstruction and/or obstruc-
tion later than 2 years and we randomly picked another 46 patients by selecting the study 
number above and below the patients with obstruction. Patients with hotspots were excluded.
The dose in the trigone point according the manual procedure correlated highly with the dose 
in the trigone point according the automated dose mapping procedure (Pearson correlation 
coefficient was 0.92). The mean dose in the selected obstruction group (n = 23) was 57.3 Gy 
according the dose mapping and 58.0 Gy according to the manual procedure. For the group 
without obstruction (n = 46) these numbers were 47.2 Gy and 47.5 Gy, respectively. The mean 
Figure 1. Figures. 1A and 1B. Coronal and sagittal view of a CT scan in the prostate/bladder region for the template patient (blue: 
bladder, black: prostate, dark red: rectum). The cross indicates the trigone point 2 cm above the starting point of the prostatic 
urethra, in a coronal slice where the urethra is visible. The asterisk in Fig. 1B indicates the region where the largest dose differences 
are found (Fig. 1EF).
Figures 1C and 1D. The average planned dose for all patients, in corresponding coronal and sagittal view. Apart from the delineated 
organs, contours of standard deviations are included to indicate roughly where the largest dose variations are present (green 10 Gy 
contour, orange 15 Gy, yellow 20 Gy). 
Figures 1E and 1F. Dose difference maps (coronal and sagittal view): mean dose map of patients without urinary obstruction 
subtracted from mean dose map of patients with obstruction. White region indicates significant dose differences (p<0.02), range 
4 - 12 Gy.
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distance between the two points was 0.07 cm (0.2 cm 1SD), 0.08 cm (0.2 cm 1SD) and 0.05 
cm (0.5 cm 1SD) for the left-right, cranio-caudal and anterior-posterior direction, respectively. 
Statistical analysis
We determined in a univariate analysis which parameters were significantly associated with 
late urinary obstruction and we evaluated which factors remained significant in a multivariate 
(MV) model (Cox regression). We also determined the prognostic value of relevant parameters 
separately for events < 2 years and > 2 years and for diagnosed bladder neck obstruction. 
Time-to-event was calculated from the start of RT. ©SPSS for Windows software was used for 
the analyses (release 15.0, SPSS Inc., Chicago, Illinois).  
results
General statistics
Median follow-up time was 71 months for patients alive. Table 1 shows the distribution of 
the patients with regard to T stage, dose and pretreatment characteristics. The group of 296 
patients receiving 68-72 Gy consisted of 278 patients randomized to 68 Gy and 18 patients 
randomized to 78 Gy but receiving a lower dose mainly due to dose limiting constraints. Table 2 
summarizes the calculated dose parameters and characteristics of the bladder. The cumulative 
Table 1. Characteristics of the study population.
Variable Total group (N = 557)
 N    %
Tumor stage:
 T1 / T2A 
 T2B / T3A 
 T3B / T4
RT dose VS:
 0 Gy 
 48-50 Gy
 66-78 Gy
RT dose prostate:
 68 Gy 
 70-72 Gy
 76-78 Gy 
Hormonal therapy
TURP
Diabetes
Age (mean, SD)
239	  43 %
236 	   42 %
 82 	   15 %
 
 99	  18 %
102	  18 %
356	  64 %
293	  53 % 
 3	    1 %
261	   47 % 
134	  24 % 
 65	   12 % 
 33 	    6 %
68 years                6.4 years
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incidence of urinary obstruction was 9.7 % at 7 years of follow-up for all patients, 8.4 % for 
patients receiving 68-72 Gy and 11.2 % for patients receiving 76-78 Gy (p=0.4). 
Urinary obstruction
Urinary obstruction was observed in 40 patients, mainly scored as Grade 3 toxicity. The earliest 
event was scored at 7 months after RT and the latest at 8.5 years. Nineteen events were within 
2 years and 21 later than 2 years. We studied patient files to determine the location of the 
obstruction. It was located in or close to the bladder neck for 16 patients (of whom one patient 
was known with an obstruction of both ureters). For 14 patients the location was indicated as 
“urethra” or “prostatic urethra”: it can not be excluded that it was close to the bladder neck 
as well. For 3 patients the obstruction was located in the distal urethra, and for 2 patients 
obstruction was probably caused by an enlarged prostate. The location remained unknown for 
5 patients. 
 Baseline and acute variables
A previous TURP was strongly associated with obstruction (Table 3, Fig. 2). Fig. 2 shows that 
the effect of a TURP is present during the first 2 years and also in the following years where 
the Kaplan Meier curves are still separating. Estimated Hazard Ratio’s (HR) were 3.6 and 2.8, 
respectively (Table 3). No relationships were found for diabetes, prostate volume, hormonal 
therapy, smoking and age. Predictive GU baseline complaints were (Table 3): urinary leakage 
(incidence of 12 %) and nocturia ≥ 3 (27 %). Furthermore, these factors were stronger predic-
tors for events < 2 years compared to > 2 years. 
Table 2. Bladder and dose characteristics.
Variable Total group (N = 557)
 Mean (SD) 
Bladder surface 
Bladder volume
Dose surface histogram
 Surface ≥ 20 Gy 
 Surface ≥ 40 Gy 
 Surface ≥ 60 Gy 
 Surface ≥ 80 Gy (n, %)
 0 cm2
 0 - 0.49 cm2 
 0.5 – 14.7 cm2
Dose map
 Dose trigone point 
 Dose max point
 
 241 (92) cm2
 292 (181) cm3
161 (39) cm2
127 (34) cm2
 75 (23) cm2
515 (92 %)
 8 (1 %)
 34 (6 %)
47 (14) Gy
31 (23) Gy
Chapter 4 63
Table 3. Results of Cox regression for the endpoints urinary obstruction (all events, univariate and multivariate) and for established 
bladder neck obstructions, events within 2 years and events later than 2 years (all univariate analysis).
Univariate Multivariate
Parameter / Endpoint Urinary 
obstruction
(40 events)
HR p
Bladder neck
obstruction
(16 events)
HR p
<2 years 
obstruction
(19 events)
HR p
>2 years 
obstruction
(21 events)
HR p
Urinary 
obstruction
(40 events)
HR p
Baseline
 TURP (yes/no)
 Urinary leakage (yes/no) 
 Nocturia ≥ 3 
 Acute toxicity
 Pain passing urine
 Urinary leakage (yes/no)
Dose parameter
 Surf > 80 Gy <0.5 cm2>
 Trigone point <47 Gy>
 Max point <31 Gy>“
 Prostate dose (per 10 Gy)
 Sem Ves dose (per 10 Gy)
3.2 0.001
2.9 0.003
2.7 0.004
3.1 <0.001
2.5 0.006
3.2 0.01
2.7 0.01
2.6 0.005
1.3 0.4 
1.2 0.03
2.8 0.07
1.7 0.4
2.4 0.1
3.2 0.02
2.9 0.04
6.0 0.002
5.4 0.03
5.4 0.009
1.9 0.2
1.4 0.09
3.6 0.009
3.3 0.02
5.6 0.002
4.3 0.003
5.9 0.001
5.9 0.001
1.7 0.3
1.8 0.2
1.6 0.3
1.2 0.2
2.8 0.04
2.5 0.07
1.5 0.4
2.4 0.05
1.2 0.6
1.0 1.0
4.5 0.02
3.9 0.008
1.0 0.9
1.2 0.2
3.6 0.001
2.7 0.007
-
3.4 <0.001
-
3.5 0.006
2.6 0.02
-
-
-
Time (months) since start RT
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Figure 2. Kaplan-Meier curve showing the higher incidence (p=0.001) of late urinary obstruction for patients with a previous TURP 
compared to the patient group without a previous TURP.
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Predictive acute complaints (maximum score) were: pain when passing urine (incidence of 
64 %) and urinary leakage (28 %). The correlation of obstruction with acute toxicity seems only 
to be present for events < 2 years where the HRs are very significant (p ≤ 0.001). 
Dose Surface Histogram (DSH)
In Fig. 3 DSH’s are plotted for patients with and without urinary obstruction. DSH’s are close 
to each other with large standard deviations. The total bladder surface (and volume) was on 
average slightly larger for the patients with obstruction (p = 0.2). Hotspots, which were defined 
as areas > 0.5 cm2, were significantly associated with obstruction: HR was 3.2 for area > 
0.5 cm2 vs. smaller areas (Table 3 and Fig. 4A). The HR was 6.0 for diagnosed bladder neck 
obstructions. Hotspots were mainly associated with events < 2 years (HR = 5.9) and not with 
events > 2 years (HR = 1.0). The subgroup of patients with hotspots was however small; only 
39 patients with a surface of ≥ 0.5 cm2 receiving ≥ 80 Gy.
Dose map
In Fig. 1, results of the mapping procedure are shown for an coronal (A, C, E) and sagittal (B, 
D, F) slice. In Fig. 1A and 1B the anatomy of the CT scan of our template patient is illustrated, 
including the delineated prostate, rectum and bladder. Figure 1C and 1D show mean dose 
maps of the total group with contours of standard deviations (SD). The dose difference map 
Figure 3 chapter 4 
0 20 40 60 80 100
0
50
100
150
200
250
300
350
400
S
ur
fa
ce
 (c
m
2 )
Dose (Gy)
  obstruction
  no obstruction
Figure 3. Absolute dose-surface histograms for patients with and without urinary obstruction. 
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indicated large significant dose differences up to 12 Gy (p< 0.01) superior of the PTV i.e. in the 
bladder area (Fig. 1E-1F). The trigone point is indicated with a cross. The max point, indicating 
the area with the most significant dose difference, was situated about 4 cm dorsally and 2 cm 
cranial from the trigone point (asterisk in panel B and F). The mean dose in these points was 47 
Gy and 31 Gy, respectively (Table 2). For 515 patients with no obstruction the mean dose in the 
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Figure 4 A and B. Kaplan Meier estimates for obstruction: A) cumulative incidence for patients with and 
without hotspots (surface receiving > 80 Gy below or above 0.5 cm2), and B) cumulative incidence for subgroups receiving a dose 
above and below the mean dose in the trigone point.
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trigone point was 46.7 Gy (14 Gy 1SD), and 52.1 Gy (12 Gy 1SD) for patients with obstruction. 
For established bladder neck obstruction the mean dose was 52.3 Gy (10 Gy 1SD). Patients 
with a previous TURP had on average a significantly higher dose in the trigone dose point 
(52.1 Gy vs. 46.4 Gy, p= 0.002). The dose in the trigone point and the max point were highly 
correlated and both significant predictors for obstruction and predicted especially for bladder 
neck obstruction and events > 2 years (Table 3). Fig. 4B shows the Kaplan Meier curves above 
and below the mean dose in the trigone point.
Dose to the prostate and seminal vesicles (SV)
As indicated in Table 3, dose to the prostate was no significant predictor for any endpoint 
whereas dose to the seminal vesicles was a significant predictor for urinary obstruction. Further 
explorative analyses revealed that the cranio-caudal extent of the delineated SV (calculated as 
extent of prostate + SV minus extent of the prostate) was significantly associated with urinary 
obstruction as well (p=0.03) and that the bladder volume on the planning CT scan was signifi-
cantly associated with the cranio-caudal extent of the SV (p= 0.001). The bladder volume on 
the CT scan itself (volumes > 500 cm3 vs. smaller volumes) was associated with obstruction 
(HR = 2.0, p= 0.07) for patients irradiated to the SV. These correlations strongly suggested that 
when the bladder fills, the SV are moving along. As a result, a patient with a full bladder on the 
CT scan will therefore have a larger cranio-caudal extent of the RT field to cover the stretched 
SV. For this reason, more dose will be planned to the bladder neck area, increasing the risk for 
bladder toxicity.
Multivariate analysis (MV)
When we tested the factors in an MV analysis with urinary obstruction as endpoint (Table 3), 
the urinary leakage in the acute phase, which is correlated to leakage at baseline, is no more 
significant. There seems to be only a consequential effect (acute complaints predicting for 
late) for ‘pain passing urine’. Dose to the max point and dose to the seminal vesicles were 
not entered in this model because they were highly correlated with dose to the trigone point; 
replacing the trigone point with the max point or VS dose gave similar results. 
discussion
We found baseline and acute factors to be significantly associated with urinary obstruction, 
which is in agreement with the findings of other studies. (3, 5-7) In the DSH analyses, we found 
that high dose regions (≥ 80 Gy) contributed to the development of urinary obstruction, which 
was also recently reported by others. (3, 9) The incidence of hotspots was however only 13 % 
for our high-dose group. In our study, the effect of hotspots was most apparent for diagnosed 
bladder neck obstructions, which can be expected since bladder hotspots are usually found 
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in the bladder neck area close to the CTV. Furthermore, hotspots were mainly associated with 
urinary retention < 2 years. 
By constructing dose maps, we found strong indications for a local dose-effect relationship 
in the trigonal area, which was the most outspoken for patients with diagnosed bladder neck 
obstruction and for events > 2 years. Mean local dose in the trigone point was 47 Gy. Valida-
tion of the dose map procedure showed good correspondence of the dose and anatomical 
location of the trigone point from the automated mapping procedure compared to the trigone 
point of the manual procedure. The results from the dose mapping should be interpreted with 
care; local areas of clinical interest are indicated rather than local points. It is likely that bladder 
DSH analyses can find the local dose effect for late obstruction in case the relevant area is 
delineated, providing more conclusive evidence of a dose-effect relationship. 
In our study, we had 40/557 patients with urinary obstruction at a median follow-up of 71 
months, which seems rather high. In general, we have higher Grade ≥ 2/3 incidences of GU 
toxicity in our trial compared to other similar dose escalation trials (10-12), which we attribute 
to our detailed and frequent follow-up procedures. Most other dose escalation trials have not 
reported detailed information on urinary obstruction. In the MRC RT01 study, it was reported 
that 20/422 patients receiving 74 Gy, had urethral structures (median follow-up of 63 months).
Transurethral Resection of the Prostate (TURP)
We found that a previous TURP is associated with a higher post-RT risk of GU complications, 
in this case urinary retention. As hypothesized by others, this can be explained by local damage 
caused by the TURP, relative devascularization and a decreased repair capacity of the mucosa. 
(5) A TURP was on average associated with a higher dose in the trigone area, which probably 
also contributed to the observed increased toxicity rate. This phenomenon can be explained by 
the anatomy of a prostate with a previous TURP: the base is usually broadened and therefore 
the CTV is broadened at the bladder site, leading to inclusion of a larger part of the bladder 
neck into the PTV.
Bladder neck obstruction
For 16 patients an obstruction in the bladder neck region was confirmed, which was significantly 
associated with the dose in the trigone point. We see however in the dose difference map that 
the largest dose differences occur cranial from the bladder neck, which seems counterintuitive. 
An explanation for this phenomenon could be that the dose in this area is correlated from 
one point to another; the largest (and most significant) dose differences usually appear in the 
penumbra. Therefore a higher or lower dose in the bladder neck area will be associated with 
an even more pronounced dose difference in the penumbra at a certain distance of the point 
of interest. Second, the dose next to the bladder neck area could also be relevant, since the 
bladder neck will probably move in and out of this area during treatment. Furthermore, the dose 
just cranial from the prostate is probably predictive for bladder neck obstruction, however, there 
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is only limited dose variation in this area since it is included in the PTV and will mainly receive 68 
Gy or 78 Gy. The cumulative incidence of confirmed bladder neck obstructions at 7 years was 
2.6 % and 6.1 % for the 68-72 Gy and 76-78 Gy dose groups, respectively (p= 0.2). 
The presented data highly suggest that bladder neck obstruction is a result of delivered 
dose in the trigonal area. Limiting dose to this area is often not an aim in dose planning. Omit-
ting hotspots in the bladder neck and restrict the dose to the lower part of the bladder (wall) 
would lower the risk for this severe adverse event and could therefore be a very relevant aim in 
treatment optimization.
Obstruction within and after 2 years
By defining events before and after 2 years of follow-up, we were able to discriminate between 
factors predicting for early events, late events after a lag period, or for both in this explorative 
analysis. Persisting and aggravating baseline complaints as well as TURP, acute complaints 
and high hotspots were mainly predictive for events within 2 years. The local dose in the trigone 
point was especially predictive for obstructions after 2 years. It is plausible that factors causing 
mechanical damage, like TURP and hotspots, induce tissue damage and consequential clinical 
problems after a shorter period than (is to be expected from) radiation damage. On the contrary, 
radiation effects are to be expected after a lag period. It is likely that radiation induced obstruc-
tion can be found after longer periods of follow-up then we have now. For this purpose it would 
be interesting to update the trial toxicity data up to 10-15 years of follow-up. 
Other GU endpoints
In our explorative analysis, we produced also dose maps for other endpoints: presence/absence 
of haematuria, incontinence, nocturia ≥ 4 and day frequency ≥ 16. For some endpoints, dose 
differences were noticed further away from the prostate where the dose maps are less reliable 
with respect to correspondence between patients in anatomical locations, which made it hard 
to interpret the results unambiguously. For the endpoint haematuria we found clear dose differ-
ences in the bladder wall of the lower bladder, which were most pronounced at the posterior 
side. We will further study these dose map results in future analyses.
conclusions
Urinary obstruction within 2 years after RT is associated with urinary problems existing before 
RT, acute toxicity, previous TURP and hotspots in the bladder. Events after a period of 2-7 
years are associated with the local dose in the trigonal area as well as with other correlated 
dose points in this bladder area. Limiting dose to the bladder neck area is often not an aim 
in treatment optimization. Because of the serious nature of urinary obstruction, sparing of the 
bladder neck area is however advised in order to prevent the patient from unnecessary risks.
Chapter 4 69
references
 1.  Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation 
trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72:980-8.
 2.  Elliott SP, Meng MV, Elkin EP, et al. Incidence of urethral stricture after primary treatment for prostate 
cancer: data from CaPSURE. J Urol 2007; 178:529-534.
 3.  Harsolia A, Vargas C, Yan D, et al. Predictors for chronic urinary toxicity after the treatment of prostate 
cancer with adaptive 3D conformal RT: dose-volume analysis of a Phase III dose-escalation study. Int 
J Radiat Oncol Biol Phys 2007; 69:1100-1109.
 4.  Peeters STH, Heemsbergen WD, Putten van, WL, et al. Acute and late complications after radio-
therapy for prostate cancer: Results of a multi-center randomized trial comparing 68 Gy with 78 Gy. 
Int J Radiat Oncol Biol Phys 2005; 61:1019-1043.
 5.  Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA. Long-term urinary toxicity after 
3D CRT for prostate cancer in patients with prior history of TURP. Int J Radiat Oncol Biol Phys 2000; 
48:643-7.
 6.  Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose 3D-CRT in patients with 
localized prostate carcinoma. Cancer 1999; 85:2460-8.
 7.  Karlssdottir A, Muren LP, Wentzel-Larsen T, Dahl O. Late GI morbidity after 3D-CRT for prostate 
cancer fades with time in contrast to GU morbidity. Int J Radiat Oncol Biol Phys 2008; 70:1478-1486.
 8.  Hoogeman MS, Peeters STH, De Bois J, et al. Absolute and relative dose-surface and dose-volume 
histograms of the bladder; which one is the most invariant under bladder filling changes ? Physics 
Medical Biology 2005;50:3589-97.
 9.  Cheung MR, Tucker SL, Dong L, et al. Investigation of bladder dose and volume factors influencing 
late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 
2007; 67:1059-1065.
 10.  Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radio-
therapy in prostate cancer: frist results from the MRC RT01 randomized controlled trial. Lancet Oncol 
2007; 8: 475-87.
 11.  Kuban DA, Tucker SL, Dong L, et al. Long-term results of the MD Anderson randomized dose-
escalation troal for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70:67-74.
 12.  Michalski, JM, Winter K, Purdy JA, et al. Toxicity after 3D radiotherapy for prostate cancer on RTOG 
9406 dose level V. Int J Radiat Oncol Biol Phys 2005; 62:706-713.

Chapter 5
Dose-escalation and quality-of-life in 
patients with localized prostate cancer 
treated with radiotherapy: long-term 
results of the Dutch randomized dose-
escalation trial (CKTO 96-10 trial)
Abrahim Al-Mamgani 
Wim LJ. van Putten 
Gerard J. van der Wielen 
Peter C. Levendag 
Luca Incrocci 
 Int J Radiat Oncol Biol Phys 2010 (Epub ahead of print)
C
ha
pt
er
 5
72
abstract
Purpose
To assess the impact of dose-escalation of radiotherapy on quality-of-life (QoL) in prostate 
cancer (PC) patients. 
Patients and methods
Three-hundred prostate cancer patients participating in the Dutch randomized trial (CKTO 
96-10) comparing 68 to 78 Gy are the subject of this analysis. These patients filled out the 
SF-36 QoL-questionnaires before radiotherapy (baseline) and 6, 12, 24 and 36 months there-
after. Changes in QoL over time of ≥ 10 points were considered clinically relevant. Repeated- 
measures regression analyses was applied to estimate and test the QoL-changes over time, 
the differences between the two arms and for association with a number of covariates.
Results
At 3-year follow-up, the summary-score physical-health was 73.2 for the 68-Gy arm vs. 71.6 
for the 78-Gy arm (p= 0.81) and the summary-score mental-health was 76.7 for the 68-Gy 
arm vs. 76.1 for the 78-Gy arm (p= 0.97). Statistically significant (p< 0.01) deterioration in 
QoL-scores over time was registered in both arms in 6 scales. The deterioration over time was 
more pronounced in the high-dose arm in most scales. However clinically relevant deterioration 
(> 10 points) was seen only in two scales. None of the tested covariates were significantly 
correlated with QoL-scores.
Conclusion 
Dose-escalation did not result in significant deterioration of QoL in PC-patients. In both randomi-
sation arms, statistically significant decreases in QoL-scores over time were seen in six scales. 
The deterioration of QoL was more pronounced in the physical- than in the mental-health 
domain and in some scales more in the high- than in the low-dose arm, but the differences 
between the arms were not statistically significant.
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introduction
Prostate cancer (PC) has become the most frequent malignancy in men in Western countries. 
Beside definitive radiotherapy (RT), prostatectomy, and hormonal therapy (HT), observation 
might be applied in early-stage low-risk disease. Our group and others (1-3) have demonstrated 
that escalating the dose of RT not only improves tumor control but also increases late toxicity. 
The Dutch randomized trial (CKTO 96-10) has shown that freedom from failure at 7-years was 
significantly better in the 78 Gy arm compared with the 68 Gy arm (54% vs. 47%; p= 0.04). 
While there was no difference in overall survival, late GI toxicity was increased in the 78 Gy arm 
(p= 0.04) (3). Beside the achievement of cure as primary goal of radical treatment of PC, toxicity 
and assessment of quality-of-life (QoL) have become very important secondary considerations, 
especially in view of the arguments in favour of watchful waiting. 
To date, none of the randomized dose-escalation studies have thoroughly reported on the 
impact of dose-escalation of RT on QoL by using validated QoL-questionnaires. 
The current analysis was undertaken within the framework of the Dutch randomized trial 
(CKTO 96-10) to assess the impact of dose-escalation on QoL of PC patients treated with 
either 68 or 78 Gy using 3-dimensional conformal RT techniques (3-DCRT). The analysis was 
done by intention-to-treat. We used a validated QoL-questionnaire (SF-36) (4) to investigate 
the impact of increasing the dose of RT on QoL and the changes over time in different scales 
of SF-36 in these patients. Correlation of different independent covariates with QoL was also 
investigated. 
Patients and methods 
Between June 1997 and February 2003, 669 patients with localized PC were enrolled in the 
Dutch trial (CKTO 96-10) and randomly assigned to receive either 68 or 78 Gy of 3-DCRT. The 
trial was carried out at four Dutch cancer institutions (3). Briefly, patients with localized PC with 
initial prostate-specific antigen (i-PSA) ≤ 60 mg/L were eligible. Patients with low-risk disease, 
with lymphatic or distant metastases and those having Karnofsky scores ≤70 were excluded. 
(Neo)adjuvant HT was allowed and was prescribed for a period of three years. For both arms, 
the fraction size was 2 Gy prescribed to the isocenter (the ICRU reference point). The mean 
dose to the planning target volume (PTV) was between –5% and +7% of the prescribed dose, 
and 99% of the PTV received ≥ 95% of the prescribed dose. The percentage of the rectum 
receiving ≥ 74 Gy was limited to 40%, while the small bowel dose should not be > 68 Gy. The 
PTV included the prostate with or without the SV as clinical target volume (CTV), with a margin 
of 10 mm during the first 68 Gy and 5 mm (except towards the rectum 0 mm) for the last 10 Gy 
in the high-dose arm. A verification procedure, using orthogonal portal imaging, with decision 
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rules for set-up corrections was used according to the guidelines published by a collaborative 
study in the Netherlands. By using this protocol, systematic errors should not exceed 5 mm (3).
The cohort contains only patients who were treated at the Erasmus MC-Daniel den Hoed 
Cancer Center in Rotterdam (n= 404). Patients from other participating institutions did not 
participate in the side trial on QoL. 
We elected to use the self-administered SF-36 QoL-questionnaire. The structure of SF-36 
questionnaire is shown on Table 1. In brief, it consists of 36 questions compressed into eight 
scales within physical and mental domains. These scales are assessed quantitatively, each 
on the basis of answers to multiple choice questions. The scoring of the SF-36 is a two-step 
process. First, All items are scored between 0 and 100 with a higher score indicating a better 
QoL (5). Scores represent the percentage of total possible score achieved. In step-2, items 
in the same scale are averaged together to create the 8 scales scores. Items that are left 
blank (missing data) are not taken into account when calculating the scale scores. The scales 
of SF-36 are divided into two dimensions. The first five scales make up the “physical health” 
dimension and the last five form the “mental health” dimension. The scales vitality and general-
health are two overlapping scales. The summary scores of the two dimensions and the total 
SF-36 score are based on mathematical averaging of the scale components.
QoL assessment was done before starting RT (baseline) and at 6, 12, 24, and 36 months. The 
questionnaires were handed over to the patients by the nurse of our department. Patients were 
instructed to answer the questions at the specific points in time (baseline, 6, 12, 24, and 36 
months) and return the questionnaires at their next visit to the department. QoL assessment 
stopped when the patient showed disease progression (clinical failure or the initiation of salvage 
hormonal therapy). 
QoL changes over time of ≥ 10 points were considered clinically relevant. Osaba et al. (6) have 
determined the significance of the numerical changes in time and suggested that “moderate 
changes” (mean change between 10-20) to be clinically relevant. The mean change in patients 
who indicated a “small change” (better or worse) in scores was about 5-10, and for “very much 
changes” greater than 20.
Statistical analysis
All patients with at least one QoL assessment are considered as responders and included in the 
analysis. As shown in Table 2, responders and non-responders were compared with respect 
to patient and tumor characteristics using a chi-square test for categorical variables and the 
Kruskal-Wallis test for ordinal variables. 
For all scales, missing values for the items contributing to that scale were substituted by a 
predicted value if the patient had responded to at least 50% of the items of a scale. Otherwise 
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the scale of this patient was excluded from further analysis. The predicted value was calculated 
with linear regression on the non-missing items of the scale.
QoL assessments were divided in 5 periods: baseline (before day 10 after starting RT), 6 
months (between 3 months and 9 months after starting RT), 1 year (between 9 and 18 months), 
2 years (between 18 and 30 months), and 3 years (between 30 and 42 months after starting 
RT). QoL assessments between day 10 and day 91 after starting RT and after 42 months after 
RT were excluded. 
For each of the SF-36 scales, repeated measurements regression analyses were applied to 
obtain estimates of and test for treatment effects and to test for differences over time and for 
association with covariates. The following variables were used in these models: 
[1] an indicator variable with value 1 for the 78 Gy treatment arm at baseline and value 0 
otherwise: used to test for a possible difference at baseline between the arms; [2] an indicator 
variable with value 1 for the 78 Gy treatment arm after treatment and value 0 otherwise: used to 
test for a difference between the arms after treatment; [3] an indicator variable post with value 
1 for all scores after treatment and 0 otherwise: used to test for a difference between scores 
after treatment compared to baseline; [4] a time variable measuring the time of QoL scoring in 
months since end of RT with value 0 for baseline scores: used to test for a trend over time in 
scores after RT, and in combination with the variable post to test for overall differences over 
time. Interaction terms were added to these models to test for interactions between time after 
RT and treatment arm. 
Descriptive median scores are presented in Table 3. The P-value in the baseline column is for 
the test of no difference between the two arms at baseline. The P-value in the Time column is 
for the test of no difference between baseline and post RT scores and no trend over time in 
scores post RT. The P-value in the R (randomization arm) column is for the test of no difference 
in scores between both arms post RT. The P-value in the Time by arm column is for the test of 
no interaction between arm and time post RT. 
Associations between QoL-scores and covariates were tested by adding to these models the 
following covariates: age at baseline, comorbidity at baseline (0= no, 1= yes), adjuvant hor-
monal treatment (0= no, 1= yes), and the concurrent RTOG/EORTC GI and GU toxicity scores 
measured at or before the QoL assessment. The results of these analyses are presented in 
Table 4 with P-values for all tests and the beta regression coefficients for these variables in the 
models. The sign (- or +) of these coefficients indicates the direction of the association of the 
covariable and the QoL scale. 
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To guard against false positive results due to multiple testing, a two sided p-value of 0.01 was 
considered statistically significant. All statistical analyses were performed using Stata, version 
10.0 (Stata Corporation, College Station, TX, USA). 
Table 1. The SF-36 quality-of-life scoring system and its scales and dimensions
Item’s no Items Scales Dimensions  
3a Vigorous activities
Scale 1: Physical- 
functioning
Ph
ys
ica
l d
im
en
sio
n
 
3b Moderate activities
3c Lifting or carrying groceries
3d Climb several flights of stairs
3e Climb one flight of stairs
3f Bending, kneeing or stooping
3g Walking more than a mile
3h Walking several blocks
3i Walking one block
3j Bathing or dressing yourself
4a Cut down time
Scale 2: Role-functioning 
4b Accomplished less than you would like
4c Limited in kind of work or activity
4d Had difficulty in performing work or activity
7 Pain magnitude past 4 weeks
Scale 3: Bodily-pain
8 Pain interference with your work past 4 weeks
1 General health rating
Scale 4: General- health
M
en
ta
l d
im
en
sio
n
11a Get sick easier than other people
11b As healthy as anyone
11c Expect my health to get worse
11d Excellent health
9a Feel full of pep
Scale 5: Vitality
9e Have a lot of energy
9g Feel worn out
9i Feel tired
6 Social-extent Scale 6: Social- 
functioning
 
10 Social-time
5a Cut down time
Scale 7: Role-emotional5b Accomplished less than you would like
5c Not careful in work
9b Nervous
Scale 8: Mental- Health
9c Down in dumps
9d Calm and peaceful
9f Downhearted and blue
9h Happy
2 Change in reported health past year
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results
Baseline patients’ characteristics
Of the 404 patients treated at the Erasmus MC-Daniel den Hoed Cancer Center, 300 patients 
(responders, 74%) have participated in the QoL part of the study, filling out at least one QoL 
questionnaire. There were no differences between the responders and non-responders with 
respect to age, tumor stage, PSA, adjuvant HT, or presence of comorbidity. More patients among 
responders had higher Gleason scores as compared to the non-responders (p= 0.005). Among 
the responders, the patient characteristics were similar in both randomization arms (Table 2). 
Table 2. Patient Characteristics of responders & non-responders and of both randomization arms
 
Whole group (n=404) Responders (n=300)
Responders (n=300) Non-responders (n=104) 68-Gy arm (n=140) 78-Gy arm (n=160)
% % % %
Age, years  
 Mean (years) 68 68 67 68
 Range (years) 48-80 52-81 50-80 48-80
 <= 65 34 35 42 26
 66-70 28 25 23 34
 >70 38 40 35 40
Tumor stage   
 T1 16 20 16 16
 T2 45 39 47 43
 T3 37 39 34 41
 T4 2 2 3 0
Gleason score *   
 2-6 43 58 44 42
 7 38 32 39 37
 8-10 19 10 17 21
iPSA   
 <4 9 10 9 9
 4-10 36 36 34 38
 10-20 34 34 32 35
 >20 21 20 25 18
HT   
 Yes 16 9 14 19
 No 84 91 86 81
Comorbidity ^   
 Yes 33 29 30 35
 No 67 71 70 65
Pre-existing GI 2 3 1 3
Pre-existing GU 8 7 6 10
Abbreviations: iPSA: initial prostate-specific antigen; HT: hormonal therapy; GI: gastro-intestinal; GU: genito-urinary. *significantly more 
patients among responders had higher Gleason scores, as compared to non-responders (p=0.005), all other demographics were 
equally distributed among responders & non-responders and among both randomization arms. ^Comorbidity was scores “Yes” if 
patient had diabetes mellitus, cardiovascular and/or cerebrovascular disease.
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Patient functioning by randomization arms
As shown in Table 3 and Figure 1, no statistically significant differences in any SF-36 scales 
were found between both randomization arms at baseline (P-Baseline). The SF-36 scores at 
baseline ranged from 65 to 89, which mean that the patient population functioned well within 
the tested domains. Also after RT there was no difference between the randomization arms in 
their scores on any of the scales (P-R). After 3 years, the average total summary-score physical-
health was 73.2 for the 68 Gy arm (-4.9 compared to baseline) vs. 71.6 for the 78 Gy arm 
(-8.8 compared with baseline) (p= 0.81) and the average total summary-score mental-health 
was 76.7 for the 68 Gy arm (+0.1 compared with baseline) vs. 76.1 for the 78 Gy arm (-3.5 
compared with baseline) (p= 0.97). 
Table 3. Quality-of-life scores as measured by the SF-36 QoL-questionnaires by randomization arms
SF-36 
scales
R-arms
SF-36 QoL scores by time points in months
 
B-36^ 
P-values
Baseline 6 12 24 36 Baseline* Time* R*
Time by 
R*
SSPH 68 Gy 78,1 75,4 77,6 74,4 73,2 -4.9 0,30 < 0,001 0,81 0,39
 78 Gy 80,4 75,5 76,9 73,1 71,6 -8.8
SSMH 68 Gy 76,6 78,1 78,8 77,6 76,7 0.1 0,16 0,12 0,97 0,93
 78 Gy 79,6 77,6 79,2 78,1 76,1 -3.5
PF 68 Gy 82,7 79,0 80,1 78,9 76,0 -6.7 0,13 < 0,001 0,69 0,11
 78 Gy 86,1 81,1 81,3 77,2 75,8 -10.3
RP 68 Gy 76,5 68,4 74,7 72,5 71,9 -4.6 0,25 0,24 0,84 0,18
 78 Gy 81,6 69,1 75,2 69,3 66,4 -15.2
BP 68 Gy 86,4 87,0 87,5 83,8 84,6 -1.8 0,23 0,003 0,50 0,56
 78 Gy 89,0 86,4 85,5 82,4 82,4 -6.6
GH 68 Gy 66,0 67,2 67,8 62,3 61,1 -4.9 0,66 < 0,001 0,64 0,07
 78 Gy 65,0 65,2 65,5 63,6 62,4 -2.6
VT 68 Gy 71,6 68,2 69,9 67,5 67,5 -4.1 0,19 < 0,001 0,77 0,37
 78 Gy 74,5 68,2 68,7 67,7 64,9 -9.6
SF 68 Gy 85,9 86,5 86,7 84,1 85,3 -0.6 0,63 0,43 0,46 0,93
 78 Gy 84,8 84,0 85,6 83,9 83,0 -1.8
RE 68 Gy 73,7 80,3 82,1 83,4 79,8 6.1 0,02 0,03 0,92 0,93
 78 Gy 83,3 80,0 82,7 81,2 80,1 -3.2
MH 68 Gy 76,5 79,0 78,8 78,3 75,9 -0.6 0,92 0,004 0,81 0,66
 78 Gy 76,6 79,0 79,7 79,2 76,9 0.3     
Abbreviations: R: randomization; SSPH: summary-score physical-health; SSMH: summary-score mental-health; PF: Physical- 
functioning; RP: Role-physical; BP: Bodily-pain; GH: General-health; VT: Vitality; SF: Social-functioning; RE: Role-emotional; MH: 
Mental-health; B-36^: indicates difference in QoL-scores between scores at baseline and at 36-months (only a difference of > 10 
points was regarded as clinically relevant, according to Osaba et al.(6). Clinically relevant differences were indicated in bold. The 
P-value in the Baseline column is for the test of no difference between the two arms at baseline. The P-value in the Time column 
is for the test of no difference between baseline and post RT scores and no trend over time in scores post RT. The P-value in the R 
(randomization arm) column is for the test of no difference in scores between both arms post RT. The P-value in the Time by arm 
column is for the test of no interaction between arm and time post RT. Note: statistically significant differences (P-value < 0.01) are 
indicated in bold.
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Changes in patient functioning over time
Statistically significant changes over time were observed in both randomization arms in 6 scales 
(summary-score physical-health, physical-functioning, bodily-pain, general-health, vitality, and 
mental-health) (P-Time), while clinically relevant changes over time in the mean scores (> 10 
points), according to the guidelines as outlined by Osaba et al. (6), were seen in only 2 scales 
in patients treated with 78 Gy (-15.2 for role-physical, and -10.3 for physical-functioning, 
compared with baseline). The scores on these 2 scales were also deteriorated over time in 
the low-dose arm, however less pronounced than in the high-dose arm (–4.6 for role-physical, 
and -6.7 for physical-functioning, compared with baseline). However, it should be noted that no 
statistically significant interactions were observed between time and arm on any of the scales 
(P-Time by R), which means that the apparent differences between the arms are within the 
sampling fluctuation. 
Analysis by time points by scales (Table 3)
Summary-score physical-health
At 6-months, QoL-scores in both arms registered declines followed by a slight improvement at 
12-months. Thereafter, the scores in both arms showed gradual deterioration, with the largest 
decline registered in the high-dose arm (-8.8 vs.-4.9 at 3-years, compared with baseline, p< 
0.001). 
Summary-score mental-health
Patients treated with 68 Gy registered a slight improvement at 6- and 12-months, while 
those treated with 78 Gy showed a decline at 6-months followed by a slight improvement 
at 12-months. Subsequently, a slight deterioration in QoL-scores was seen in both arms at 
24- and 36-months. At 3-years, QoL-scores for patients treated with 68 Gy was +0.1 vs. –3.5 
for 78 Gy, compared with baseline (p= 0.12).
Physical-functioning and Role-physical
Only in these two scales the deterioration in mean QoL-scores at 3-years were clinically relevant 
(> 10 decrease), compared with baseline. The pattern of changes over time on these 2 scales 
was also similar; the largest declines were registered at 6-months in both arms, with the greatest 
decrease seen in role-physical in patients treated with 78 Gy (-12.5, compared with baseline). 
While slight improvements were seen at 12-months in both arms at physical-functioning (+1 
compared with baseline), the improvements at role-physical in both arms were tremendous at 
12-months (+6 compared to 6-months). As in most scales, QoL-scores registered deteriora-
tion at 24- and 36-months on both scales and in both arms. After 3-years, patients treated 
with high-dose RT showed a clinically relevant decline, compared with baseline (-15.2 at role-
physical and –10.3 at physical-functioning). Although the scores of patients treated with 68 Gy 
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Figure 1. Quality-of-life scores of prostate cancer patients treated with 68-Gy (dashed line) or 78-Gy (solid line) of 3-demensional 
conformal radiotherapy. For all scales of the FS-36 questionnaire, a higher score reflects a better quality-of-life. The horizontal axis 
indicates the 5 times points where quality-of-life was scored (at baseline, 6, 12, 24, and 36 months). The vertical axis indicates the 
mean scores. Bars represent 95% confidence intervals.
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at 3-years were also deteriorated, as compared with baseline (-4.6 at role-physical and –6.7 at 
physical-functioning), these declines were clinically non relevant. 
Bodily-pain
Patients treated with 78 Gy showed a continuous but gradual deterioration in QoL-scores over 
time, with the largest declines observed at 6- and 24-months. Patients treated with 68 Gy 
showed a fluctuating pattern of changes over time, with slight improvements at the early stages 
after treatment. At both arms, the scores at 3-years were lower than baseline (-6.6 vs.-1.8 for 
78 and 68 Gy arms, respectively) (p= 0.003). 
General health 
Both arms showed a similar pattern of changes over time, with slight improvements at 6- and 
12 months, followed by slight deteriorations at 24- and 36-months. Again, the scores at 3-years 
were lower than baseline in both arms. However, the deterioration of scores on this scales (and 
on mental-health) were less pronounced in patients treated with 78 Gy than in those treated 
with 68 Gy (-2.6 vs. 4.9, respectively, p= <0.001).
Vitality
The most significant deterioration seen in both arms was registered at 6 months. These declines 
were followed by slight improvement at 12-months and subsequently by gradual deterioration 
at the last time periods. Beside the fact that changes over time were statistically significant at 
this scale (p< 0.001), the changes in patients treated with high-dose RT were almost clinically 
relevant (-9.6, compared with baseline).
Social-functioning 
The changes in scores over time in both arms showed mild fluctuations from baseline. The 
scores at 3-years were slightly lower than at baseline (-0.6 and –1.8 for 68 and 78 Gy, respec-
tively, p= 0.43).
Role-emotional
At baseline, patients treated with 78 Gy had higher QoL-scores than patients treated with 68 
Gy (p= 0.02). Patients treated with 68 Gy registered improvements at first 3 time points, with 
the largest increase seen at 6-months (+6.6). Despite the deterioration seen at 36-months, 
these patients ended up with higher scores (+6.1), compared with baseline. Patients treated 
with high-dose RT showed a similar pattern of changes over time, as seen in summary-score 
physical-health, summary-score mental-health, physical-functioning and role-physical, and 
social-functioning. These patients had lower scores at 3-years compared with baseline (-3.2). 
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Mental-health
Both arms registered improvements at early time points followed by a gradual deterioration at 
later time points. The changes over time on this scale were statistically significant (p=0.004), 
but patients from both arms ended up with nearly similar scores (-0.6 for 68 Gy vs. +0.3 for 78 
Gy), compared with baseline.
Relation between QoL and selected covariates
None of the tested covariates showed a statistically significant correlation with any scale of the 
SF-36 questionnaire. However, late GI and GU toxicity scores showed, as one would expect, 
a negative correlation with most QoL scales, i.e. higher grades of late GI or GU toxicity were 
associated with lower QoL-scores (Table 4). 
Regarding the two scales (role-physical and physical-functioning) where deterioration of QoL 
over time was clinically relevant in the high-dose arm, a borderline significant correlation with late 
GI toxicity (p= 0.02) and GU toxicity (p= 0.05) was found for role-physical and with comorbidity 
and age (p= 0.02) for physical-functioning. In all other scales, no statistically significant correla-
tion was found between the tested covariates and QoL. 
discussion
Several factors make the assessment of the impact of any treatment modality on QoL extremely 
important in patients with localized PC. Firstly, most patients are asymptomatic due to the early 
diagnosis because of the elevated PSA level. Secondly, there are several treatment modalities 
available and watchful waiting is an alternative option for early-stage PC, especially in elderly 
men with a short expected life-span. Thirdly, patients may survive for a considerable period 
even in the presence of metastatic disease. Finally, none of the published randomized studies 
Table 4. P-values for association between selected covariates and SF-36 scores 
SF-36 scales Age Comorbidity  Hormonal therapy  GI toxicity GU toxicity
SSPH p-value 0,65 0,14 0,54 0.07 0,10
 beta -0.071 -4.078 -1.57 -1.129 -0.969
SSMH p-value 0,78 0,91 0,24 0,57 0.07
 beta 0.043 0.301 -3.012 -0.345 -1.014
PF* p-value 0,02 0,02 0,94 0,47 0,26
 beta -0.347 -6.482 0.196 -0.452 -0.646
RP* p-value 0,67 0,61 0,07 0,02 0,05
 beta 0.118 -2.5 -7.979 -3.462 -2.757
Abbreviations: SSPH: summary-score physical-health; SSMH: summary-score mental-health; PF: Physical-functioning; RP: Role-
physical; GI: gastro-intestinal, GU: genito-urinary. Notes: p-value < 0.01 was regarded as statistically significant. Beta: regression 
coefficient for the repeated measurements regression analysis. *These two scales were analyzed separately, because only on these 
2 scales clinically relevant changes (≥ 10 points) in QoL-scores over time were seen. In all other scales the changes in scores over 
time were clinically non relevant.
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have shown a survival benefit (1-3). Accurate reporting of the side effects and the impact on 
QoL is, therefore, very essential to facilitate decision-making by both patients and clinicians.
To our knowledge, this is the first randomized dose-escalation trial reporting on the impact of 
increasing the dose of RT on QoL of patients with localized PC by using a validated QoL-ques-
tionnaire. The randomized dose-escalation trial of the M.D. Anderson Cancer Center showed, 
after 3-years follow-up, that rectal bleeding had improved, erectile function had decreased, and 
urinary urge incontinence had increased in both dose-arms (70 and 78 Gy). In that study, a 
radiation dose-effect on bowel and bladder functions was not seen (7). 
In the present study, escalating the dose of RT from 68 to78 Gy did not significantly decrease 
the QoL-scores as measured by SF-36 questionnaire (P-value R-column at Table 3). Analysis 
of time trends revealed statistically significant deterioration in QoL-scores over time in both 
randomisation arms on 6 scales (P-value Time column at Table 3), but these changes were 
clinically relevant only in physical-functioning and role-physical (> 10 points). These clinically 
relevant deteriorations over time were seen only in the high-dose arm (-15.2 for role-physical, 
and -10.3 for physical-functioning, compared with baseline). The scores over time on these 
2 scales were also deteriorated in the low-dose arm, however less pronounced than in the 
high-dose arm. However, no statistically significant interactions were observed between time 
and arm on any of the scales (P-value Time by R column at Table 3), which means that the 
apparent differences between the arms are within the sampling fluctuation. 
In summary, the SF-36 questionnaire demonstrates a complicated and mixed pattern of changes 
following RT for localized PC. However, three general patterns of changes in QoL-scores could 
be distinguished. Firstly, the most appreciable treatment-related deteriorations in QoL measures 
were observed in physical-health domain. Secondly, in both randomization arms there was 
temporary improvement in almost all scales at 12-months, followed by gradual deterioration of 
scores at 24- and 36-months. The SF-36 scores of most scales at 3-years were lower than 
at baseline. Lastly, the deterioration in QoL-scores were, in general, less pronounced in the 
low-dose as compared to the high-dose arm, but the differences between the two arms over 
time were not statistically significant.
It should not be totally surprising that almost all items of QoL have temporarily improved at 
12-months after the registered declines at 6-months. The first possible explanation for this 
temporary improvement is the identification of benefit from adversity, a phenomenon known as 
“benefit finding” (8). Evidently, most patients not only experience negative effects but also certain 
positive effects after an encounter with the diagnosis and treatment of cancer. Secondly, many 
patients have accepted the early side effects of RT as inevitable consequences of having been 
treated for PC, a disease that yet perceived by many people to be the most life-threatening 
event. However, the temporary improvements were followed by gradual deterioration of scores 
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at 24- and 36-months. At 3-years the scores of most scales were lower than at baseline. 
However, the deterioration was clinically relevant only in 2 scales (physical-functioning and 
role-physical). Possible explanations are: changes in perceived health-related QoL may lag 
behind the mergence of symptoms. The decrements in scores may develop slowly, as men live 
with these problems and readjust their appraisals of health-related limitations in their functional 
status. The longer follow-up in our study, compared to that of other investigators (9-11), had 
therefore the advantage to detect these late changes in QoL-scores. Furthermore, different fac-
tors as aging, comorbidity and the development of late GI and GU toxicities might have resulted 
into worse QoL-scores in these patients after 2-3 years of follow-up. Lips et al. (9) compared in 
a prospective and longitudinal study QoL after 70 Gy of 3-DCRT with QoL after 76 Gy of IMRT in 
patients with PC and concluded that IMRT seems to provide a possibility to escalate the dose of 
RT without deterioration in QoL. The same conclusions were drawn by Yoshimura et al. (10) and 
Kupelian et al. (11) after 1 and 2 year of follow-up, respectively, in patients treated with IMRT to 
a relatively high-dose. However, it is not fair to compare these studies with our study, because 
these studies are not randomized, the radiation dose was on average lower than 78 Gy, the 
follow-up is short (6, 12, and 24-months, respectively), and the number of patients is small (92, 
60, and 51 patients, respectively). Furthermore, those patients were treated with IMRT with 
possibly less late side-effects.
To explore whether there was any correlation between selected clinical covariates and QoL, 
these covariates were added to the repeated measurements regression multivariate models. 
None of the tested covariates showed statistically significant correlation with QoL. However, 
late GI and GU toxicity showed a borderline significant correlation with both summary-score 
physical-health and summary-score mental-health, respectively (p= 0.07). Regarding the two 
scales where deterioration of QoL over time was clinically relevant in high-dose arm, there was 
a trend toward significant correlation with late GI toxicity and GU toxicity for role-physical and 
with comorbidity and age for physical-functioning.
In the present analysis, we did not study the late side-effects of dose-escalated RT (GI, GU 
or sexual functioning) separately since these late effects were thoroughly described by other 
investigators from our group (12, 13). The effect of dose-escalation on sexual function was 
studied by van der Wielen et al. (12). In that study, patients were censored at the moment they 
started with HT, in order to estimate the effect of RT only. They found a significant increase in 
the prevalence of erectile dysfunction after RT (38% cumulative incidence at 3-years in patients 
without erectile dysfunction prior to the RT). Escalating the dose of RT from 68 to 78 Gy did not 
significantly worsen the sexual function. The incidence of erectile dysfunction at 3-years was 
39% and 37% for the low- and high-dose arms, respectively (12). Although raising the dose to 
the prostate from 68 to 78 Gy resulted in higher incidence of acute and late GI and GU toxicity, 
but these differences were not significant at 3-years. The 3-year cumulative incidence of late 
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grade ≥ 2 GI toxicity of patients treated within the Dutch randomized dose-escalation trial (CKTO 
96-10) were 23.2% and 26.5% for low- and high-dose arms, respectively (p=0.3). The figures 
for late grade ≥ 2 GU toxicity were 28.5% and 30.2% (p=0.3) (13). Like others, we believe that 
clinicians should be aware of the fact that assessment of general QoL-dimensions as physical, 
mental, and social (as measured by SF-36 or other validated QoL-questionnaires) are of equal 
or even greater significance for QoL than specific organ-related morbidity (sexuality and bladder 
and bowel symptoms). Lilleby et al. (14) found that fatigue, physical and emotional functions 
(all are items of the SF-36 questionnaire) were the 3 independent parameters predictive for 
QoL, whereas the impact of specific organ-related morbidity did not reach the level of statistical 
significance in the multivariate analysis. Clark et al. (15) reported no decline in the SF-36 scores 
as a result of new urinary, bowel, or sexual problems during the follow-up.
conclusions
QoL-scores in PC patients as measured by SF-36 questionnaire did not appear to be signifi-
cantly decreased by escalating the dose of RT from 68 to 78 Gy. However, the decrease in 
QoL-scores, in general, was more pronounced in the high- than in the low-dose arm and in 
the physical- than the mental-health domain. In both randomization arms, statistically significant 
decrease in QoL-scores over time were seen in 6 scales, but the deterioration over time was 
clinically relevant only in role-physical and physical-functioning scales in patients treated in 
the high-dose arm. None of the tested covariates in the repeated measurements regression 
analysis correlated significantly with QoL changes over time. However, late GI and GU toxicity 
showed a trend toward significant correlation.
Given the slight deterioration in different QoL-scales, albeit statistically non-significant, 
seen by escalating the dose of RT from 68 to 78 Gy, the possible risks of complications and 
deterioration of QoL must, therefore, be carefully weighted against the risk of relapse during 
the patient’s expected life span. When the expected toxicity of high-dose RT in that particular 
patient is high, the expected life span is relatively short and the risk of local recurrence is 
predicted to be low (based on iPSA, Gleason score, and T-stage), dose-escalation should, in 
our opinion, be avoided.
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abstract
Purpose
To investigate the effect of dose-escalation within prognostic risk-groups in prostate cancer. 
Patients and Methods
Between 1997 and 2003, 664 patients with localized prostate cancer were randomly assigned 
to receive 68- or 78-Gy of radiotherapy. Two prognostic-models were examined: a risk-group-
model (low-,intermediate-,and high-risk) and PSA-level groupings. High-risk patients with 
hormonal therapy (HT) were analyzed separately. Outcome variable was freedom from failure 
(FFF) (clinical failure or PSA nadir + 2 mg/L).
Results
In relation to the advantage of high-dose radiotherapy, intermediate-risk patients benefited most 
from dose-escalation. However no significant heterogeneity could be demonstrated between 
the risk groups. For two types of PSA level groupings: PSA < 10 and ≥ 10 mg/L, and < 8, 
8-18 and > 8 mg/L, the test for heterogeneity was significant (p= 0.03 and 0.05, respectively). 
Patients with PSA 8-18 mg/L (n = 297, HR= 0.59) derived the greatest benefit from dose-
escalation. No heterogeneity could be demonstrated for high-risk patients with and without HT.
Conclusion 
Intermediate-risk group derived the greatest benefit for dose-escalation. However, from this trial 
no indication was found to exclude low-risk or high-risk patients from high-dose radiotherapy. 
Patients could be selected for high-dose radiotherapy based on PSA-level groupings: for 
patients with an PSA < 8 mg/L high-dose radiotherapy is probably not indicated, but should be 
confirmed in other randomized studies. 
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introduction
Prostate cancer currently is the most common malignant disease in western countries. Although 
the outcome of radiotherapy for localized prostate cancer has improved with dose-escalation, the 
risk of cancer recurrence remains substantial (1-5). The Dutch randomized trial (1) showed that 
freedom from failure (FFF) (clinical failure or PSA nadir plus 2) at 7-years was significantly better in 
the 78-Gy arm compared with the 68-Gy arm: FFF-rates 56% vs. 45%, respectively; p= 0.03). 
There were no differences between both arms in terms of freedom from clinical failure and overall 
survival. With the advent of screening programs and increased public awareness of the disease in 
the last decades, there has been a gradual stage migration with subsequently an increase in patient 
referral for radical treatment. The question which patients should receive high-dose radiotherapy 
has become a very important issue to be addressed, especially in view of the arguments in favour 
of observation. From the current literature, it is well-known that dose escalation is associated with a 
higher risk of complications and therefore an impact on quality of life (1-5). Furthermore, the lifetime 
risk of dying from prostate cancer is 3%, indicating that a significant proportion of patients die from 
intercurrent diseases or second cancer (6). Therefore, the selection of patients who should receive 
high-dose radiotherapy remains a common and vexing clinical problem. 
In the current study, we performed an analysis to study whether subgroups of patients could 
be identified who might benefit from high-dose radiotherapy and who might not benefit. This 
subgroup analysis was done in patients with localized prostate cancer treated within the Dutch 
phase III trial randomizing between 68- and 78-Gy of three-dimensional conformal radiotherapy 
(3-DCRT). This subgroup analysis was performed in an intent-to-treat manner.
Patients and methods
Between June 1997 and February 2003, 664 patients with stage T1b-T4 localized prostate 
cancer with initial prostate-specific antigen (iPSA) < 60 mg/L were enrolled in the Dutch dose-
escalation trial and randomly assigned to receive either 68-Gy (n = 331) or 78-Gy (n = 333) of 
3-DCRT. Patients with cytologically or histologically proven positive regional lymph nodes were 
excluded. TNM-classification was done according to the AJCC-1997 guidelines. The details of 
the study design have been published previously (1,5). In brief, patients were stratified by hospital 
(A, B ,C , and D), use of hormonal therapy (HT) (yes vs. no), age (≤ 70 year vs. > 70 year), and 
treatment groups (I, II, III, and IV). These four treatment groups were defined depending on the risk 
of involvement of the seminal vesicles (SV), according to Partin et al. (7) (Table 1). Patients who 
belong to treatment group I have an estimated risk of SV involvement of < 10%, while patients in 
group II have an estimated risk of 10-25%. Patients in group III and IV have an estimated risk of 
SV involvement of > 25%, whereas this risk was 100% for the T3b patients in group IV. 
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For each treatment group, a specific planning target volume (PTV) was defined. The PTV 
included the prostate with or without the SV as clinical target volume (CTV), with a margin of 10 
mm during the first 68-Gy and 5 mm (except toward the rectum: 0 mm) for the last 10-Gy in the 
high-dose arm. The CTV for treatment group I was defined as the prostate only, and for group 
IV, it was the prostate with SV. For treatment group II and III the CTV included the prostate with 
SV, but the SV was excluded from the CTV after 50-Gy and 68-Gy, respectively. The dose was 
specified to the isocenter (ICRU point). The dose to PTVs was between -5% and +7% of the 
prescribed-dose, and 99% of the PTVs were treated to at least 95% of the prescribed-dose. 
Institutions A, B and D used a three-field technique and institution C a four-field technique. 
For 41 patients in the high-dose arm, an IMRT-technique was used with the simultaneous 
integrated boost in institution B (8). All the patients in the 68-Gy arm received the prescribed 
dose. In the high-dose arm, however, 11% received a dose lower than 78-Gy, partly because 
of the dose constraints for rectum and small bowel (for details (5)).
Prognostic models
Two existing models of outcomes prediction were examined. The first was the single-factor 
risk-group model of Chism et al. (9), using three risk-groups: patients with T1-2 and Gleason ≤ 
6 and PSA ≤ 10 mg/L, were at low risk, whereas patients with T3-4 or Gleason 8-10 or iPSA > 
20 mg/L were at high risk. All the other patients were at intermediate risk. The second prognostic 
model was based on iPSA level, because iPSA is the strongest single pre-treatment predictor 
of FFF (2, 10, 11). We analyzed our data according to the most commonly used iPSA-cut-off 
value in the literature (< 10 and ≥ 10 mg/L). Furthermore, we studied in an exploratory analysis 
whether a patient group could be identified based on PSA level groupings, who benefited 
most from dose-escalation. In patients who received HT in combination with external-beam 
radiotherapy, we analyzed the FFF-rates separately in order to explore the independent role of 
dose-escalation in this group of patients. 
Outcome variables
Failures were defined as clinical failures (CF) or biochemical failures (BF) according to the 
Phoenix definition (PSA nadir + 2 mg/L after RT) because of the recent recommendation in the 
Table 1. Treatment groups, according to the risk of involvement of the SV, Partin et al. #
  T1b, T1c, T2a* T2b, T3a* T3b, T4*
Gleason 
score
Differentiation 
grade
PSA 0-4 PSA 4-10 PSA 10-20 PSA 20-60 PSA 0-60 PSA 0-60
2-4 Good I I I II III IV
5-7 Moderate I II II III III IV
8-10 Poor II III III III III IV
* According to the American Joint Committee on Cancer 1997 guidelines. # Treatment groups defined by Partin: I = risk of seminal 
vesicles (SV) involvement of < 10%, II = risk of SV involvement of 10-25%, III and IV: risk of SV involvement of >25%.
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literature that this definition of biochemical failure is a better approximation of eventual CF than 
the ASTRO-definition (three consecutive rises in PSA with backdating to midway between the 
nadir and the first rise) (12). CF was defined as local relapse (palpable and/or biopsy-proven), 
regional relapse, or distant metastases. Initiation of salvage HT only because of a rising PSA 
level was also considered as a CF. 
Statistical analysis
We summarized the subgroup analysis of the different models in Forest Plots. This method 
provides estimates of the Hazard Ratio’s (HRs) (high-dose arm vs. low-dose arm) with its 95% 
confidence interval for each defined subgroup. Chi-square statistics for heterogeneity across 
the defined strata were calculated. We illustrated a number of subgroup analysis by calculating 
Kaplan Meier curves and we estimated the 6-year FFF rates with their 95% confidence interval. 
Software used was SPSS version 15.0.0 (SPSS Inc., Chicago, IL, USA). Review Manager was 
used to construct the Forest Plots (Rev Man, version 5.0, Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2008). We considered p values of 0.05 or below, as 
statistically significant.
results
General characteristics
The distribution of baseline characteristics according to the randomization arms was well bal-
anced (1, 5). The median age was 68 years and the median follow-up time was 70 months 
for both arms. Seventy nine patients (12%) had an iPSA of 0-5 mg/L, 179 (29%) an iPSA of 
5-10 mg/L, 250 (38%) an iPSA of 10-20 mg/L and 156 an iPSA 20-60 mg/L. One hundred and 
nineteen patients (18%) were at low risk, 179 (27%) were at intermediate risk and the majority 
(366, 55%) were in the high risk group. (Neo)adjuvant HT was allowed and prescribed in 143 
patients: mostly to high-risk patients (n=125) and rarely to intermediate- or low-risk patients 
(n=18). Institution A gave long-term neo-adjuvant HT (3 years) (n=79), while institution B used 
short-term HT (6 months) (n=64). Seventy-three patients (22%) in the low-dose arm and 70 
patients (21%) in the high-dose arm received HT.
Interactions, Hazard Ratios and Kaplan Meier estimates
Risk groups
There was no significant (p=0.21) interaction between dose-arm and risk-group (Figure 1A). 
This result shows that high-dose radiotherapy is not more or less beneficial in either of these 
risk groups. The HRs were 1.26, 0.55 and 0.81 for the low-, intermediate- and high-risk groups, 
respectively. The HR for the whole group was 0.78 (95% CI: 0.61-0.99, p= 0.04).
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The overall 6-years FFF-rates for the whole group were 51% (95% CI: 45-58%) and 63% 
(95% CI: 57-68%) for the 68- and 78-Gy arms, respectively. FFF-rates for low-risk group at 
6-years were 84% (95% CI: 73-95%) and 80% (95% CI: 69-91%) for the low-dose arm and the 
high-dose arm, respectively (p= 0.57) (Figure 2A). Kaplan-Meier estimates for intermediate-risk 
patients were 54% (95% CI: 41-66%) and 78% (95% CI: 68-87%) for the 68 and 78-Gy arms, 
respectively (p= 0.023) (Figure 2B). The figures for high-risk group were 40% (95% CI: 31-48%) 
and 49% (95% CI: 41-57), respectively (p= 0.15) (Figure 2C). 
PSA groupings
For patients according to an iPSA level < 10 mg/L or ≥ 10 mg/L, the test for heterogeneity was 
significant (p=0.03) (Figure 1B). The HRs were 1.22 and 0.66 for the iPSA level < 10 mg/L and 
≥ 10 mg/L group, respectively. Patients with iPSA ≥ 10 mg/L who were randomized in the high-
dose arm showed significantly (p= 0.005) better FFF (6-year FFF rate 62%, 95% CI: 55–69%) as 
compared to those in the low-dose arm (6-year FFF rate 40% 95% CI: 32–48%) (Figure 3B). For 
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Figure 1. Forest plots with numbers of events and the corresponding hazard ratios (with 95% CI) showing the effect of radiation 
dose on (1A) freedom from failure (FFF) for low-, intermediate-, and high-risk groups according to Chism et al. (9), (1B) FFF for 
iPSA-groupings (< 10 and ≥ 10 mg/L), (1C) FFF for iPSA-groupings (< 8, 8-18, and > 18 mg/L), and (1D) FFF for high-risk 
patients treated with or without hormonal therapy.
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patients with iPSA < 10 mg/L, there was no significant (p= 0.4) difference in the 6-year FFF rates 
(Figure 3A). 
An explorative analysis of our data showed the most optimal dose-effect for patients with an 
iPSA between 8-18 mg/L (297 patients, 45% of the study population). Therefore we decided to 
analyse our data with PSA level groupings according to three groups: < 8, 8-18 and > 8 mg/L. 
The test of heterogeneity was significant (p= 0.05) (Figure 1C). Patients with iPSA between 8 
and 18 mg/L seem to derive the most benefit from high-dose radiotherapy, as compared to 
other the PSA-groups (HR= 0.59 for iPSA 8-18 mg/L, 0.83 for iPSA > 18 mg/L, and 1.34 for 
iPSA < 8 mg/L). 
Patients with iPSA 8-18 mg/L who were randomized in the high-dose arm showed significant 
(p= 0.008) better FFF (6-year FFF rate 70 %, 95% CI: 62–78%) as compared to those in the 
low-dose arm (6-year FFF rate 52 %, 95% CI: 41–62%) (Figure 4B). For patients with iPSA <8 
Figure 2. Freedom from failure for patients in the low-risk (2A), intermediate-risk (2B) and high-risk groups (2C) by randomization arm.
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Figure 3B chapter 6
Figure 3. Freedom from failure for patients with iPSA< 10 (A) and ≥ 10 mg/L (B) by randomization arm.
Figure 4. Freedom from failure for patients with iPSA < 8 (4A), 8-18 (4B), and > 18 mg/L (4C) by randomization arm.
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mg/L and iPSA> 18mg/L, there were no significant (p= 0.4 and p= 0.3, respectively) differences 
in the 6-year FFF rates (Figure 4A and 4C).
With respect to the use of HT in high-risk patients, the test for heterogeneity was not signifi-
cant (Figure 1D). FFF-rates were better in patients treated with HT and radiotherapy, compared 
to those treated with radiotherapy alone (HRs were 0.68 and 0.87, respectively). 
discussion
In our trial, we found an overall significantly better FFF in patients treated with a higher dose for 
localized prostate cancer. We investigated in this study whether we could identify significant 
heterogeneity in dose-response among the trial patients, who had a wide range in expected 
tumor control based on their Gleason score, iPSA level and/or tumor stage. Separating patients 
on iPSA, we found similar results as reported in literature: patients with low iPSA levels do not 
seem to benefit from dose escalation. We found however an indication that the most optimal 
cut-off was around 8 mg/L instead of 10 mg/L and moreover that patients with relatively high 
iPSA levels did not profit either from dose-escalation in our trial. We also evaluated the effect 
of combined treatment of RT with HT for the high-risk patients and concluded that there was 
no indication that these patients would not profit from dose-escalation, which also confirms 
observations of other groups.
Low-, intermediate-, and high risk groups as defined by Chism et al.
The tests of interaction between risk group and dose-arm was not significant, indicating that 
based on our trial no risk-group should be excluded from high-dose radiotherapy. The Kaplan 
Meier curves were shown to illustrate FFF as a function of time (Figures 2A-C). It should be 
stressed here, that one should not conclude that high-dose radiotherapy is not indicated for 
the low- and high-risk patients (with p values of 0.4 and 0.15, respectively), since there was no 
significant interaction. 
Dearnaley et al. (4) performed a similar subgroup analysis and found, as in our study, no hetero-
geneity of effect (p= 0.44). Therefore, neither of these analyses could exclude nor recommend 
high-dose radiotherapy in either of these risk-groups. In the MGH/LLUMC proton dose escala-
tion trial (3), the overall significant differences persisted for low-risk (p< 0.001) and intermediate-
risk (p= 0.02) patients, but was lost in the small number (n= 33) of high-risk patients (p= 0.49). 
However, in this study a test of interaction was not performed.
When the data from the MRC trial (4) and our trial were pooled, the test of interaction was still 
negative but the HR was improved from 0.78 in our study to 0.65 in the pooled data from 
both studies (p= 0.0001) (Figure 5). Therefore, a meta-analysis from the data of all mature 
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randomized dose-escalation trials would help us to decide whether low-risk patients should 
receive high-dose radiotherapy or not. 
In the literature, the role of dose-escalation in the intermediate-risk group is undisputed (1-5, 10, 
13, 14), whereas the importance of high-dose radiotherapy for high-risk patients is definitively 
more complex, especially in studies were HT were allowed, as in our study. The use of HT in 
these studies makes it difficult to determine the role of dose-escalation separately. Because of 
the improved local control, distant metastases-free survival and even overall survival achieved 
with HT (10, 15), it is not justified to exclude high-risk patients using HT from high-dose radio-
therapy. If we do so, we might withhold these patients from the essential synergistic role of RT 
and HT to control their disease in a proper way. In our study the FFF was better in those patients 
who received high-dose radiotherapy in combination with HT (HR= 0.68).
Only one prospective randomized trial (the MRC trial of the Institute of Cancer Research and 
Royal Marsden Hospital) showed a benefit of dose-escalation in patients treated with HT (4). 
One prospective non-randomized trial (16) demonstrated a 79% freedom from biochemical 
failure (FFBF) at 5-years in high-risk patients treated with HT and high-dose radiotherapy, 
comparable with the 5-year FFBF seen in the low-risk group (80%). Interestingly, these patients 
consistently experienced a significant benefit from higher radiation doses (63% for < 72 Gy vs. 
84% for ≥ 72 Gy) (p=0.003). Zelefsky et al. (10) observed a benefit for HT in high-risk patients 
who also received higher doses of radiotherapy, but also concluded a strong interdependence 
on the use of neo-adjuvant HT and higher doses; patients who offered neo-adjuvant HT were 
significantly more likely to receive higher dose of radiotherapy than patients who did not receive 
HT (p< 0.0001). 
Table 2 shows an updated overview of subgroup analyses from different randomized and non-
randomized trials of dose-escalation of radiotherapy for localized prostate cancer. As illustrated 
in Table 2, all randomized-controlled trials (RCT) showed a benefit of dose-escalation in the 
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Figure 5. Forest plots with numbers of events and the corresponding hazard ratios (with 95% CI) showing the effect of radiation 
dose on freedom from failure for low-, intermediate-, and high-risk groups according to Chism et al. (9) in the pooled data from our 
study (A from Al-Mamgani et al.) and the MRC RT01 trial of the Institute of Cancer Research and Royal Marsden Hospital (D from 
Dearnaley et al. (4)).
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intermediate- and high-risk group, with the exception of the trial of the Massachusetts General 
Hospital and Loma Linda University Medical Center (3). A benefit from dose-escalation in low-
risk patients were observed in all RCT, except in our study. Subgroup analyses were also 
performed in two large non-randomized studies. Zelefsky et al. (10) treated more than 2000 
patients with localized prostate cancer to different dose levels ranged from 66 to 86.4-Gy 
and found a significant improvement in outcomes for patients with intermediate- and high-risk 
patients but no differences were observed among low-risk patients for the various dose-groups. 
Kuban et al. (13) pooled the results of 4839 patients from different institutions and showed a 
significant dose-effect relationship (doses < 72 vs. ≥ 72-Gy) in intermediate- and high-risk 
patients but not in the low-risk group. 
PSA-level groupings 
For the two studied types of PSA level groupings: PSA < 10 and ≥10 mg/L, and < 8, 8-18 and 
> 18 mg/L, the test for heterogeneity was significant (p= 0.03 and 0.05, respectively). These 
results indicate that patient selection for high-dose radiotherapy based on iPSA level might be 
indicated. The exact number(s) of iPSA cut-off points is still to be determined. Our data showed 
that patients with iPSA between 8 and 18 mg/L benefited most from dose-escalation; FFF-rates 
were significantly better in the high-dose arm as compared to the low-dose arm (p= 0.008). 
Table 2. Subgroup analyses, randomized and non-randomized trials of DE of radiotherapy for localized prostate cancer
Trial Size Dose (Gy) Subgroup FF(B)F; high-dose vs. low-dose Statistics
RCT MD Anderson (2) 301 70 vs. 78 PSA >10 78% vs. 39% at 8-years p= 0.001
LRG 88% vs. 63% at 8-years p= 0.042
IRG+PSA >10 94% vs. 65% at 8-years p= 0.076
HRG 63% vs. 26% at 8-years p= 0.004
RCT MRC RT01 (4) 843 64 vs. 74 LRG 85% vs. 79% at 5-yeras HR= 0.78
IRG 79% vs. 70% at 5-years HR= 0.74
HRG 57% vs. 43% at 5-years HR= 0.60
RCT MGH/LLUMC (3) 393 70.2 vs. 79.2 LRG 98% vs. 85% at 5-years p< 0.001
IRG 91% vs. 79% at 5-years p= 0.02
RCT Current Dutch study 664 68 vs. 78 PSA > 10 62% vs. 40% at 6-years HR= 0.66
PSA 8-18 70% vs. 52% at 6-years HR=0.59
IRG 78% vs. 54% at 6-years HR= 0.55
HRG 49% vs. 44% at 6-years HR= 0.81
NRT Multicenter study (13)* 4,839 < 72 vs. ≥ 72 IRG 64% vs. 50% at 8-years p< 0.0001
HRG 36% vs. 27% at 8-years p= 0.007
NRT MSKCC (10) 2,047 66-86.4 IRG 84% vs. 68% at 5-years p< 0.001
HRG 71% vs. 40% at 5-years p< 0.001
Abbreviations: DE: dose-escalation; FF(B)F: freedom from biochemical failure or freedom from any failure; RCT: randomized 
controlled trial; NRT: non-randomized trial; PSA: prostate-specific antigen level; LRG: low-risk group; IRG: intermediate-risk 
group; HRG: high-risk group; HR: hazard ratio; MRC: Institute of Cancer Research and Royal Marsden Hospital; MGH/LLUMC: 
Massachusetts General Hospital and Loma Linda University Medical Center; MSKCC: Memorial Sloan-Kettering Cancer Center. * 
Kuban et al. (13) pooled and published the results from different centers including MD Anderson, MSKCC, Cleveland, Fox Chase 
Cancer Center, and more.
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Other groups analyzed their data as well, based on a cut-off value of 10 mg/L. The MDACC 
trial (2), reported a benefit from dose-escalation in patients with iPSA > 10 mg/L and no 
dose-response could be demonstrated for patients with iPSA ≤ 10 mg/L. However, no test of 
interaction was performed in this study. Pinover et al. analyzed the Fox Chase Cancer Centre 
cohort with iPSA ≤ 10 mg/L (n=488) (stratification < 72.5, 72.5-75.9 and ≥ 76 Gy) and found 
no significant dose-response for the entire group and for good prognosis patients. Only poor 
prognosis patients (> T2a and Gleason > 6) with iPSA ≤ 10 mg/L benefited from escalating the 
radiation dose to ≥76 Gy (17).
Since a relatively large part of prostate cancer patients has iPSA between roughly 7 and 10 mg/L, 
it is a clinically relevant question whether these patients might benefit from dose-escalation. Our 
data do not support the findings of other investigators that patients with iPSA <10 mg/L do not 
profit form high-dose radiotherapy (2, 17). From our data one could conclude that patients with 
an iPSA < 8 mg/L have no benefit of high-dose radiotherapy. 
Our results also suggest that there could be an upper limit of iPSA, above which there is no 
advantage for high-dose radiotherapy. This finding should be confirmed by other studies.
General remarks
Despite the fact that our study has been carried out within the framework of a randomized trial, 
one should be aware of the weaknesses and pitfalls of such an exploratory analysis of prospec-
tively collected data. We performed tests of heterogeneity to assess whether a treatment effect 
differed between subgroups. The test of interaction in our analysis was not significant between 
dose-arm and the prognostic risk groups. Therefore no conclusion could be made of the value 
of high-dose radiotherapy in any of these risk groups separately. However, based on the two 
iPSA level groupings, we found significant interactions. Therefore we might conclude that for 
patients with an iPSA < 8 mg/L high-dose radiotherapy is probably not indicated.
The results of our analyses suggest that iPSA grouping is probably a better predictor for a 
possible benefit of dose escalation rather than the risk grouping. The studied risk groups are 
however also partly based on iPSA-grouping. In a multivariate analysis of prognostic factors for 
FFF with iPSA as a continuous variable and risk-group, dose-arm and use of HT as co-variables 
(data not shown), the iPSA level and risk grouping both are significant factors. Therefore the 
iPSA level is probably of a higher importance than accounted for in the current risk group-
ing. Moreover, within the context of the value of high-dose radiotherapy, one might explore in 
the future other definitions of prognostic groups, including not only factors like iPSA, T-stage, 
Gleason sum and but also parameters like e.g. vascular or perineural invasion, multiple positive 
biopsies, or high iPSA level/velocity. Such a study should preferably be undertaken in a meta-
analysis from the data of all mature randomized dose-escalation trials.
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conclusions
In our study, no conclusion could be drawn with regard to the value of high-dose radiotherapy 
in the three risk-groups and specifically no indication was found to exclude low-risk patients 
from high-dose radiotherapy. FFF-rates were improved in patients treated with hormonal therapy 
in combination with high-dose radiotherapy, compared to those treated with low-dose radio-
therapy and hormonal therapy. PSA-level groupings showed significant interactions with the 
dose-arm. For patients with an iPSA < 8 mg/L high-dose radiotherapy is probably not indicated, 
but this should be confirmed in other studies. 
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abstract
Background
In high-risk prostate carcinoma, there is controversy whether these patients should be treated 
with escalated-dose (≥ 74 Gy) or conventional-dose radiotherapy (< 74 Gy) combined with 
hormonal therapy. Furthermore, the issue of the optimal duration and timing of hormonal therapy 
are not well crystallized. 
Patients and Methods
A search for evidence from randomized- and large non-randomized studies in order to address 
these issues, was therefore initiated. For this purpose, MedLine, EMbase, and PubMed and the 
data base of the Dutch randomized dose-escalation trial, were consulted. 
Results and Conclusions
From this search it was concluded that the benefit of hormonal therapy in combination with 
conventional-dose radiotherapy (< 74 Gy) in high-risk prostate cancer is evident (Level 2 
evidence); Level 2 and 3 evidence was provided by several studies supporting the use of esca-
lated-dose radiotherapy in high-risk prostate cancer. For the combination of hormonal therapy 
with escalated-dose radiotherapy in these patients, there is Level 2 evidence for moderately 
escalated dose (74 Gy) and high escalated dose (≥ 78 Gy). The optimal duration and timing 
of hormonal therapy are not well defined. More randomized-controlled trials and meta-analyses 
are therefore needed to clearly determine the independent role of dose-escalation in high-risk 
patients treated with hormonal therapy and the optimal duration and timing of hormonal therapy.
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introduction
Since 2002, prostate cancer (PC) has overtaken lung cancer to become the most common 
cancer in men. Annually, in the USA, approximately 186,000 new cases of PC are diagnosed 
with 29,500 PC-related deaths [1]. Of the newly-diagnosed cases, at least 30% have high-
risk disease [2]. The four randomized dose-escalation trials of radiotherapy (RT) [3-6] included 
2,201 patients with localized PC. Of those patients; 39% were at high-risk for biochemical 
failure. The most commonly used definitions of high-risk PC are the single-factor risk-group 
model of Chism et al. [7] (stage T3-4 or iPSA > 20 mg/L, or Gleason-score 8-10) and the very 
similar National Comprehensive Cancer Network criteria [8] (stage T3 or Gleason score 8-10 
or iPSA > 20 mg/L). High-risk PC is clinically a very heterogeneous group and, therefore, a 
challenge to the oncologists in terms of diagnosis, management and prognosis. This group 
contains a wide spectrum of diseases, ranging from patients with locally aggressive disease to 
those with widespread occult distant metastases (DM). 
Different studies have shown that patients with high-risk PC have a higher incidence of bio-
chemical and clinical failures when treated with monotherapy (hormonal therapy (HT) or RT) [9, 
10]. Widmark et al. [9] recently published the results of the Scandinavian randomized-controlled 
trials (RCT) comparing HT-alone with the combination of HT and standard-dose RT in 875 
patients with locally-advanced PC. In that study, the addition of local RT to HT halved the 
10-year cancer-specific mortality (CSM) in high-risk PC and substantially improved local control 
and overall survival (OS) with a fairly acceptable toxicity profile. It is also well-known that long-
term outcome after conventional-dose RT alone in locally-advanced PC is poor: treating those 
patients with 60-66 Gy of RT alone in the pre-PSA era resulted in poor disease-free survival 
(DFS) (15-30%), and OS (10-20%) at 15-years [11]. The need for increasing the dose of RT to 
above those levels was first suggested by dose-response observations by Perez et al. [12] and 
Hanks et al. [10] and confirmed, later on, by different RCTs [3-6].
Patients and methods
In this article, we will give an overview of the following issues for high-risk PC patients:
1. The use of HT in combination with standard-dose RT
2. The effect of dose-escalation of RT
3. The independent role for RT dose-escalation for patients on HT
4. Short- vs. long-course HT 
5. Neoadjuvant, concomitant, adjuvant HT or in a combination of these
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In order to address these issues, a thorough and critical literature review was performed through 
literature searches (in MedLine, EMbase and PubMed) for evidence from randomized and large 
non-randomized studies to support either the use of conventional-dose or escalated-dose RT in 
high-risk PC combined with HT. Data from the Dutch randomized dose-escalation trial were also 
used for this review [6]. Only relevant peer reviewed papers published in English after the era of 
combined-modality treatment (HT and RT) were included. The search terms used were: “high-
risk PC”, “locally-advanced PC”, “radiotherapy”, “hormonal therapy”, and “dose-escalation”. 
According to National Cancer Institute (NCI) guidelines [13], the levels of evidence supporting 
recommendations for the different strategies are reported in the text and summarized as follow:
Level 1. Randomized controlled clinical trials: 
- Double-blinded. 
- Nonblinded treatment delivery. Subset analyses should be placed in the next lower category 
of study design (nonrandomized controlled clinical trials).
Level 2. Nonrandomized controlled clinical trials. 
Level 3. Case series. 
- Population-based, consecutive series. 
- Consecutive cases (not population-based). 
- Nonconsecutive cases. 
results 
Combining HT with conventional-dose RT in locally-advanced PC (Table 1) 
First it should be mentioned that the RCTs mentioned in this paragraph were performed for 
locally-advanced PC. This group of patients only partly overlap with the high-risk patients group.
The Radiation Therapy Oncology Group (RTOG) has conducted three large RCTs to evaluate the 
role of combined-modality treatment (HT added to conventional-dose RT) in locally-advanced 
PC [14-16]. These trials enrolled almost 3000 patients between 1987 and 1995. RTOG 86-10 
was the first RCT to evaluate the effect of neoadjuvant HT in combination with 65-70 Gy of 
RT [16]. In that study, 456 patients were randomly assigned to receive either RT-alone or RT 
in combination with HT starting 2 months before the RT and continued during the course of 
radiation. In that study, DFS (any kind of failure, death from any cause or starting salvage HT), 
freedom from distant metastases (FFDM), and cancer-specific mortality (CSM) were significantly 
better in the combined-modality arm without increasing risk of fatal cardiac events. OS was also 
better in the combined-modality arm, but did not reach statistical significance (Table 1). 
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In the second RTOG-trial (85-31) [15], 977 patients with locally-advanced PC were randomized 
to be treated with either RT and immediate HT (arm I), started in the last week of radiation 
course (65-70 Gy) and continued indefinitely or until signs of progression or RT and delayed 
HT at relapse (arm II). DFS (survival in the absence of locoregional or distant metastasis), and 
CSM were significantly better in patients treated with adjuvant HT (arm I) The absolute survival at 
10 years was also significantly better in arm I compared with arm II (49% vs. 39%, respectively, 
p=0.002). 
The largest RTOG-trial (92-02) included 1554 patients with locally-advanced PC [14]. All patients 
were treated with HT before and during the RT (4 months) and followed by randomization to 
either no further HT (arm I) or 24-months of goserelin (arm II). In that study, DFS was defined as 
survival without any kind of failure, including biochemical failure, starting additional HT or death. 
At 10-years, arm II showed significant improvements in all endpoints except OS. However, in 
the subgroup analysis, a significant OS benefit was observed in patients with Gleason score of 
8-10 treated in arm II (45% vs. 32%, p=0.006).
Table 1. RCT of conventional-dose RT alone or in combination with HT in patients with locally-advanced prostate cancer
Trial P (N) Timing HT Duration HT Dose RT Outcomes RT arm vs. RT + HT arm P-value
RTOG 92-02 
[14]
1,554
NHT/CHT vs. 
NHT/CHT/AHT
24 months 70 Gy
10-years OS 52% vs. 54% 0.36
10-years DFS 13% vs. 23% <0.0001
10-years CSM 16% vs. 11% 0.004
RTOG 85-31 
[15]
977 AHT Indefinitely 65-70 Gy
10-years OS 39% vs. 49% 0.002
10-years DFS 23% vs. 37% <0.0001
10-years CSM 22% vs. 16% 0.005
RTOG 86-10 
[16]
456 NHT/CHT 4 months 65-70 Gy
10-years OS 34% vs. 43% 0.12
10-years DFS 3% vs. 11% <0.0001
10-years CSM 36% vs. 23% 0.01
AMCM [17] 206  NHT/CHT/AHT 6 months 70 Gy
8-years OS 61% vs. 74% 0.01
8-years CSM 14% vs. 4% 0.007
EORTC [18] 415 CHT/AHT 3 years 70 Gy
5-years OS 62% vs. 78% <0.0001
5-years DFS 40% vs. 74% <0.0001
5-years CSM 21% vs. 6% <0.0001
TROG 96-01 
[19]
818 NHT
3 months 66 Gy
5-years DFS 32% vs. 49% 0.0001
5-years CSM 9% vs. 8% 0.7
6 months 66 Gy
5-years DFS 32% vs. 52% <0.0001
5-years CSM 9% vs. 6% 0.04
Swedish [20] 91 Orchidectomy  65 Gy
17-years OS 13% vs. 24% 0.03
17-years CSM 57% vs. 36% 0.02
Abbreviations: RCT: randomized-controlled trials; RT: radiotherapy; HT: hormonal therapy; P (N): patients’ numbers; AHT: adjuvant HT; 
NHT: neo-adjuvant HT; CHT: concurrent HT, OS: overall survival; DFS: disease-free survival; CSM: cancer-specific mortality; RTOG: 
Radiation Therapy Oncology Group; AMCM: Academic Medical Centers Massachusetts; EORTC: European Organization for Research 
and Treatment of Cancer; TROG: Trans-Tasman Radiation Oncology Group;
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D’Amico et al. [17] published the results of the RCT of 6-months of adjuvant HT plus RT (arm I) 
vs. RT-alone (arm II) for 206 patients with localized but unfavorable PC. In arm I, 70 Gy of RT was 
combined with 6-months of HT; started 2 months before, continued during and for 2-months 
after the RT. Combined-modality treatment showed significant improvements in CSM and OS. 
Only four patients died from PC in the combined modality arm compared to 14 patients in the 
RT- alone arm at 8 years (p=0.007).
Bolla et al. [18] reported significant improvements in DFS (locoregional or distant failures), 
and OS at 5-years in 415 patients with localized PC treated with either 70-Gy of RT-alone 
or combined with 3-years of adjuvant HT, started on the first day of irradiation. Of the whole 
study population, 129 patients (31%) were at high-risk. The improvements seen in all endpoints 
persisted in the high-risk patients in the subgroup analysis (Table 1).
The Trans-Tasman Radiation Oncology Group (TROG) [19] has randomized 818 patients with 
locally-advanced PC to receive either 66-Gy alone (arm I) or 66 Gy of RT in combination with 
3-months HT starting 2 months before RT (arm II) or 6-months HT starting 5 months before 
RT (arm III). At 5-years, DFS (no evidence of clinical failure at any site, start of salvage HT, 
no biochemical failure or death) was significantly improved in arm II as compared to arm I. 
Regarding CSM at 5 years, the rates were comparable in both arms (9% for arm I vs. 8% for 
arm II, p=0.7). However, all endpoints of the study were significantly improved with increasing 
the duration of the adjuvant HT from 3 to 6 months plus RT (arm III), including reduction or delay 
in the appearance of DM (HR=0.67, p=0.04).
The long-term results of the Swedish RCT comparing orchidectomy and RT vs. RT-alone, 
showed that CSM at 17 years was significantly higher in the RT-alone arm (57% vs. 36%, 
p=0.02) [20]. OS was also significantly improved in the combined modality arm ( 24% vs. 13%, 
p=0.03). 
In conclusion, the results of the seven RCTs comparing the use of conventional-dose RT-
alone vs. the addition of HT to RT substantiate a powerful beneficial effect of adjuvant HT in 
patients with locally-advanced PC. Subgroup analysis in some of these studies showed that 
the adjuvant effect was also apparent in the high-risk patient subgroup. Therefore these studies 
provided Level 2 evidence supporting the use of HT in combination with conventional-dose RT 
as a standard of care in high-risk PC. 
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Dose-escalation of RT in high-risk prostate cancer 
Non-randomized studies of dose-escalation in high-risk PC (Table 2) 
Zelefsky at al. [21] reported the experience of MSKCC treating 2,047 patients with clinically local-
ized PC with 3D-CRT or IMRT with different dose-levels ranged from 66 to 86.4 Gy. About half 
of the patients (48%) were treated with 3 months of neoadjuvant HT. Intermediate- and high-risk 
patients appeared to benefit most from escalating the dose of RT above conventional-levels. In 
patients with high-risk PC, multivariate-analysis showed that radiation dose is not only a signifi-
cant predictor for freedom from biochemical failure (FFBF) (Phoenix definition [22]: an increase in 
PSA level of more than 2 mg/L above the post-treatment nadir) (p<0.0001), but also for FFDM 
(p=0.01). Because neoadjuvant HT and higher radiation doses were closely associated in this 
study, specific high-dose levels were not longer significant in the setting of neoadjuvant HT. 
Kupelian et al. [23] reported the results of 9 institutions (n = 1,325). In that study, the 5-year 
FFBF (ASTRO definition [24]: 3 successive increases in PSA level, with the failure backdated to 
a point halfway between the first increase and the last non-increasing value) for the whole group 
of patients received a dose ≥ 72 Gy was significantly better as compared with those treated with 
< 72 Gy (69% vs. 63%, p=0.046). However, for the 221 high-risk patients the difference (46% 
vs. 38%) was no longer significant (p=0.13).
A moderately-strong evidence for the need of dose-escalation in high-risk PC was also 
provided by the group of William Beaumont Hospital [25]. They performed a prospective trial 
of pelvic external-beam RT (46 Gy) interdigitated with dose-escalating highly-conformal HDR-
brachytherapy (BT), using two dose-levels (low BED <93 Gy and high BED >93 Gy). The 5-year 
FFBF (ASTRO definition) and CSM were significantly better in the high-BED group (p<0.001 and 
0.014, respectively). 
At the University of Michigan [26], 1473 localized PC were treated with 3D-CRT. Prescribed 
dose-levels ranged from 60 to 80.4 Gy. For intermediate-risk patients, the effect of the total 
dose on the FFBF (ASTRO definition) was significant (HR=0.92, p=0.005). However, for the 
high-risk patients (n=456), the effect of the total dose was not significant (HR=1.02, p=0.3). 
Randomized-controlled studies of dose-escalation in high-risk PC (Table 3)
The first RCT of dose-escalation was undertaken by Pollack and colleagues from the M.D. 
Anderson Cancer Center. In the recent update of that study [3], FFBF (Phoenix definition), free-
dom from clinical failure (FFCF), and FFDM were significantly improved by escalating the dose 
of RT from 70 to 78 Gy. In the entire cohort, the 8-year FFBF was significantly improved in the 
high-dose arm (78% vs. 59%, p=0.004). In the subgroup analysis, high-risk patients (33% of the 
whole study population) benefited significantly from high-dose RT, with FFBF at 8-year of 63% for 
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the high-dose arm, compared with 26% for the low-dose arm (p=0.004). FFCF (93% vs. 82%, 
respectively) and FFDM (4% vs. 17%, respectively) were also significantly better in the high-dose 
arm. No OS benefit was seen in that study. However, more patients died of PC in the 70-Gy arm.
At the Massachusetts General Hospital and Loma Linda University Medical Center, 393 patients 
with localized PC were randomized to receive either 70.2- or 79.2 Gy [4]. The primary endpoint 
of that study was FFBF, defined using the ASTRO criteria. In the entire study population, the 
5-year actuarial FFBF was 93% for the high-dose arm as compared with 81% for low-dose 
arm (p<0.001). These significant differences between both arms also persisted when patients 
were divided into low-risk (84.7% vs. 97.8%, p<0.001) and intermediate-risk (79.1% vs. 90.9%, 
p=0.02) subgroups, but lost in the small number (n=33) of high-risk patients (p=0.8). 
In the RCT of Medical Research Council (MRC), 843 patients were randomly assigned to 
receive a standard-dose (64 Gy) or escalated-dose RT (74 Gy) [5]. All patients received neo-
adjuvant and concomitant HT for 3-6 months. FFBF in that study was defined as increase in 
PSA concentration to greater than the nadir by at least 50% and >2 ng/mL 6 months or more 
after the start of RT. In the entire cohort, the 5-year FFBF was significantly improved in the high-
dose arm (71% vs. 60%, HR=0.67, 95%CI = 0.53-0.85, p=0.0007). Of the whole group, 362 
patients (43%) were at high-risk. The 5-year FFBF-rates for high-risk PC treated with high-dose 
vs. low-dose were 57% vs. 43%, respectively (HR=0.6, 95% CI = 0.44-0.81).
The Dutch RCT enrolled 664 patients; of those, 362 (55%) were at high-risk [6]. Of the high-risk 
patients, 125 patients (34%) received 6- or 36-months of HT. Of the whole group, the 6-year free-
dom from failure (FFF) (biochemical (Phoenix definition) or clinical) was improved from 51% in the 
low-dose arm to 63% in high-dose arm (p=0.04). In the subgroup analysis, the difference between 
both arms was not statistically significant in the high-risk group (49% vs. 40%, p=0.15) [27].
In conclusion, a significant benefit from dose-escalation was seen in high-risk patients in some 
randomized and non-randomized trials. These positive studies generate Level 2 and Level 3 
evidence supporting the use of dose-escalation in high-risk PC. A meta-analysis of all mature 
RCTs would strengthen the level of evidence. The questions which emerge: Is high-dose RT 
really required in patients with high-risk PC on hormonal treatment? 
Dose-escalation combined with HT in high-risk PC (Table 2)
Several studies have shown that conventional-dose RT in combination with HT yielded a sig-
nificantly better outcome than RT-alone [15-20]. However, the mechanism mediating the better 
outcome in the combined-modality arm remains unclear. Whether the benefits observed are 
due to hormone-induced radiosensitization or due to the elimination of occult micrometastses 
remains to be proven. In order to identify a possible independent role of dose-escalation in 
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high-risk PC, we analyzed data from different non-randomized and randomized studies where 
this issue was addressed separately.
Non-randomized studies of dose-escalation of RT in combination with HT
The hypothesis that escalated-dose RT is also needed in high-risk patients treated with HT 
was already tested by different prospective and retrospective studies of external beam therapy 
(EBRT), brachytherapy (BT) or the combination of both modalities of RT (Table 2 and 3).
Only one prospective non-randomized study has addressed the independent role of dose-
escalation in high-risk patients who also received HT. Zapatero and colleagues [28] treated 
160 patients with high-risk PC with 3D-CRT (dose 64.2-82.6 Gy) combined with adjuvant HT 
(24-months). The results demonstrated a 84% FFBF (ASTRO definition) at 5- years in high-risk 
patients treated with HT and radiation dose ≥ 72 Gy, compared to 63% in patients treated with 
dose < 72 Gy (p=0.003).
Zelefsky et al. [21] reported in the recent update of their retrospective analysis (n = 2,047) a 
benefit for HT in high-risk patients who also received higher doses of RT. Because neoadjuvant 
HT and higher radiation doses were closely associated in this study, specific high-dose levels 
were not longer significant in the setting of neoadjuvant HT.
Table 2. Non-randomized studies of dose-escalation of RT with or without HT in patients with high-risk prostate cancer
Trial P (N) HRG (N) HT Duration HT Dose RT Outcomes Statistics 
Zelefsky [21] 2,047 752 No/Yes 3 months
< 70 Gy 5-years FFBF 40% 
p<0.0001
75.6 Gy 5-years FFBF 61% 
81 Gy 5-years FFBF 66% 
86.4 Gy 5-years FFBF 71% 
Kupelian [23] 1,325 221 No  
< 72 Gy 5-years FFBF 38%
p=0.13
≥ 72 Gy 5-years FFBF 46%
Zapatero [28] 416 160 Yes 24 months
< 72 Gy 5-years FFBF 63% 
p=0.003
≥ 72 Gy 5-years FFBF 84% 
Nguyen* [29] 296 88
Yes for 
<75 Gy
3 months
< 75 Gy 5-years FFBF 35%
p=0.02
≥ 75 Gy 5-years FFBF 57%
Martinez [25] 207 207 No  
46 Gy EBRT+ HDR BT:  
p<0.001BED < 93 Gy 5-years FFBF 52%
BED > 93 Gy 5-years FFBF 87%
Stone [30] 5,889 1078 No/Yes 3-9 months
45 Gy EBRT+ LDR BT:
p<0.001
BED < 200 Gy 5-years FFBF 76% 
BED 200-220 Gy 5-years FFBF 83% 
BED > 220 Gy 5-years FFBF 88% 
Abbreviations: HT: hormonal therapy; P (N): number all patients included in that study; HRG (N): number of patients with high-risk 
included in that study; RT: radiotherapy; EBRT: external-beam radiotherapy; BT: brachytherapy; * Matched-pair analysis; FFBF: 
freedom from biochemical failure; HDR: high-dose rate; LDR: low-dose rate; BED: biological equivalent dose.
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In order to address the question if short-term HT is a substitute for dose-escalation in high-risk 
PC, Nguyen and colleagues from Fox Chase Cancer Center [29] did a separate matched-pair 
analysis between high-risk patients treated with short-term HT and radiation dose < 75 Gy 
(group A) and those with a dose ≥ 75 Gy without HT (group B). FFBF (ASTRO definition) at 
5-years was significantly better in group B (57% vs. 35%, p=0.02). The results in that small 
study suggest that short-term HT was not a substitute for a higher dose RT.
The benefit of dose-escalation of RT in high-risk PC was also suggested by a study were 
high-dose RT using BT (as a boost after EBRT) was given partly in combination with HT. Stone 
et al. [30] reported the data of 1078 high-risk (Gleason 7-10) patients collected from 6 cancer 
centers in the USA. In that study, patients were treated with high-dose RT consisted of 45 Gy of 
EBRT followed by BT. Of the whole group, 61.8% was treated with HT. FFBF (Phoenix definition) 
at 5 years was significantly better (p<0.001) as the BED increased from less then 200 Gy to 
larger then 220 Gy. 
Randomized studies of dose-escalation of RT in combination with HT
From the 4 mature RCTs of dose-escalation of RT [3-6], a possible independent role of 
escalated-dose RT in high-risk patients treated with hormones was only be examined in the 
MRC trial [5]. In this trial HT was given to all patients and in the high-risk subgroup the effect 
of dose escalation was still present. In this trial however, the escalated dose was relatively low 
(74 Gy). In the first two RCT of the M.D. Anderson Cancer Center and Massachusetts General 
Hospital/ Loma Linda University Medical Centre [3, 4] the escalated dose was high (78 Gy and 
79.2 Gy, respectively), but HT was not allowed.
Table 3. Randomized-controlled trials of dose-escalation of RT with or without HT in patients with high-risk prostate cancer
Trial Randomization arms HT Duration HT P (N)
HRG 
(N)
FF(B)F high-dose vs. low-dose arm Statistics
MDACC [3] 78 vs. 70 Gy No  
301 78% vs. 59% at 8-years p=0.004
 101 63% vs. 26% at 8-years p=0.004
MGH/LLUMC 
[4]
79.2 vs. 70.2 Gy No  
393 93% vs. 81% at 5-years p<0.001
 33 Very small number of patients 0.8
MRC [5] 74 vs. 64 Gy Yes 3-6 months
843 71% vs. 60% at 5-years
HR=0.67, 
95%CI:0.53-
0.85
 362 57% vs. 43% at 5-years
HR=0.60, 
95%CI:0.44-
0.81
Dutch trial [6] 78 vs. 68 Gy Yes/No 6-36 months
664 63% vs. 51% at 6-years p=0.04
 362 49% vs. 40% at 6-years p=0.15
Abbreviations: RT: radiotherapy; FFF: freedom from failure; FFBF: freedom from biochemical failure; P (N): total number of patients 
treated in that trial; HRG (N): number of high-risk patients treated in that trial; HR: hazard ratio; MDACC: M.D. Anderson Cancer 
Center; MGH/LLUMC: Massachusetts General Hospital, Loma Linda University Medical Centre; MRC: Medical Research Council.
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The Dutch trial randomized 664 patients with localized PC to receive either 68 Gy (n = 331) or 78 
Gy (n = 333) of 3D-CRT [6]. In the high-dose arm, 11% (n = 37) received a dose lower than the 
prescribed dose of 78 Gy. Therefore, we divided our study population into two non-overlapping 
dose-groups: patients who received < 73 Gy (median dose 68 Gy) and those received ≥ 73 Gy 
(median dose 78 Gy). Of the whole group, 362 patients (55%) were at high-risk. Of this high-risk 
group, 125 patients (35%) received HT.
We analyzed FFF-rates in high-risk PC who received combined-modality treatment (RT plus 
HT) separately in order to explore the independent role of dose-escalation in those patients. 
As shown in Figure 1, a trend towards a significant difference between both dose-levels was 
observed. The 6-year actuarial FFF-rates in high-risk patients who received HT and escalated-
dose RT (≥ 73 Gy) were better than in patients who were treated with HT and conventional-dose 
RT (< 73 Gy) (66% vs. 50%, respectively) (p=0.07). 
In conclusion, there is some evidence (Level 2 and 3) supporting the independent role of 
high-dose RT in high-risk PC treated with hormones. These results need, therefore, to be 
consolidated by a powerful RCT or addressing the exact role of high-dose RT in high-risk PC 
treated with hormones as well. 
Duration of HT
The Canadian-trial [31] randomized 387 PC-patients to either 3- or 8-months of neo-adjuvant 
HT in combination with 66-Gy of RT. The DFS (defined as survival without biochemical failure 
(Phoenix definition), locoregional or distant failure) at 5-years was significantly improved for high-
risk patients in the 8-months arm (71% vs. 42%, p=0.01), but not in intermediate- and low-risk 
Figure 1. Kaplan-Meier estimates 
of freedom from failure for high-risk 
prostate cancer patients treated 
within the Dutch dose-escalation trial 
with hormonal therapy and either 
conventional-dose RT (< 73 Gy) or 
escalated-dose RT (≥ 73 Gy).
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group, suggesting that high-risk patients are at higher risk of harboring micrometastases. 
The recently published subset analysis of this trial showed that the biochemical response to 
neo-adjuvant HT, but not duration, appeared to be the most significant predictor of outcome, 
especially in high-risk patients. That study suggests that tailoring neo-adjuvant HT, based on 
biochemical response before RT, would improve therapeutic gain by minimizing the duration of 
androgen deprivation therapy and its related toxicity [32]. 
Individually-tailored duration of neo-adjuvant HT based on clinical and biochemical response 
was also suggested by Heymann et al. [33]. In a Phase II study, 123 patients were treated 
with neo-adjuvant HT for 9-months. RT initiation was individualized to begin after a maximum 
response to androgen deprivation therapy as assessed by monthly rectal digital examination 
and PSA-level. At 5-years excellent FFBF (ASTRO definition), FFCF and OS were achieved 
(63%, 75%, and 89%, respectively). However, in the subgroup of patients were no maximum 
response was obtained, significantly lower FFBF and FFCF (RR 1.0, p=0.03) were observed.
In a retrospective study of high-risk patients treated with high-dose RT (23-Gy BT and 42-Gy EBRT) 
[34] 252 patients received RT in combination with and 308 patients without neo-adjuvant HT. In 
a multivariate analysis, neo-adjuvant HT was a borderline significant (p=0.03) risk factor for DM.
The meta-analysis of 5 RTOG-trials [35] has assessed the impact of short- and long-term HT 
on disease-specific survival (DSS) and OS in 2200 patients with localized PC treated with RT. 
Patients were stratified by prognostic risk groups. High-risk patients (T3/T4 or Gleason 8-10) 
were noted to have an 16% higher OS at 8-years with the addition of long-term HT (p=0.0004). 
OS at 8-years in patients with high-risk PC treated with long-term HT, vs. short-term HT vs. 
RT-alone were 44%, 36%, and 28%, respectively (p=0.03). The figures for DSS were 69%, 
49%, and 42%, respectively (p=0.001). 
Contrary to the aforementioned results supporting the use of long-term adjuvant HT, D’Amico 
and colleagues [36] pooled data from three RCTs of HT in combination with RT in high-risk PC 
and found no OS-benefit with 3-years compared with 6-months of HT. However, we cannot 
exclude in that study that unknown confounding factors might have affected these results, 
for instance the differences in radiation dose and field size used in those RCTs. Finally, there 
are parallels between breast and prostate cancers. In both diseases, long-term outcome was 
improved by the combination of HT and RT as compared with either alone. Since the long-term 
HT significantly improves OS in patients with breast cancer [37], one should, therefore, not be 
surprised if PC behaves similarly by using prolonged course of HT. 
In conclusion, there is moderately-strong evidence (Level 2 and 3) that the duration of neo-
adjuvant HT should be tailored by the biological response. There is level 2 evidence that 
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long-term adjuvant HT is preferred above short-term adjuvant HT. However, the optimal duration 
of long-term HT must be confirmed by RCTs by including patients in multiple-arms study. The 
answer to this question is quite essential, especially in view of the arguments of the cost and 
long-term side effects of a prolonged-course HT. 
Timing of HT
The addition of 4-months (neo-adjuvant and concurrent) HT to the RT improved FFBF (PSA >2 
ng/mL at ≥1 year from the date of randomisation), DFS (any kind of failure, death from any cause 
and starting salvage HT), and FFDM without OS-benefit in patients with unfavorable PC in the 
RTOG-8610-trial [16]. Adding another 2-years of HT adjuvantly to the 4-months (neoadjuvant 
and concurrent) in 1554 patients with locally-advanced PC treated within the RTOG-9202 trial, 
improved all endpoints, including OS in patients with Gleason score 8-10 [14]. The efficacy 
of combining neoadjuvant, concurrent with adjuvant HT was also demonstrated by D’Amico 
and colleagues [17]. In that study, as well OS as CSM were improved by adding two months 
adjuvant HT to the neoadjuvant and concurrent androgen deprivation therapy.
The question when should HT be administered in combination with RT (neoadjuvantly, concomi-
tantly, adjuvantly or the combination of the 3), remains unanswered. In order to address this 
critical issue, RTCs including high-risk patients in multiple-arms studies are warranted.
conclusions
In high-risk PC, the benefit of HT in combination with conventional-dose RT (< 74 Gy) is evident 
(Level 2 evidence). Level-2 evidence supporting the use of escalated-dose RT in high-risk PC 
was also provided by several RCTs. For the combination of hormonal therapy with escalated-
dose radiotherapy in these patients there is Level 2 evidence for moderately escalated dose (74 
Gy) and high escalated dose (≥ 78 Gy).
Regarding the optimal duration and timing of HT, there is moderately-strong evidence sup-
porting the use of long-term adjuvant HT in high-risk PC. Further RCTs are, therefore, warranted 
to clearly determine the independent role of dose-escalation in high-risk patients using HT 
as well as the optimal duration and timing of HT. Until then, the treatment of high-risk PC is 
individualized and includes hormones in combination with conventional- or dose-escalated RT. 
When the expected risk of high-dose RT is high and the risk of local recurrence is predicted to 
be low, dose-escalation could be avoided.
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discussion
With the exception of skin cancers, prostate cancer has become the most common cancer in 
men in Western countries since 2002 (1). Radical prostatectomy and radiotherapy (RT) are cur-
rently standard treatment modalities for localized prostate cancer. Regarding RT, available data 
indicate a clear dose-response relationship for localized prostate cancer (2-4). These studies 
suggest that long-term outcome of localized prostate cancer critically depends on adequate 
radiation dose. Prostate cancer patients treated in the pre-PSA era with conventional-dose 
RT (60-66 Gy), showed a poor disease-free survival (DFS) (15-30%) and overall survival (OS) 
(10-20%) at 15-years (4). Few years after the first paper on dose-response correlations, it 
became evident that local control is of critical importance not only for the local treatment of the 
disease but also for overall survival, being a critical denominator for the occurrence of distant 
metastases (5). Although retrospective studies (4-6) have proven a better local control with 
dose escalation, increasing the dose over 66 Gy was limited by a rise in late toxicity. With the 
implementation of new treatment techniques such as 3-dimentional conformal RT (3DCRT) and 
intensity-modulated RT (IMRT) improved conformality was observed. 
As a result of the promising high local control rates observed in different prospective dose 
escalation studies in the USA (7-9), a feasibility dose escalation study was performed in the NKI/
AvL, The Netherlands. It was concluded that 3DCRT offers acceptable complication rates with 
high dose of radiation. However, randomized phase III studies were needed to validate these 
results. Therefore, the CKVO study 96-10 was initiated in The Netherlands in 1997 investigating 
the tumor control and toxicity as a consequence of dose escalation, comparing the standard 
dose of 68 Gy with the experimental dose of 78 Gy (10). This study was carried out in four 
cancer institutes in the Netherlands (Daniel den Hoed Cancer Center in Rotterdam, Nederlands 
Kanker Instituut-Antonie van Leeuwenhoek Hospital in Amsterdam, Radiotherapie instituut 
Friesland in Leeuwarden, Zeeuws radiotherapie instituut in Vlissingen).
The tumor control and toxicity of the Dutch phase III dose escalation trial after a median follow-
up of 70 months, has been reported in chapter 2. As in other randomized dose-escalation trials 
(10-14), our study has also demonstrated improved biochemical control by increasing the dose 
to the prostate. Statistically significant improvement in freedom from failure (FFF) was seen in 
patients treated with 78 Gy but without improvement of OS and at the cost of increased late GI 
toxicity. Furthermore, none of the published individual dose escalation trials (9-11) have shown 
an OS benefit by increasing the RT dose above conventional dose levels, probably because 
of the competing risk of death from intercurrent diseases, the short follow-up period and/or 
because of lack of statistical power in these studies. One could, therefore, argue regarding the 
value of dose escalation in prostate cancer. Actually, the same problem was also seen initially 
by analyzing the data of different randomized controlled trials on the benefit of postoperative 
RT in breast cancer patients treated by breast-conserving surgery. None of the trials on its 
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own showed a significant OS benefit for the RT-arm. However, after a long follow-up period, a 
statistically significant benefit from postoperative RT in terms of OS was seen in the pooled data 
of 7,300 patients from 10 randomized controlled trials comparing breast-conserving surgery 
with or without RT (15-year breast cancer mortality risks 30·5% versus 35·9%; reduction 5·4%, 
SE 1·7, p=0·0002; overall mortality reduction 5·3%, SE 1·8, 2p=0·005) (15). Therefore, it is to 
be expected that the advantage of dose escalation in prostate cancer in terms of OS become 
evident only after long follow-up and/or after performing a meta-analysis of all mature dose 
escalation trials. Therefore, we still believe that dose escalation is necessary in patients with 
localized prostate cancer because biochemical control has been shown to correlate not only 
with local failure but also with distant metastases, cause-specific survival and disease-free 
survival (11, 16-18). 
Besides our study, different other randomized trials have also shown that better local control 
rates are achieved with dose escalation at the cost of increased late GI toxicity. The radiation 
oncology community continues to struggle with the question how to further reduce these late 
complications of RT, because decreasing these complications has an important impact on the 
quality of life of prostate cancer patients. IMRT is a new conformal RT technique that produces 
highly conformal dose distributions, facilitating selective escalation to the target volume with 
lower dose to normal tissues. Different prospective studies showed lower GI toxicity rates in 
patients treated by means of IMRT, compared to those treated with 3DCRT with the same dose 
(19, 20). In chapter 3, we analysed the toxicity of 41 prostate cancer patients treated with IMRT. 
A very interesting finding was the significant reduction in acute GI toxicity by implementing IMRT 
in those patients, as compared to patients treated by means of 3DCRT to the same dose-level 
at the same hospital. IMRT was also of benefit in reduction of late toxicity, albeit statistically not 
significant. The explanation might be the short follow-up and/or the small number of patients 
treated with IMRT in our study (21). From a radiobiological point of view, the significant reduction 
of acute toxicity achieved by using IMRT should be translated in the future into a significant 
decrease in late toxicity. Heemsbergen et al. (22) concluded that acute GI toxicity is the most 
significant predictor of late toxicity, suggesting a consequential component in the develop-
ment of late grade ≥ 2 GI toxicity. We believe that the recent implementation of image-guided 
RT (IGRT) at our institute will further enhance the safety and accuracy of IMRT and achieve, 
therefore, further decrease in the late toxicity. 
In chapter 4, we specifically studied the relationship between different clinical and dosimetric 
variables and the occurrence of late urinary obstruction in our study population. The cumulative 
incidence of urinary obstruction at 7-years was 2.6% and 6.1% for the low- vs. the high-dose 
groups (p=0.2). Patients with pre-existing GU symptoms, those who experience acute GU 
toxicity during the RT, and patients with previous TURP were found to be at risk of urinary 
obstruction within 2 years after RT. An interesting dosimetric finding is that hotspots in the 
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bladder were also associated with urinary obstruction at early stages after RT. Events after a 
period of 2-7 years were associated with local dose in the trigonal area/bladder neck. Because 
of the serious nature of this RT-related complication, avoiding hotspots in the region of bladder 
neck and keeping the dose to the region of bladder neck/trigon as low as possible are quite 
challenging from treatment planning pint of view, because these issues were never used as 
constraints in treatment optimization (23).
Besides the achievement of excellent local control as primary goal of radical treatment of 
prostate cancer, toxicity and assessment of quality-of-life (QoL) have become very important 
secondary considerations in the design of clinical trials, especially given the arguments in 
favour of watchful waiting in patients with early-stage disease. The cohort studied at chapter 5 
contains 404 patients who were treated at the Erasmus MC-Daniel den Hoed Cancer Center 
in Rotterdam. The CKVO 96-10 is the first randomized dose escalation trial reporting on the 
impact of dose escalation on QoL of patients with localized prostate cancer by using a vali-
dated QoL-questionnaire (SF-36 questionnaires). QoL-scores did not appear to be significantly 
decreased by escalating the dose of RT from 68 to 78 Gy. However, the decrease in QoL-
scores, in general, was more pronounced in the high- than in the low-dose arm and more in 
the physical- than the mental-health domain. Late GI and GU toxicity showed a trend towards 
significant correlation with decrease in QoL-scores. Given the slight deterioration in different 
QoL-scales, albeit statistically non-significant, seen by escalating the dose of RT from 68 to 78 
Gy, the possible risks of complications and deterioration of QoL must, therefore, be carefully 
weighted against the risk of relapse during the patient’s expected life span. When the expected 
toxicity of high-dose RT in that particular patient is high, the expected life span is relatively short 
and the risk of local recurrence is predicted to be low, dose escalation should, in our opinion, 
be avoided (24). 
The increased rate of GI toxicity and the slight deterioration of QoL-scores in patients received 
higher dose RT raise the question which subgroup of prostate cancer patients really need a 
higher dose of RT in order to control their disease appropriately?. A subgroup analysis was 
performed within the framework of this randmozed trial in order to identify subgroups of patients 
who might benefit from high-dose RT and those who might not benefit (chapter 6). It was 
shown that intermediate-risk patients benefited most from high-dose RT. Because of the small 
number of low-risk patients treated in our trial, no indication was found to exclude this subgroup 
from dose-escalation, also because of the negative test of interaction found in the subgroup 
analysis. The results in high-risk patients were more complicated, because this group was 
very heterogeneous and contained patients who were treated with either RT alone or with 
combination of RT and hormonal therapy (HT). Furthermore, not all high-risk patients allocated 
to the high-dose arm received the intended high-dose RT; that is 11% of this group received a 
dose lower than 78 Gy. Regarding PSA-groupings, patients with PSA > 10 mg/L and those with 
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PSA between 8 and 18 mg/L benefited most from dose escalation. In patients with iPSA lower 
than these levels, high-dose RT is probably not indicated, but this should be confirmed in other 
randomized controlled trials (25).
In chapter 7, we performed a thorough literature review in order to investigate different con-
troversial aspects of the management of high-risk prostate cancer, including the role of dose 
escalation with or without HT as well as the optimal time and duration of HT. In this review, 
we concluded that the role of dose escalation in patients with localized prostate cancer is 
undisputed. Although, there is not arguing about the need for a combined modality treatment 
(HT and RT) in this subgroup of patients, the exact role of high-dose RT in high-risk patients who 
receive HT as well is is not yet well-defined. There is a moderately strong evidence suggesting 
the necessity of long-term HT (of at least 2 years), beside high-dose RT (26). 
future PersPectives
Because the significant improvement achieved in local control in different randomized dose-
escalation trials was associated with increased late GI toxicity (10-14), radiation oncology 
community continues to search for strategies to reduce the rate of this radiation-induced 
complication. Modulating different aspects of the current treatment of localized prostate cancer 
were explored and subsequently implemented in our institute in order to achieve this purpose.
Prostate motion and image-guided radiotheraPy
Integration of more conformal radiation techniques with smaller radiation fields into the clinical 
setting has necessitated a better understanding of the shape and the location of the prostate 
during treatment and between daily treatments. The fact that prostate motion could result in 
potential geographical misses and consequently can lead to worse clinical outcome, was 
demonstrated by de Crevoisier et al (32). They found that patients with a distended rectum at 
the time of treatment planning had > 30% worse PSA outcomes versus those that had a normal 
rectum filling. Radiation oncologists must thus design a treatment strategy that will account for 
prostate motion that occurs between daily treatments (interfraction motion) and that during the 
treatment itself (intrafraction motion); that is, a treatment strategy that limits geographical misses. 
Implantation of 3 to 4 fiducial markers in and around the prostate is nowadays a daily routine 
for every prostate cancer patient treated by means of IMRT in our institute. This simple procedure 
subsequently enables us to digitize these markers before every fraction. Such stereographic 
targeting yields systematic and random prostate positioning errors of < 1mm. Differences of 
more than 2 mm with the pre-treatment position would be corrected immediately online with 
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< 1 min of added treatment time (33). Using such stereographic targeting technique made a 
reduction of the margin of the CTV to the PTV and towards the rectum feasible and safe without 
compromising the target coverage. This step would eventually achieve further reduction of the 
late GI toxicity at our institute. 
With the ability to use on-board Computed Tomography (CT) imaging modalities; the prostate, 
bladder and rectum can be imaged before each treatment and the actual doses delivered to 
these organs can be computed using the “anatomy of the day”. Using kilovoltage cone-beam 
CT, the treatment plans can be adapted based on the image feedback from daily scans, to allow 
the actual delivered doses to closely approximate the original planned doses. Drawbacks to the 
use of the cone-beam CT in IGRT are the inter-observer variation in delineation of the prostate 
on cone-beam CT, because of the low resolution and the fact that acquisition of cone-beam 
CT is time-consuming (34). This makes cone-beam CT less suitable for on-line positioning cor-
rection. However, with a new Linac control software, namely volumetric modulated arc therapy 
(VMAT, Elekta Synergy), in-treatment cone-beam CT-imaging become clinically feasible (35). 
Automatic soft tissue and non-rigid registration tools (36-38) have been developed. These tools 
could potentially eliminate the inter-observer variations.
Another possibility to reduce the radiation dose to the structures surrounding the prostate 
and seminal vesicles is by reducing the margin of the CTV to the PTV. Cyberknife (Accuray 
Incorporated, Sunnyvale, CA, USA) is an excellent device for administering hypofractionated 
schedules. This noval 4-dimensional IGRT system corrects for both patient and tumor motions 
during treatment. Another advantage of this advanced RT system is the ability to deliver a high 
biological dose to the tumor and a minimal dose to the surrounding normal tissue because of 
the rapid fall-off outside the target volume. In order to validate this approach, Aluwini et al. (39) 
from our institute performed a pilot study on 10 early-stage low-risk prostate cancer patients 
who were not suitable for the standard treatment with HDR brachytherapy. The prescribed 
dose was 38 Gy in four daily fractions of 9.5 Gy. They concluded that such regimen was well 
tolerated, is feasible with excellent dose coverage of the prostate. Data collection is ongoing for 
further assessment of tumor control, toxicity, and QoL. 
Despite the tremendous gains achieved with IGRT, a strong quality control is still required 
for safety and proper prospective evaluation of the clinical benefit of IGRT. Other venues for 
investigation include the potential role of protons, of MRI to reduce the uncertainties caused 
by delineation of the prostate and seminal vesicles and the necessity of including the whole 
seminal vesicle in the CTV, and the feasibility of dose recalculation and dose-guide adaptive 
radiation therapy.
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general conclusions and recommendations from the ckvo 
96-10 study
·	 The benefit of dose escalation of RT for localized prostate cancer in terms of freedom from 
failure is undisputed. 
·	 Patients with intermediate-risk prostate cancer and those with iPSA between 8 and 18 mg/L 
seem to benefit most from high-dose RT. However, from the current knowledge, neither 
low-risk nor high-risk patients could be safely excluded from high-dose RT because of the 
negative test of heterogeneity. Randomized trials are warranted to answer this important 
issue.
·	 The associated increased late GI toxicity would be reduced by the recent implementation of 
image-guide intensity-modulated radiotherapy at our institute. 
·	 Despite the increased late GI toxicity seen in patients treated in the high-dose arm, dose 
escalation did not appear to decrease QoL-scores significantly in these patients. 
·	 Predictive models need to be developed in order to identify patients at high risk of toxicity 
from high-dose RT. The possible risks of complications and deterioration of QoL-scores 
must be carefully weighted against the benefit from dose escalation in terms of local control. 
·	 The optimal combination of HT and RT in high-risk prostate cancer patients are not yet 
well-defined.
·	 More attention should be paid to the optimization of treatment planning, with regard to the 
dose of RT to the bladder neck and avoidance of hotspots in the bladder, in order to reduce 
the rate of late GU complications.
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samenvatting
Prostaatkanker is, na huidkanker, de meeste voorkomende soort kanker bij mannen in de Wes-
terse wereld. Radicale prostatectomie en radiotherapie (RT) zijn de standaard behandelopties 
voor een gelokaliseerde prostaatkanker. In verschillende studies is een duidelijke dose-response 
effect aangetoond bij radiotherapie. Uit deze studies is gebleken dat lange termijn uitkomst van 
RT voor prostaatkanker sterk afhankelijk is van de adequate bestralingsdosis. Patiënten die in 
het verleden behandeld zijn met conventionele dosis RT (60-66 Gy), hebben 15 jaar na de RT 
een slechte ziektevrije overleving (15-30%) en overall survival (10-20%).
Verschillende retrospectieve studies hebben aangetoond dat hoge dosis RT tot een betere 
lokale controle zou kunnen leiden. Toch werd in het verleden, door de hoge kans op late 
bijwerkingen, nauwelijks een bestralingsdosis boven de 66 Gy (dosisescalatie) gegeven. Door 
het ontwikkelen en implementeren van nieuwe RT technieken zoals 3-dimensional conformal 
RT (3DCRT) en intensity-modulated RT (IMRT) werd het toedienen van hoge dosis RT (alsnog) 
mogelijk gemaakt. 
In het NKI/AvL werd een haalbaarheidsonderzoek verricht, naar aanleiding van de belo-
vende resultaten van de dosisescalatie studies uit de VS, waarbij verbetering werd gezien van 
de lokale controle door het toedienen van hoge dosis RT. Uit dit onderzoek is gebleken dat 
dosisescalatie middels 3DCRT goed mogelijk is met aanvaardbare bijwerkingen. Gezien de 
uitkomsten van deze studie, is in 1997 de Nederlandse gerandomiseerde studie (CKVO 96-10) 
geïnitieerd. In deze studie werden de uitkomst en de toxiciteit van de standaard arm (68 Gy) 
vergeleken met die van de experimentele arm (78 Gy). Voor deze studie werden patiënten uit 
4 centra in Nederland geïncludeerd (Daniel den Hoed kliniek te Rotterdam, Nederlands Kanker 
Instituut-Antonie van Leeuwenhoek ziekenhuis te Amsterdam, Radiotherapie Instituut Friesland 
te Leeuwarden, Zeeuws Radiotherapie Instituut te Vlissingen). 
Na de algemene introductie in hoofdstuk 1, worden de lokale controle en de toxiciteit van de 
Nederlandse fase III dosisescalatie studie beschreven in hoofdstuk 2. Zoals in andere geran-
domiseerde studies, heeft ook de Nederlandse studie aangetoond dat freedom from failure 
(FFF) (zowel biochemische als klinische recidieven) significant verbeterde door het verhogen 
van de bestralingsdosis aan de prostaat. Na een mediaan follow-up van 70 maanden, was FFF 
significant beter in de 78-Gy arm t.o.v. de 68-Gy arm (respectievelijk 56% vs. 45%, p=0.03). 
De verbeterde lokale controle ging echter niet gepaard met verbetering van de overleving. 
Patiënten die een hogere dosis RT hebben gekregen (78 Gy), hadden hogere incidentie van 
late darmtoxiciteit. Er zijn meerdere redenen mogelijk waarom geen enkele dosisescalatie studie 
een verbetering van de overleving heeft aangetoond. Dit zijn namelijk het overlijden aan andere 
aandoeningen, de korte follow-up in deze studies en/of vanwege het beperkt aantal patiënten. 
Men zou daarom kunnen twijfelen over het nut van de dosisescalatie bij prostaatkanker. Echter, 
hetzelfde probleem had men ook gezien bij het analyseren van verschillende gerandomiseerde 
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studies over de winst van de postoperatieve RT na een mammasparende operatie. Geen van 
deze studies heeft een verbetering aan kunnen tonen in de overleving. Echter na het poolen van 
de data van 10 gerandomiseerde studies in een grote meta-analyse (7,300 patiënten), werd 
een significante verbetering gezien in de overleving van patiënten die postoperatieve RT hebben 
gekregen na de mammasparende operatie (15-jaar risico op mortaliteit van mammacarcinoom 
in de RT-groep was 30.5% t.o.v. 35.9% voor patiënten die geen RT hebben ontvangen, dit komt 
overeen met een mortaliteitsreductie van 5.4%, p=0·0002). Het valt daarom te verwachten dat 
dosisescalatie bij patiënten met prostaatkanker uiteindelijk zal leiden tot verbetering van de over-
leving na lange follow-up en/of na het verrichten van een meta-analyse van alle dosisescalatie 
studies die verricht zijn in de VS, GB en Nederland. 
Naast de Nederlandse dosisescalatie studie, hebben ook andere gerandomiseerde studies 
aangetoond dat hoge dosis RT gepaard gaat met toename van late darmtoxiciteit. Men 
probeerde daarom RT technieken te ontwikkelen en vervolgens te implementeren zodat deze 
bijwerking gereduceerd zou kunnen worden. IMRT is een nieuwe behandeltechniek waarbij 
de RT-dosis gemoduleerd kan worden. Hierbij kan een hogere dosis aan de prostaat gege-
ven worden en tegelijk kan de dosis in de omringende organen zo laag mogelijk gehouden 
worden. In hoofdstuk 3 wordt de toxiciteit van 41 prostaatkankerpatiënten, die behandeld 
werden met IMRT binnen onze studie, beschreven. Een belangrijke conclusie van deze studie 
is de significante reductie van acute darmtoxiciteit bij patiënten die behandeld zijn met IMRT 
vergeleken met de toxiciteit van patiënten die behandeld zijn met 3DCRT. De incidentie van late 
darmtoxiciteit was ook lager bij patiënten die behandeld zijn met IMRT, hoewel statistisch nog 
niet significant. Dit zou verklaard kunnen worden door het beperkt aantal patiënten en/of de 
korte follow-up. Radiobiologisch gezien zou, door het implementeren van IMRT, de significante 
reductie in acute toxiciteit zich moeten vertalen in een reductie van late toxiciteit. Uit eerdere 
publicaties van deze studie is gebleken dat acute toxiciteit de belangrijkste voorspeller is voor 
het optreden van late bijwerkingen (consequentiële bijwerkingen).
In hoofdstuk 4, werd de relatie tussen verschillende klinische en dosimetrische variabelen en 
het optreden van late urine obstructie uitvoerig bestudeerd. The cumulatieve incidentie van urine 
obstructie was 2.6% voor 68-Gy arm en 6.1% voor de 78-Gy arm (p=0.2%). Uit deze studie 
is verder gebleken dat patiënten met pre-existerende mictieklachten, patiënten met acute RT-
gerelateerde mictieklachten, patiënten met recente TUR-prostaat en patiënten met hotspots in 
de blaas een hoger risico hebben op het optreden van urine obstructie binnen 2 jaar na de RT. 
Urine obstructie 2-7 jaar na de RT werd vaker gezien bij patiënten waar hotspots werden gezien 
in de blaashals. Gezien het belang van de reductie van deze ernstige complicatie, dient bij de 
planning meer aandacht besteed te worden aan het voorkomen van hotspots in de blaas(hals).
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Het verhogen van de RT-dosis in onze studie zorgde niet alleen voor verbetering van de lokale 
controle, maar helaas ook voor hogere kans op late darmtoxiciteit, zoals werd beschreven in 
hoofdstuk 2. In hoofdstuk 5 werd het effect van de dosisescalatie op kwaliteit van leven (QoL) 
van deze patiënten uitvoerig onderzocht. Alle patiënten die geïncludeerd en behandeld werden 
in het Erasmus MC- Daniel den Hoed kliniek (n=404) hebben deelgenomen aan een side-study, 
waarbij de QoL op verschillende tijdstippen werd onderzocht. Deze patiënten hebben de SF-36 
QoL formulieren ingevuld vòòr starten van de RT (baseline) en 6, 12, 24, 36 maanden na het 
afronden van de behandeling. Uit deze side-study is gebleken dat er geen significante ver-
slechtering van QoL is bij patiënten die 78 Gy hebben gehad ten opzichte van patiënten die 68 
Gy hebben ontvangen. Echter, patiënten die behandeld werden in 78 Gy arm hadden over het 
algemeen wat lagere QoL-scores. Dit was met name het geval op het fysieke domein en minder 
op mentale domein van het SF-36. Late darm en blaas toxiciteit blijken enige invloed te hebben 
op de achteruitgang in de QoL-scores (trend maar niet significante correlatie). Gezien de lichte 
verslechtering van QoL-scores bij patiënten die hoge dosis RT hebben ontvangen, dient het nut 
van doesescalatie bij iedere prostaatkankerpatiënt voorzichtig afgewogen te worden tegen het 
risico van verhoogde darmtoxiciteit en de eventuele verslechtering van QoL-scores. Wanneer 
de kans op te verwachten bijwerkingen bij een patiënt hoog is, de levensverwachting relatief 
kort is en de kans op lokaal recidief laag is, dient doesescalatie vermeden te worden bij deze 
patiënt.
Gezien het feit dat dosisescalatie gepaard gaat met een verhoogd risico op late darmtoxiciteit 
en mogelijk ook enige verslechtering van QoL-scores, ontstaat een zeer belangrijke vraag die 
beantwoord dient te worden; welke subgroepen van prostaatkanker zullen baat hebben bij 
hoge dosis RT en welke niet? Teneinde een antwoord te kunnen geven op deze essentiële 
vraag, werd een subgroep analyse verricht binnen onze patiëntenpopulatie (hoofdstuk 6). Uit 
deze analyse is gebleken dat patiënten met intermediate-risk prostaatkanker de meeste baat 
zullen hebben bij hoge dosis RT. Echter, er werd geen indicatie gevonden uit deze subgroep 
analyse om patiënten met low-risk of high-risk prostaatkanker uit te sluiten van dosisescalatie. 
Het aantal low-risk patiënten die behandeld zijn in onze studie is te klein om daarover een 
degelijke conclusie te kunnen formuleren. In de high-risk groep, is de situatie nog ingewikkelder 
omdat 20% van high-risk patiënten naast de RT ook met hormonen zijn behandeld. Patiënten 
die hormonen en hoge dosis RT (78 Gy) hebben gekregen, hadden betere lokale controle ten 
opzichte van patiënten die naast de hormonale behandeling lage dosis RT (68 Gy) hadden 
gehad. Wat betreft het PSA gehalte, het is gebleken uit deze subgroep analyse dat patiënten 
met PSA > 10 mg/L en in het bijzonder patiënten met PSA tussen 8 en 18 mg/L, de meeste 
baat hadden bij dosisescalatie. Bij patiënten met een PSA gehalte < 8 mg/L is hoge dosis RT 
waarschijnlijk niet noodzakelijk. Dit moet echter in de toekomst bewezen worden in een groot 
gerandomiseerde studie.
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In hoofdstuk 7, kunt u de resultaten van de review lezen aangaande verschillenden con-
troversiële aspecten in de behandeling van high-risk prostaatkanker. We hebben de rol van 
dosisescalatie met en zonder hormonale behandeling in deze heterogenen groep patiënten, 
de optimale duur en timing van de hormonale behandeling geanalyseerd. Uit dit overzichtartikel 
kunnen wij concluderen dat de rol van dosisescalatie onomstreden is in patiënten met gelokali-
seerde prostaatkanker. Ondanks het feit dat de combinatie van RT en hormonale therapie zeer 
noodzakelijk is in high-risk patiënten, dient de exacte rol van dosisescalatie in deze patiënten 
nog uitvoerig onderzocht te worden in een gerandomiseerde studie. Verder is uit deze studie 
gebleken dat er redelijk sterke aanwijzingen zijn dat hormonen voor een minimale periode van 2 
jaar gegeven moeten worden aan patiënten met high-risk prostaatkanker.
nieuwe ontwikkelingen 
Uit verschillende gerandomiseerde studies is gebleken dat de lokale controle significant verbetert 
met dosisescalatie in vergelijking met lage dosis RT. Echter de verbeterde lokale controle (FFF) 
ging in deze studies gepaard met een hoge incidentie van late darmtoxiciteit. Men is daarom al 
jaren bezig met allerlei nieuwe ontwikkelingen om de darmtoxiciteit te kunnen verminderen en 
de uitstekende lokale controle te kunnen behouden.
Het is bekend dat de prostaat en de zaadblaasjes bewegen tijdens en tussen de bestralin-
gen in. De beweeglijkheid wordt (ook) van buiten af beïnvloed door de vulling van de endeldarm. 
Wanneer men geen rekening houdt met deze beweeglijkheid, zou een deel van de prostaat 
gemist kunnen worden, terwijl een deel van de endeldarm onnodig bestraald wordt (dit feno-
meen heet geographical misser waardoor de lokale controle slechter zou kunnen worden en 
endeldarmbelasting hoger zou kunnen uitvallen). Wanneer de beweeglijkheid van de prostaat 
en de zaadblaasjes tijdig opgespoord wordt, kan men het plan online zodanig aanpassen/
corrigeren dat het bewegen van de prostaat geen negatieve invloed zal hebben op de uitkomst 
van de RT. Dit concept vormt de basis van het zogenaamd image-guided RT (IGRT). 
In ons instituut wordt IGRT op verschillende fronten bedreven. Tegenwoordig worden bij alle 
prostaatkankerpatiënten 3-4 markers geplaatst in en om de prostaat. Deze markers kunnen 
vervolgens digitaal opgespoord worden. Gebruik makend van de zogenaamd “stereographic 
targeting”, kan men systematische en random fouten in de positie van de prostaat detecteren. 
Bij afwijkingen van > 2 mm zal men onmiddellijk een correctie toepassen zonder dat er sprake 
zal zijn van verlenging van de behandeltijd. 
Het gebruik van de nieuwe imaging techniek (cone-beam CT; VMAT, Elekta Synergy) vòòr het 
toedienen van de bestraling geeft een uitstekend beeld van de “anatomy of the day”. Hierdoor 
kan men het plan dagelijks aanpassen aan de positie van de prostaat en de zaadblaasjes, maar 
ook aan de positie van kritieke organen, namelijk de endeldarm en de blaas. 
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Patiënten met “very low-risk” prostaatkanker kunnen tegenwoordig behandeld worden in 
ons instituut met de Cyberknife ( Accuray Incorporated, Sunnyvale, CA, USA), een 4-dimen-
sional IGRT systeem waarbij onmiddellijk een correctie voor beweging van tumor en organs at 
risk toegepast kan worden. In een pilot studie, zijn inmiddels 10 patiënten met “very low-risk” 
prostaatkanker behandeld in ons instituut met de Cyberknife (4 fracties van 9.5 Gy). Deze 
behandeling bleek haalbaar te zijn en werd goed getolereerd door patiënten. Men heeft ook 
een uitstekende coverage van het doelvolume kunnen bereiken met optimale sparing van de 
endeldarm, de blaas en de urethra. 
Door het toepassen van verschillende image-guidance technieken (stereographic target-
ing, cone-beam CT en het gebruiken van de Cyberknife) wordt bestraling van prostaatkanker 
steeds veiliger. Hierdoor kunnen de marges van het CTV naar het PTV kleiner gemaakt worden 
waardoor de darm en de blaas minder belast worden. Vervolgens zullen de acute en late 
bijwerkingen van de RT verminderd worden.
Algemene conclusies and aanbevelingen van de CKVO 96-10 studie
·	 Het nut van dosisescalatie bij prostaatkankerpatiënten is onomstreden.
·	 Patiënten met intermediate-risk prostaatkanker en met een PSA gehalte van 8-18 mg/L 
hebben de meeste baat bij dosisescalatie. Echter, uit deze studie kan men noch low-risk 
noch high-risk patiënten hoge dosis RT veilig onthouden. Grote gerandomiseerde studies 
dienen deze vraag in de toekomst te beantwoorden.
·	 Door het implementeren van IGRT, zal de late darmtoxiciteit fors verminderd worden.
·	 Ondanks de toename van late darmklachten bij patiënten die behandeld zijn met hoge 
dosis RT, heeft dosisescalatie in onze studie niet geleid tot significante verlaging van de 
QoL-scores.
·	 Men dient “predictive models” voor toxiciteit te ontwikkelen om vervolgens patiënten te 
identificeren die hoog risico lopen op RT-gerelateerde bijwerkingen. Bij deze patiënten, dient 
het nut van dosisescalatie in termen van lokale controle voorzichtig te worden afgewogen 
tegen het risico op bijwerkingen en eventuele achteruitgang van QoL.
·	 De optimale combinatie van RT en hormonale behandeling in high-risk prostaatkanker is niet 
helemaal uitgekristalliseerd. 
·	 Meer aandacht dient besteed te worden aan het optimaliseren van de RT-planning. Met het 
oog op het verminderen van incidentie van ernstige late urine obstructie dienen hotspots in 
de blaas(hals), wanneer mogelijk, voorkomen te worden.
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